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In this introductory chapter, first an overview of  the coagulation pathways will be given, 
followed by a detailed description of  the anticoagulant protein activated protein C 
(APC) and the glycosaminoglycan, heparin. These biomolecules do not only function as 
anticoagulants, but more interestingly possess several cytoprotective properties. Selective 
inhibition of  the anticoagulant properties of  APC or administration of  exogenous APC 
or heparin can, in our opinion, be beneficial in several disease models that are outlined 
next. Finally, the design of  engineered APC and heparin biomolecules with reduced 
anticoagulant properties is described. We hypothesize that these variants can potentially 
be used as novel therapies to treat coagulation disorders and inflammatory diseases.
Coagulation
In vivo coagulation is initiated by exposure of  tissue factor (TF) to the blood. TF is 
expressed at extravascular sites such as adventitial fibroblasts and vascular smooth 
muscle cells. At sites of  vascular injury where the endothelium is disrupted, TF 
is exposed and factor (F)VII is activated to FVIIa (figure 1). The extrinsic pathway 
of  coagulation is initiated by formation of  the extrinsic tenase complex by TF and 
factor FVIIa (1), that activates the inactive precursor (zymogen) serine protease FX. 
Alternatively, FX can be activated by the intrinsic tenase complex consisting of  FIXa 
and its cofactor FVIIIa on a surface that contains negatively charged phospholipids. 
Subsequently FXa forms, together with its cofactor FVa, the prothrombinase complex 
on a surface of  negatively charged phospholipids. This complex converts prothrombin 
to thrombin, the key-enzyme of  the coagulation cascade that mediates conversion of  
soluble fibrinogen to an insoluble cross-linked fibrin clot. 
Thrombin further enhances coagulation via a positive feedback mechanism by activation 
of  the cofactors for the prothrombinase complex (FV) and intrinsic tenase complex 
(FVIII) and by FXI activation. FXIa on its turn can activate FIX, which is important for 
FX activation via the intrinsic tenase complex. Furthermore, thrombin facilitates clot 
stabilization by activation of  FXIII, a transglutaminase that cross-links fibrin polymers 
and thereby supports formation of  an insoluble fibrin clot (2-4).
An alternative mechanism by which the coagulation cascade can be initiated is the 
intrinsic pathway (figure 1). This pathway is initiated by the activation of  FXII by binding 
to a negatively charged surface, such as glass, resulting in conversion of  prekallikrein 
to kallikrein. High molecular weight kininogen (HMWK) is a cofactor for both the 
activation of  FXII and kallikrein. The newly formed kallikrein accelerates conversion 
of  FXII to FXIIa, that subsequently activates FXI (5, 6).
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Activated protein C 
Protein C (PC) is a vitamin K-dependent glycoprotein of  62 kDa that circulates as an 
inactive zymogen in human plasma at an average concentration of  65-70 nM (7, 8). 
Thrombin can activate the proteolytically inactive PC by cleavage at arginine (R) 169, 
resulting in removal of  the activation peptide and generation of  the serine protease 
activated PC (APC). In the absence of  its cofactors thrombomodulin (TM) and 
endothelial protein C receptor (EPCR), thrombin is a poor activator of  PC (9). However, 
when thrombin is bound to the endothelium associated transmembrane receptor TM, 
the activation of  PC is accelerated several orders of  magnitude (10). Binding of  the 
thrombin-TM complex to EPCR, another receptor that is present on the surface of  
vascular endothelial cells, enhances its catalytic activity 20-fold (11). The interactions of  
PC with both EPCR and the thrombin-TM complex are Ca2+-dependent (12).
APC is the central enzyme of  the natural anticoagulant protein C pathway that helps 
to regulate thrombin formation via proteolysis of  active coagulation factors V (FVa) 
Figure 1: Overview of the coagulation cascade
Both the intrinsic and extrinsic pathway can initiate the common coagulation pathway, resulting in 
formation of  thrombin (IIa) and finally in formation of  an insoluble fibrin clot. Activated Protein C, 
antithrombin (AT) and Tissue factor pathway inhibitor (TFPI) are anticoagulant proteins that inactivate 
several coagulation proteins. The inactivation of  FXa and thrombin by AT is more than 100-fold increased 
in the presence of  heparin. The cofactor activities of  protein S (PS) and factor V (FV) are essential for 
respectively inactivation of  FVa and FVIIIa by APC.
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and VIII (FVIIIa) (figure 1). The cofactor activities of  protein S (PS) and factor V 
(FV) are essential for respectively inactivation of  FVa by proteolysis at R306, R506 
and R679 and inactivation of  FVIIIa by proteolysis at R336, R562 and R740 (13-15). 
The crucial role of  the APC pathway for maintenance of  the haemostatic balance is 
indicated by the increased risk for thromboembolic events observed in individuals with 
heterogeneous PC deficiency (16, 17) and the life threatening thrombotic complications 
that occur, even in the presence of  aggressive anticoagulant therapy, in individuals with 
homozygous PC deficiency (18, 19).
Initially APC has been identified and characterized as an anticoagulant protein; 
however recent research (20-25) has shown that APC possesses neuroprotective and 
cytoprotective functions that likely explain the protective effects of  APC in animal 
models of  diseases like ischemic/embolic stroke, myocardial infarction, sepsis and 
lung injury. These cytoprotective effects of  APC are protease activated receptor 1 
(PAR-1) and EPCR-dependent and comprise of  anti-inflammatory, anti-apoptotic and 
endothelial barrier stabilizing effects on different cell types (26, 27). 
Heparin
Heparin is a highly sulfated anticoagulant polysaccharide belonging to the family 
of  glycosaminoglycans (28). It has the highest negative charge density of  all known 
biological molecules and is biosynthesized and stored in mast cells of  particularly the 
liver, lung and intestinal mucosa (29). All heparin preparations contain polydisperse 
linear polymers with heterogeneous sequences, so the molecular weight (MW) cannot 
be uniquely described (30). For unfractionated heparin (UFH) isolated from porcine 
intestinal mucosa most polymers are in the range from 17 to 20 kDa. Low molecular 
weight heparin (LMWH) preparations have an average MW ranging from 3.6 to 6.5 
kDa (30). Heparin has been used for years as a potent anticoagulant. Binding of  
heparin to antithrombin changes the conformation of  antithrombin and thereby greatly 
accelerates its inhibitory activity towards mainly serine proteases thrombin and FXa, 
but also towards FIXa, FXIa and FXIIa (31). Only heparin molecules that contain 
a specific pentasaccharide motif, including the unusual 3,6 di-O-sulfated 2-N-sulfated 
glucosamine residue, and that besides this have sufficient chain length (minimum 5 kDa) 
to bind both antithrombin and thrombin, can potentiate inhibition of  thrombin (30). 
Therefore, LMWH has drastically reduced anti-thrombin specific activity compared to 
UFH.
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Disease models studied in this thesis
Hemophilia A
Hemophilia A is an X chromosome-linked bleeding disorder caused by mutation of  
the FVIII gene. Usually, affected men have inherited the mutated gene from their 
mothers that are non-symptomatic carriers, although 30 percent of  mutations arise 
spontaneously without any family history of  hemophilia A. The incidence of  hemophilia 
A is estimated at 1 in 5000 male life births (32). Hemophilia A patients can be divided 
into three categories depending on their FVIII levels. Patients with severe hemophilia 
A have <1% FVIII levels and experience spontaneous bleedings into muscles, joints 
and soft tissue, predominantly in the absence of  a haemostatic challenge like injury, 
trauma or surgery. Patients with a moderate form of  hemophilia A (1-5% FVIII level) 
usually show prolonged bleeding after minor trauma or surgery and occasionally pass 
through spontaneous bleedings. In patients with mild hemophilia A (>5% FVIII level) 
spontaneous bleedings are rare, but severe bleeding after  major trauma or surgery 
occurs regularly (33).
For hemophilia A treatment FVIII concentrates are used preferably. Based on the 
estimated half-life of  infused FVIII protein (8-12 hours) and on the pharmacokinetics 
of  FVIII in an individual patient, subsequent intravenous infusions with FVIII 
concentrates should be scheduled to keep FVIII levels in circulation above a threshold 
needed to protect patients from bleeding complications. An alternative is continuous 
infusion, that has the advantage that peaks and troughs in FVIII levels are avoided, but 
the disadvantage that patients should be monitored frequently for pump failure (33). In 
spite of  optimal medical care and infusions with FVIII concentrates, individuals with 
severe hemophilia regularly face musculoskeletal complications. Another treatment-
related complication is the development of  neutralizing antibodies to infused FVIII 
concentrates. This occurs in 20-30% of  patients with severe hemophilia A and 5-10% 
of  patients with mild or moderate hemophilia A and makes the infusions no longer 
useful for coagulation (33).
Atherosclerosis
Atherosclerosis is a progressive chronic inflammatory disease that is characterized by 
the formation of  lesions in the vessel walls of  large and medium-sized arteries. Already 
in children the earliest lesions, called fatty streaks, start to develop. These small lesions 
are localized just beneath the endothelial layer of  the arterial wall and consist of  lipid-
containing macrophage-derived foam cells and T lymphocytes (34). 
Endothelial dysfunction probably plays an important role in the formation of  
atherosclerotic lesions. Dysfunctional endothelium secretes vasoactive molecules, 
cytokines and growth factors, has an increased permeability and upregulated expression 
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of  cellular adhesion molecules like vascular cell adhesion molecule-1 (VCAM-1), 
resulting in transmigration of  monocytes and T lymphocytes into the vessel wall 
(34, 35). Risk factors for endothelial dysfunction and thereby the development of  
atherosclerosis are hypercholesterolemia, hypertension, free radicals, diabetes mellitus, 
hyperhomocysteinemia and infectious microorganisms such as herpesvirus and 
Chlamydia pneumonia (36). When these risk factors remain present, the inflammatory 
process and plaque formation will progress over time by migration and proliferation 
of  smooth muscle cells into the lesion, resulting in intermediate lesions. Macrophages 
and lymphocytes keep multiplying, become activated and secrete cytokines, chemokines 
and enzymes that promote cell death and necrotic core formation. Gradually the lesion 
enlarges and restructures. A fibrous cap is formed over the core of  lipid and necrotic 
tissue and an advanced, complicated lesion arises (36). The thin fibrous cap is prone 
to rupture, and when rupture occurs, this leads to formation of  a thrombus that can 
occlude the vessel, resulting in ischemia of  the heart, brain or extremities (34, 36). 
When these processes, that illustrate the close interplay between vascular wall changes, 
inflammatory processes and thrombus formation, occur in the heart or brain, they give 
rise to what is commonly described as cardiovascular infarction or ischemic stroke.
Thus, not only inflammation, but also coagulation is involved in the pathology of  
atherosclerosis. Extensive bidirectional cross-talk between both systems has been 
established in atherosclerosis (37). Platelets play an important role in pro-inflammatory 
conditions. They adhere to both dysfunctional endothelial cells and to circulating 
immune cells and secrete atherogenic mediators. Numerous coagulation proteins, such 
as FXa, thrombin and the TF-FVIIa complex are present in atherosclerotic lesions 
and induce pro-inflammatory signaling via a class of  G-Protein coupled receptors 
called protease activated receptors (PARs). Furthermore, FXIII, fibrinogen and fibrin 
degradation products were found in progressed atherosclerotic lesions. Notably, 
heterozygous protein C deficiency in mice and low levels of  APC in clinical studies are 
associated with a greater extent or severity of  atherosclerosis (37).
Myocardial ischemia/reperfusion injury
Coronary heart disease (CHD), characterized by plaque formation in coronary arteries, 
is the main cause of  myocardial ischemia/reperfusion (I/R) injury. According to the 
World Health Organisation (WHO), CHD is the leading cause of  death (12.8% of  
all deaths) and disability worldwide (38). When a coronary artery is occluded, the part 
of  the myocardium that is dependent on this artery for its blood supply will become 
ischemic. This results in several pathological changes in the ischemic part of  the 
myocardium, including increased intracellular calcium and sodium concentrations, 
mitochondrial membrane depolarization, depletion of  ATP, decrease of  pH due to 
anaerobic respiration, loss of  contractile function, production of  reactive oxygen 
species, apoptosis, endothelial dysfunction, platelet aggregation and microembolization. 
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The immune system becomes activated, resulting in neutrophil accumulation and cell 
mediated damage caused by infiltrated macrophages and T lymphocytes (38, 39). 
Although reperfusion itself  also induces cardiomyocyte death, it is important that 
therapeutic interventions to restore blood flow, like thrombolytic therapy and primary 
percutaneous coronary intervention, will be started as soon as possible to reduce I/R 
injury and limit the size of  myocardial infarction (38). 
Sepsis
Sepsis arises when the body responds to an infection, of  either bacteria, fungi or viruses, 
and the response culminates into a systemic inflammatory response that inflicts damage 
to own tissues and organs (40). Based on extrapolation of  the number of  treated 
sepsis patients in the United States, the estimated worldwide incidence rate of  sepsis 
is 19 million cases per year, (41). According to official criteria (42) sepsis is diagnosed 
by a proven or suspected clinical infection in combination with at least two systemic 
inflammatory response syndrome (SIRS) criteria: 1) a body temperature greater than 
38 °C or less than 36 °C; 2) a heart rate greater than 90 beats/minute; 3) tachypnea, 
manifested by a respiratory rate greater than 20 breaths/minute or hyperventilation, as 
indicated by a PaCO2 of  less than 32 mmHg; 4) an alteration in the white blood cell 
count, such as a count greater than 12.000/mm3, a count less than 4.000/mm3, or the 
presence of  more than 10% immature neutrophils. Severe sepsis is diagnosed when 
patients meet the aforementioned criteria and have developed sepsis-induced organ 
dysfunction, hypoperfusion abnormality (lactic acidosis, oliguria, acute alteration of  
mental status) or hypotension. Patients are diagnosed with septic shock when they meet 
the severe sepsis criteria and have hypotension despite adequate fluid resuscitation. 
Although advances are made in the treatment of  sepsis patients by the improved 
availability of  potent antibiotics and the more advanced supportive therapy for failing 
organs, mortality rates are still 20-30% for sepsis patients and even higher for severe 
sepsis and septic shock patients (40). 
Increased concentrations of  histones and nucleosomes were found in circulation of  
patients with trauma, systemic inflammation and sepsis (43,44,45). Histones are cationic 
nuclear proteins that package and order DNA into structural units called nucleosomes. 
Nucleosomes consist of  a superhelix of  146 base pairs DNA wrapped around an 
octamer containing two copies of  histones H2A, H2B, H3 and H4. These extracellular 
histones and nucleosomes could originate from either excessive apoptotic and necrotic 
cell death or neutrophil extracellular trap (NET) formation (46-48). NETs are intricate 
fibrous networks that contain DNA as their major structural component, as well as 
antimicrobial proteins such as histones and neutrophil elastase. Extracellular traps are 
not exclusively released by activated neutrophils. Recently it was discovered that other 
immune cells like macrophages, eosinophils and mast cells can also release extracellular 
traps to disarm and kill bacteria (48). Extracellular histones possess bactericidal activity 
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(49), but unfortunately also exhibit cytotoxic activity towards host cells, including 
endothelial cells (50, 51). So, release of  histones into circulation may trigger a positive 
feedback loop, resulting in more cell death and additional histone release (52).
The mechanism of  histone-mediated cytotoxicity is not exactly known yet. One 
hypothesis is that histones induce channel formation in phospholipid membranes of  cells 
and platelets, resulting in calcium influx, plasma-membrane depolarization and finally 
cell death (53-55). Another hypothesis is that extracellular histones act as pathogen-
associated molecular patterns (PAMPs) through activation of  Toll-like receptors (TLR) 
2 and TLR4 in vivo, leading to production of  cytokines. These cytokines cause severe 
sterile inflammation and tissue injury and can ultimately lead to development of  organ 
failure and death in mice (56).
Adjustment of the functional properties of APC and heparin to optimize their 
biological effectiveness 
Activated protein C
First, we aimed to selectively inhibit the anticoagulant properties of  APC with small 
molecular inhibitors. We believe that this can be beneficial in individual with bleeding 
tendencies, like hemophilia A patients.
In the murine myocardial ischemia/reperfusion injury and atherosclerosis studies, we 
did not only investigate the in vivo effects of  wild type (wt) APC administration, but we 
also tested the effect of  the so-called S360A-APC variant, firstly described by Gale et al. 
(57). In this APC variant, the active site serine was mutated to alanine, yielding a protein 
that lost the ability to proteolyze FVa and FVIIIa, but still retained limited anticoagulant 
activity through competition with coagulation factors Xa and IXa for binding to 
respectively FVa and FVIIIa (57, 58). S360A-APC is not able to cleave PAR-1 and is 
therefore regarded as being devoid of  cytoprotective activity (59). However, S360A-
APC can still bind to EPCR via its γ-carboxyglutamic acid (Gla) domain and thereby 
achieve coupling of  PAR-1 to a G(i/o) family of  G-proteins, resulting in initiation of  
protective signaling after cleavage of  PAR-1 by either APC or thrombin (60). 
For the in vitro studies on the proteolysis of  histones by APC, we used a second APC 
variant. In this variant three lysine (K) residues in the 191 loop and two arginine residues 
in the calcium binding loop of  APC were mutated into alanine (KKK191-193AAA and 
RR229-230AA). Both loops are part of  a positively charged exosite on the surface of  
APC that is important for FVa and FVIIIa binding and cleavage (61, 62). Mutation of  
these 5 residues yields a variant (5A-APC), firstly described by Mosnier et al. (59), with 
minimal anticoagulant activity that retains normal cytoprotective activity (63).
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Antithrombin affinity depleted heparin 
Antithrombin affinity depleted heparin (AADH) consists of  the subfraction of  UFH 
that is not able to bind to a column to which antithrombin was covalently immobilized 
(64). AADH possesses greatly diminished anticoagulant activity, that is independent 
of  antithrombin-mediated activities and can be attributed to heparin cofactor II 
stimulation, the plasma concentration of  which does not allow complete inhibition of  
thrombin formation (64).
Outline of the study
In this study we investigate the diverse properties of  the anticoagulant biomolecules 
APC and heparin both via in vitro and in vivo methods. For some in vivo purposes it is, in 
our opinion, beneficial to limit the anticoagulant functions of  these biomolecules, while 
preserving their other (cyto)protective properties.
Chapter 2 starts with an extensive overview of  the current knowledge on the structure 
of  APC and its dual anticoagulant and cytoprotective functions. Next, the intricate 
structure-function relationship of  APC is elaborately explored using data from various 
studies that have investigated the effects of  different naturally occuring and engineered 
mutations in APC on the various APC functions, to dissect areas that are important for 
anticoagulant, cytoprotective and other properties of  APC.     
When normal thrombin formation is compromised and the haemostatic balance is 
tipped towards bleeding tendencies, such as in hemophilia A, it would be beneficial 
to limit the anticoagulant activity of  APC. In chapter 3 we use a validated structure-
based virtual screening approach to discover small drug-like molecules that inhibit the 
interaction between a predominant APC exosite and its substrate FVa. We hypothesize 
that specific inhibition of  this substrate-binding exosite in circulating APC, results in 
promotion of  thrombin formation without affecting the cytoprotective properties 
of  APC. The small molecules identified by in silico screening where tested in vitro by 
functional screening and direct binding analysis. 
Due to its anti-inflammatory properties, we hypothesized that APC has the potential 
to protect against the development of  diseases wherein acute or chronic inflammation 
plays a major role in the pathogenesis. In chapter 4 we investigate the effects of  
exogenous wt- and S360A-(A)PC administration in murine models of  acute myocardial 
I/R injury and the chronic inflammatory disease atherosclerosis. We analyze effects 
of  wt- and S360A-(A)PC on infarct size, atherosclerotic plaque area and phenotype, 
cytokine levels in circulation and on the innate and adaptive immune system. 
In addition to its anticoagulant and cytoprotective properties, it was recently discovered 
that APC is able to proteolyze histones. In chapter 5 we investigate the proteolytic 
activity of  wt-APC and 5A-APC towards histone H3 and the influence thereon of  
varying concentrations of  calcium and phospholipids. Subsequently, we investigate the 
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cytotoxicity of  histone H3 cleavage products towards endothelial cells and identify the 
cleavage sites for APC in histone H3. 
Increased concentrations of  extracellular histones or nucleosomes were found in the 
circulation of  patients with traumatic injury and sepsis. In chapter 6 we measured 
histone H3 levels in plasma samples of  a group of  43 sepsis patients and investigated 
whether these correlate with disease severity, mortality and parameters reflecting 
coagulation and tissue homeostasis. 
Histones are strongly positively charged proteins and therefore we hypothesize that 
heparin, a negatively charged polysaccharide, can bind to histones and block their 
cytotoxicity. The disadvantage of  heparin is that it can potentially cause bleeding 
complications. In chapter 7 we describe the development of  a non-coagulant 
antithrombin affinity depleted heparin (AADH) that may be used to neutralize the 
cytotoxic properties of  histones, without increase of  the bleeding tendency. In vitro, 
we investigated the binding properties of  AADH to free histones and histones 
incorporated in NETs and the potency of  AADH to protect endothelial cells against 
the histone-induced cytotoxicity. Lastly, we investigated the in vivo efficacy of  AADH 
administration to oppose histone-mediated cytotoxicity and mortality in mouse models 
of  sterile inflammation and sepsis.
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Abstract
Protein C is the central enzyme of  the natural anticoagulant pathway and its activated 
form APC (activated protein C) is able to proteolyse non-active as well as active 
coagulation factors V and VIII. Proteolysis renders these cofactors inactive, resulting 
in an attenuation of  thrombin formation and overall down-regulation of  coagulation. 
Presences of  the APC cofactor, protein S, thrombomodulin, endothelial protein C 
receptor and a phospholipid surface are important for the expression of  anticoagulant 
APC activity. Notably, APC also has direct cytoprotective effects on cells: APC is able 
to protect the endothelial barrier function and expresses anti-inflammatory and anti-
apoptotic activities. Exact molecular mechanisms have thus far not been completely 
described but it has been shown that both the protease activated receptor 1 and EPCR 
are essential for the cytoprotective activity of  APC. Recently it was shown that also other 
receptors like sphingosine 1 phosphate receptor 1, Cd11b/CD18 and tyrosine kinase 
with immunoglobulin-like and EGF-like domains 2 are likewise important for APC 
signalling. Mutagenesis studies are being performed to map the various APC functions 
and interactions onto its 3D structure and to dissect anticoagulant and cytoprotective 
properties. The results of  these studies have provided a wealth of  structure-function 
information. With this review we describe the state-of-the-art of  the intricate structure-
function relationships of  APC, a protein that harbours several important functions for 
the maintenance of  both humoral and tissue homeostasis.
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Introduction
Protein C (PC) is a vitamin K-dependent serine protease of  62 kDa, which is present 
in human plasma at an average concentration of  70 nM (1). PC circulates in plasma as 
an inactive zymogen and is activated by thrombin bound to the endothelium associated 
transmembrane receptor thrombomodulin (TM). TM-bound thrombin removes the 
158–169 activation peptide of  PC via cleavage at R169, thus generating activated PC 
(APC). The catalytic activity of  the thrombin-TM complex is 20-fold higher when 
PC is bound to the endothelial protein C receptor (EPCR) on the surface of  vascular 
endothelial cells (2). Both the interactions of  PC with the thrombin-TM complex and 
with EPCR are Ca2+-dependent. Once PC is activated, APC has anticoagulant as well as 
cytoprotective functions, which will be described in detail in the next paragraphs. 
Two-dimensional (2D) and three-dimensional (3D) structural protein analyses have 
shown that PC has a mosaic domain structure containing a N-terminal γ-carboxyglutamic 
acid (Gla)-domain (residues 1–45), including a helical aromatic segment (residues 38–
45), two epidermal growth factor (EGF)-like domains (residues 46–92 and 93–136), a 
linking peptide (residues 137–157), a small activation peptide (residues 158–169) and 
a trypsin-like serine protease domain (residues 170–419) which harbours the active 
site triad composed of  the residues D257, H211 and S360 (1, 3, 4). Residue numbers 
for all proteins mentioned refer only to the mature human protein with the exception 
for the catalytic domain of  PC, where chymotrypsin-based residue numbers are given 
in parentheses. During post-translational processing the single chain PC is cleaved 
between residues 157 and 158 in the Golgi apparatus, and next the amino acids 157 and 
156 are removed by a carboxypeptidase B. The resulting fully processed PC circulates as 
a heterodimer consisting of  a 41 kDa heavy chain and a 21 kDa light chain that are held 
together via a single disulphide bond (3). Both heavy and light chains carry N-linked 
carbohydrates at residues 97, 248 (93), 313 (150) and 329 (166) (5).
It has been demonstrated that small amounts of  APC circulate in human plasma at a 
concentration of  around 40 pM (1). With the half-life of  APC being approximately 20 
minutes, this suggests that there is a continuous formation of  minute quantities of  APC. 
Down regulation of  APC activity in plasma occurs via inhibition by α2-macroglobulin 
and by the serine protease inhibitors (serpins) α1-antitrypsin (AAT), protein C inhibitor 
(PCI) and α2-antiplasmin (6, 7). Recently it is shown that APC activity can also be 
inhibited by Zn2+ in purified systems (8).
Although identified and initially characterised as an anticoagulant (9, 10), recent interest 
in PC focuses more on the cellular functions of  this protease. In the following sections 
both functions of  PC, i.e. anticoagulant and cytoprotective, will be detailed.
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Anticoagulant function of  APC
PC is the central enzyme of  the natural anticoagulant pathway that helps to control 
thrombin formation. APC generated by the thrombin-TM complex is able to proteolyse 
the active coagulation factors V (FVa) and VIII (FVIIIa) (Figure 1A). Important 
cofactors in the inactivation of  FVa and FVIIIa are respectively protein S and factor 
V (FV). APC can inactivate FVa by proteolysis of  three different peptide bonds at 
positions R306, R506 and R679 (11–13). The cleavage at R506 is kinetically favoured, 
protein S-independent and yields a FVa intermediate with decreased factor X (FX)
a-cofactor activity (12). The slower cleavage at R306 is stimulated by protein S and 
completely inactivates FVa. The exact mechanism through which protein S appears 
to stimulate cleavage at R306 in FVa remains unclear. It has been proposed that upon 
binding of  protein S to APC the protease domain of  APC undergoes a rotational and/
or translational movement, thereby decreasing the distance of  APC’s active site to the 
membrane (14, 15). This hypothesis has been challenged, however, by the observation 
that both R306 and R506 appear to be present at ~80Å from the membrane, whereas 
only R306 cleavage appears to be dependent upon protein S. Also, mutagenesis studies 
of  FVa in a proposed APC binding site, for cleavage at R306, showed increased rates 
of  APC catalysed FVa inactivation, that are apparently independent of  the cleavage 
site:membrane distance (16), nor does protein S stimulate the binding of  APC to FVa 
(17). The cleavage at R679 plays a minor role in the inactivation of  FVa (12). APC 
targets both free FVa and the prothrombinase complex, with the latter inactivation 
being two orders of  magnitude slower (12, 18). APC-catalysed inactivation of  FVIIIa, 
at homologous positions in the FVIII A-domains at R336 and R562 and at a third 
cleavage site at R740, which can also be cleaved by thrombin (19, 20), is stimulated not 
only by protein S but also by FV, through an hitherto unknown mechanism (21). It was 
shown, however, that the presence of  the FV B-domain and an R506 cleavage site are 
required for the cofactor activity of  FV in the APC-catalysed inactivation of  FVIIIa 
(22, 23). It should be noted that in contrast to FVa, FVIIIa in solution is subject to 
rapid decay caused by dissociation of  the A2 domain from the rest of  the molecule. As 
a result, the majority of  FVIIIa activity (70–80%) is lost spontaneously (24). Remaining 
FVIIIa activity is then lost by APC-catalysed cleavage at R336. Thus, the greater part 
of  FVIIIa activity is not lost by proteolytic action of  APC but rather by spontaneous 
FVIIIa subunit dissociation. This observation is likewise illustrated by the apparently 
several fold lower affinity of  APC for FVIIIa, as compared to that of  FVa (17).
Resistance to APC, as observed in FVLeiden, a FV gene with a single missense mutation 
of  R506 to Q, is the most common genetically determined hypercoagulability disorder 
in Caucasians (25, 26). FVLeiden causes APC resistance through several mechanisms: 
(i) the absence of  the cleavage site at position R506 results in slow inactivation of  
FVaLeiden by cleavage at R306 only; (ii) the absence of  a proper binding site for APC, 
which includes residue R506, blocks the ability of  APC to directly inhibit thrombin 
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formation by dissociating the FXaFVaLeiden complex; and (iii) FVLeiden does not enhance 
APC-catalysed FVIIIa inactivation (27).
The anticoagulant PC pathway is vital to normal haemostasis. Reduced levels of  
circulating APC are an independent risk factor for both venous and arterial thrombosis. 
Individuals with heterogeneous PC deficiency have a significantly increased risk to 
develop thrombosis (28–31). Individuals with homozygous protein C deficiency may 
suffer from catastrophical and fatal complications like neonatal purpura fulminans 
and venous thrombosis already as neonates (32). Even in the presence of  aggressive 
anticoagulant therapy, homozygous PC deficiency can be life threatening (33–35).
Cytoprotective functions of  APC
The widely observed beneficial effects of  APC in animal models of  sepsis, pulmonary 
injury, stroke and wound healing (36–44) cannot be explained solely by APC’s 
anticoagulant effects. APC administration, and not anticoagulants like antithrombin 
III and TFPI (45, 46), has been successfully used to reduce mortality in severe sepsis 
patients (Prowess trial [47]). There is, however, controversy as to the general use of  
APC in the treatment of  severe sepsis and septic shock patients since a recent meta-
analysis did not confirm the overall beneficial effects of  APC on 28-day survival (48). 
Collectively these and other data have manifested the dual functions of  APC in both 
anticoagulation and cytoprotection. Protease activated receptor 1 (PAR-1) and EPCR 
were shown to be required for APC-dependent cytoprotective effects. PAR-1, a trans-
membrane protein receptor, which is activated upon limited proteolysis, is present 
on many cell types, including endothelial cells, epithelial cells, myocytes, fibroblasts, 
astrocytes and neurons (49, 50). Most of  these cell types also express EPCR (51–54). 
APC has cytoprotective effects in different cell types by anti-inflammatory, anti-apoptotic 
and endothelial barrier stabilising effects. These effects, rather than the anticoagulant 
activity of  APC, likely explain the protective effect of  APC administration in animal 
studies of  sepsis, lung injury, myocardial infarction and ischaemic stroke (37–39, 41–44, 
55–57). There are still uncertainties with regard to the exact roles that EPCR and PAR-
1 play in APC-induced cell signalling. Recently, the involvement of  other cell-receptors 
such as Tie2, S1P1, CD11b/CD18, ApoER2 (LRP8) and epidermal growth factor 
receptor in APC signalling was shown, thereby providing yet additional insights into 
the molecular mechanism that underlies the cell-protective properties of  APC (58–60).
APC-induced cytoprotection can be attributed to any of  or a combination of  a 
number of  cellular responses, including an altered inflammatory response, a modified 
anti-apoptotic response and/or an improved barrier function of  the endothelium. 
The different cytoprotective effects and molecular mechanisms identified so far are 
described in detail below and are illustrated in Figure 1B-D.
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Anti-inflammatory activities
The effects of  APC on endothelial cells and leukocytes are summarized in Figure 1B. 
APC modulates transcription of  genes involved in the major inflammatory pathways. 
In both endothelial cells and leukocytes, APC reduces via PAR-1 and EPCR gene 
expression levels and functional activity of  nuclear transcription factor κB (NFκB) 
(61). In leukocytes, APC leads via PAR-1, sEPCR, proteinase-3 (PR3) and CD11b/
CD18 to increased concentrations of  sphingosine kinase-1 (Sphk-1) and sphingosine 1 
phosphate (S1P), resulting in suppression of  pro-inflammatory activity (55, 59). Both 
inhibition of  NFκB and upregulation of  S1P result in inhibition of  cytokine signalling, 
down-regulation of  cell surface adhesion molecules and increased expression of  anti-
inflammatory genes like interleukin 10 (IL-10) (27, 55, 61).
Ultimately this results in reduced leukocyte transmigration through the endothelium 
and less tissue damage in the underlying tissue (55). Recent results from Kerschen et 
al. have shown that APC targets EPCR-positive CD8+ dendritic cells in mice, which 
results in a reduction of  mortality after induction of  endotoxaemia (62).
Anti-apoptotic activity
Apoptosis is an intrinsic program of  cell death that occurs in various physiological and 
pathological situations. It can be induced by both the death receptor (extrinsic) pathway 
and mitochondrial (intrinsic) pathway. Caspase-8 activation in the extrinsic pathway 
and release of  cytochrome c, apoptosis inducing factor (AIF) and pro-caspases in the 
intrinsic pathway finally lead to caspase-3 activation and apoptosis (55).
Figure 1C shows a summary of  the different anti-apoptotic effects of  APC on endothelial 
cells. APC can reduce apoptosis induced by hypoxia, t-PA and staurosporine in different 
types of  endothelial cells (61, 63, 64). In these experimental conditions, the presence 
of  APC resulted in decreased caspase-3 and –8 activation, reduced DNA degradation 
and p53 expression, as well as decreased nuclear translocation of  AIF, decreased 
translocation of  phosphatidyl serine to the outer cell membrane and normalisation of  
the Bax/Bcl-2 ratio (27, 55, 65). Via PAR-1 cleavage, APC induces phosphorylation of  
extracellular signal regulated protein kinases 1/2 and members of  the mitogen-activated 
protein kinase family (66), resulting in restraint of  the mitochondrial permeability 
transition pore, inhibition of  cytochrome C release into the cytoplasm and prevention 
of  apoptosis signalling (67).
Protection of  the endothelial barrier function
In healthy individuals, the intact endothelial layer forms the first natural physical barrier 
that protects underlying tissues from blood-borne pathogens by controlling passage 
of  molecules and migration of  leukocytes into and from the tissues. Excessive or 
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Figure 1: Humoral and cellular effects of APC
A) Anti-coagulation. Upon binding of  APC to either FVa or FVIIIa, APC ablates cofactor activity through 
competition with the respective serine proteases (FXa or FIXa, respectively). Subsequent proteolysis of  FVa 
and FVIIIa renders these cofactors inactive, resulting in irreversible attenuation of  thrombin formation 
and overall downregulation of  coagulation. Protein S and FV are important cofactors of  APC in this 
process. 
B) Anti-inflammation. PAR-1 and EPCR dependent signalling of  APC in endothelial cells and leukocytes 
inhibits NFκB / AP-1 signalling, resulting in an inhibition of  inflammatory mediator release and 
downregulated expression of  adhesion molecules. Binding of  APC to sEPCR, PR3 and CD11b/CD18 on 
leukocytes activates PAR-1, resulting in upregulation of  Sphk-1 and S1P. Subsequently binding of  S1P to 
its receptor S1P1 suppresses the pro-inflammatory activity of  leukocytes. These effects of  APC result in 
decreased leukocyte chemotaxis and lower infiltration of  leukocytes in the endothelium. 
C) Anti-apoptosis. Apoptosis can be initiated by binding of  TNFα or FasL to death receptors (TNFR1/
FasR) on the cell membrane of  endothelial cells (extrinsic pathway) or by DNA damage, hypoxia and 
oxidative stress that increase the permeability of  the mitochondrial outer membrane (intrinsic pathway). 
Activation of  both pathways results in activation of  caspases APC inhibits caspase activation, suppresses 
the expression of  pro-apoptotic genes (p53 + Bax) and upregulates the transcription of  anti-apoptotic 
genes (Bcl2). The suppression of  Bax and up-regulation of  Bcl2 leads to a normalization of  the Bax/Bcl-2 
ratio on the mitochondrial membrane and inhibition of  apoptosis. 
D) Endothelial barrier protection. APC protects the endothelial barrier function by induction of  SphK-1 
and up-regulation of  the bioactive lipid S1P. Binding of  S1P to S1P1, leads to improved cell survival and 
barrier protection via activation of  the PI 3-kinase/Akt pathway, upregulation of  both RAC-1 GTPases 
and Ang1 and downregulation of  Ang2. Ang1 leads via binding to Tie2 to further activation of  the PI 
3-kinase/Akt pathway and enhancement of  endothelial barrier integrity.
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prolonged increases in permeability of  the endothelial monolayer barrier, as seen in 
cases of  (chronic) inflammation, may lead to tissue oedema/swelling (68). The effects 
of  APC on endothelial barrier function are summarised in Figure 1D. APC improves 
the integrity of  the endothelial barrier by upregulation of  sphingosine kinase-1 (Sphk-
1), sphinghosine 1 phosphate (S1P), angiopoietin 1 (Ang1), tyrosine kinase with 
immunoglobulin-like and EGF-like domains 2 (Tie2) and tight junction protein zona 
occludens (69). APC also stimulates the migration of  smooth muscle cells (SMCs) into 
the endothelium. These SMCs form a sheath around the endothelium that decreases 
the permeability of  the membrane. For APC’s barrier stabilising effects, the presence 
of  the receptors EPCR, PAR-1, sphingosine 1 phosphate receptor 1 (S1P1) and Tie2 is 
required (69). The improved endothelial barrier limits the infiltration of  inflammatory 
cells through the endothelium into the subendothelial space (55, 61, 70).
Effect of mutations on the function of APC
The dissection of  anticoagulant and cytoprotective properties of  APC, as has been 
demonstrated through mutagenesis studies from several groups (17, 70–77), illustrates 
the different structure-function facets of  APC. Several variants have been designed 
and tested for their functional properties and it appears that specialised surface areas 
convey different properties to the APC molecule. Meanwhile, numerous natural 
variants of  protein C have been reported that cause functional defects of  the protein. 
In an attempt to provide a 3D properties map of  APC, we have collected available 
structure-function data of  APC and have placed these in the perspective of  the 3D 
structure of  the protease, in order to better understand the interactions of  APC with 
its many physiological binding partners. Since the naturally occurring type I deficiencies 
(decreased PC expression levels with normal specific activity) are of  less interest from 
a structure-function point of  view, we have restricted ourselves to type II deficiencies 
(normal PC expression levels with decreased specific activity). It is important to mention 
that many PC variants are tested for their respective expression levels, as well as for 
their amidolytic activities on chromogenic substrates and their activities in plasma or on 
macromolecular substrates. Measurement of  expression levels allows detection of  type 
I deficiencies and measurement of  amidolytic activities probes only the consistency of  
the active site. Thus, even though the enzymatic capacity of  APC as such is unaltered, 
changes in substrate recognition sites (exosites) or in cofactor or membrane binding 
sites may still result in an overall reduced biological activity of  an APC variant. Effects 
of  mutations in different regions of  protein C are described below and summarised 
in Table 1). In Figure 2, the human PC sequence is shown with important regions and 
residues indicated to help the reader follow the discussion of  different APC variants. 
Likewise, Figure 3 aids the reader in mapping each of  the mentioned variations/
mutations onto a 3D representation of  human APC.
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Figure 2: Human protein C amino acid sequence 
Indicated is the amino acid sequence for hPC from the UniProt database (identifier ID: 
P04070,PROC_HUMAN, ref.4). Domain boundaries are as defined in the UniProt database, 
Numbering below the sequence represent hat for the mature protein, numbering above the 
sequence indicates numbering according to the alternative chymotrypsin nomenclature 
equivalents. Active site residues are indicated by red stars. Boxes indicate the domain boundaries, 
with color coding as used in Figure 6: green for the Gla-domain, red for EGF-1 domain, orange 
for EGF-2 domain and blue for the catalytic, serine protease, domain. 
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Light chain: Gla-domain mutations
The N-terminal Gla-domain (residues 1–45) confers PC its membrane and EPCR 
binding capacity and contributes to the binding between APC and protein S. In general, 
Gla-domain containing proteins bind to phospholipid (PL) vesicles in at least two 
stages. First, two or three cation binding-sites in the Gla-domain are occupied, resulting 
in a conformational change of  the Gla-domain. Second, a group of  four or five divalent 
cation binding sites with a high specificity for Ca2+ become occupied, enabling binding 
of  the protein to acidic PL vesicles. A cluster of  hydrophobic side chains that extend 
away from the core of  the protein (F4, L5, and L8, see also Figure 4) was shown to 
be part of  a PL binding site (78–80). These side chains are flanked by H10, which was 
suggested to participate in the formation of  a pore in the protein that may be important 
for the formation of  a protein-PL ion pair in aqueous medium (81, 82).
In the presence of  calcium, seven Ca2+-ions occupy a channel through the Gla-domain 
of  APC. These Ca2+-ions are important for maintenance of  the overall structure of  the 
Gla-domain, for the anticoagulant function of  APC and the interaction with EPCR (83) 
(Figure 4). A crystal structure of  a complex between the Gla-domain of  PC and sEPCR 
has been determined (84). In this structure, PC binds to sEPCR via hydrogen bonds 
at Gla-residues 7, 25, 29 and via hydrophobic interactions at residues F4, E7 and L8 to 
EPCR (84). Notheworthy, these interactions are highly specific for the interaction of  
the hAPC Gla domain and EPCR, as it was shown that hAPC FX- and prothrombin 
(PT) Gla-domain chimeras do not exhibit any cytoprotection (85). 
Both natural (R9H) and engineered (F4Q, L5Q, L8Q, H10P) APC variants show reduced 
anticoagulant activities, although they have a normal Ca2+-dependent conformation of  
the Gla-domain (78–82, 86). It is likely that these mutants have either suboptimal PL 
binding or disorientated binding to the PL membrane which results in poor alignment 
of  the active sites towards the complementary cleavage sites of  FV/FVa and FVIII/
FVIIIa (78, 80). For variants L8Q and R9H, the reduced affinity for EPCR can contribute 
to the reduced anticoagulant activity (78, 80, 86).
To investigate which Gla-residues are essential for the anticoagulant activity of  APC, 
different mutants were expressed wherein the nine E residues of  the Gla-domain of  
APC were substituted (83). Kinetic parameters for chromogenic substrate (S-2366) 
conversion were normal for all variants. Single mutations of  Gla-residues at positions 
6, 7, 16, 20, 26 or 29 resulted in APC variants with less than 10% of  the anticoagulant 
activity of  wt-APC in an APTT based assay. E25D-APC expresses ~20% of  wt-APC 
anticoagulant activity and Gla-residues 14 and 19 do not contribute to anticoagulant 
function. Furthermore, E16D-PC and E26K-PC were not activated by the thrombin-
TM complex on endothelial cells and showed no binding to sEPCR (86). Collectively, 
Ca2+ interactions are essential for the anticoagulant functions of  APC and are influenced 
by mutations in different regions of  the Gla-domain (83, 87, 88).
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Figure 3: Mapping of APC mutations on its overall 3D structure 
The mosaic protein architecture of  APC is shown, with the left representation being 180 degrees rotated 
along a vertical Y-axis . The different domains are shown in their ribbon structure. From N terminus to 
C-terminus are shown: green, the Gladomain, residues 1-37, residue numbers refer to the mature protein) 
including a helical aromatic segment, residues 38-45; red, EGF-1 and EGF-2 domains, residues 46-92 
and 93-136 respectively; yellow, a linking peptide (residues 137-157); blue, the trypsin-like serine protease 
domain, residues 170-419 (16-254). Side chains are shown for those residues that are mentioned in the text 
to indicate their approximate position in the protein.
These aforementioned results are in agreement with the analysis of  PC that was isolated 
from type II PC deficient patients. Both the E7D (89, 90) and E20A/V34M (Protein 
C Vermont, [91]) are associated with thrombotic complications, despite the fact that 
carriers of  these mutations have normal PC antigen levels and APC amidolytic activities.
Site directed mutagenesis of  R15 shows that this residue is critical for the Ca2+-
dependent conformation of  the Gla-domain required for PL binding and hence for 
APC’s anticoagulant activity (92). In agreement with this is the fact that individuals who 
carry a mutation at R15 (R15W or R15G, with the latter also known as PC Yonago) 
have an increased thrombotic tendency (93, 94). Mutation of  hexapeptide disulfide loop 
residue C22 to serine, results in a complete loss of  anticoagulant activity in an APTT 
based clotting assay and less than 5% of  the activity of  wt-APC toward inactivation of  
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Figure 4: 3D structure of the APC-Gla-domain 
3D structural model of  the human APC-Gla-domain (residues 1–45), represented as a ribbon diagram 
with helix and loop regions visible of  the published crystal structure for the APC Gla-domain (residues 
1–33) (84) onto which the helical aromatic segment at the C terminus of  the domain is manually grafted 
(coordinates for residues 34–45 were kindly provided by Dr. Villoutreix, University of  Paris 7, France) 
according to the overall orientation from the crystal structure for the bovine prothrombin Gla-domain 
(123). The side chains of  Gla-residues are shown in red with calcium ions represented as pink spheres. 
The amino acid side chains of  residues F4, L5, L8 and H10, involved in formation of  a PL binding site 
are shown in yellow. In orange the hexapeptide disulphide loop is shown which connects residues C17 
and C22. The C-terminus of  this fragment, which connects to the helical segment and EGF-1 domain, is 
indicated. For orientation, Gla residue numbers are given.
FVIIIa (87, 88). Residues R15, C22 and Gla-residues 6, 7, 16, 20, 25, 26 and 29 are thus 
absolutely required for APC’s anticoagulant function.
The C-terminus of  the Gla-domain (residues 25–45) and particularly D35, D36, L38 
and A39 were shown to interact with protein S (79). Each of  these four residues was 
individually replaced by the corresponding PT amino acid residue to investigate their 
functional importance (95). The amidolytic activities and anticoagulant properties of  
these mutants were not severely affected in the presence of  protein S, except for the 
L38D mutant which exhibited 20-fold impaired anticoagulant activity as compared to 
wt-APC in plasma or in protein S dependent assays using purified proteins. Notably, in 
the absence of  protein S, L38D-APC was indistinguishable from wt-APC. L38D-APC 
binds EPCR with equal binding affinity as wt-APC. All mutants tested in this study (95) 
inhibited apoptosis to a similar degree and had similar barrier-protective capacities as 
wt-APC in the absence of  protein S.
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Light chain: Mutations in EGF domains and linking peptide
The EGF domains of  APC have been described to be involved in the interaction of  
APC with Ca2+ and protein S (96–98). In D71E-APC, in which the β-hydroxyaspartic 
acid was replaced by glutamate, a Ca2+-dependent epitope for the interaction with 
protein S in the EGF-1 domain was lost, resulting in only 10% of  the anticoagulant 
activity of  wt-APC (97).
The so-called “linking peptide” (residues 137–157) precedes the activation peptide, which 
is excised upon PC activation. A special position here is taken by E149. Mutagenesis 
of  this residue into alanine resulted in a three-fold increased anticoagulant activity in 
an APTT-based clotting assay (75). In an amidolytic assay, probing the conversion of  
a small chromogenic substrate, and in the absence of  protein S, no difference between 
E149A-APC and wt-APC was observed. In thrombin generation and FVa inactivation 
studies, E149A-APC required lower concentrations of  protein S than wt-APC to achieve 
half-maximal effects. Taken together, E149A-APC expresses increased anticoagulant 
activity in the presence of  protein S, likely through enhanced affinity for protein S. 
The improved anticoagulant effect was verified in an in vivo murine thrombosis model 
(75). Remarkably, the cytoprotective effects of  E149A-APC were severely diminished, 
despite a normal cleavage of  PAR-1 and normal binding to EPCR (75). E149A-APC 
expressed only 6% of  the anti-apoptotic activity of  wt-APC in a staurosporine-induced 
apoptosis model in endothelial cells and was unable to down-regulate IL-6 release in 
lipopolysaccharide (LPS) treated U937 monocytes (75). The molecular mechanism 
which reconciles the loss of  cytoprotective effects, while amidolytic activities and PAR-
1 and EPCR-binding are normal, is at present not available.
Heavy chain: Mutations in the activation peptide and C terminus of  the catalytic domain
Since the activation peptide (residues 158–169) is excised during PC activation, 
mutagenesis in this region is expected to affect PC activation. Three variants have been 
studied: D167F/D172G-PC, P168V-PC and R169W-PC (96, 99, 100). At saturating 
Ca2+ concentrations, the activation rates of  D167F/D172G and P168V mutants and 
wt-PC by the thrombin-TM complex were comparable, but the mutants required four-
fold higher Ca2+ concentrations than wt-APC to achieve half-maximal activation rates. 
When only thrombin was present, Ca2+ was not able to influence the activation of  
the D167F/D172G and P168V mutants, though Ca2+ effectively inhibits activation of  
wt-PC by thrombin (96). R169W-PC can not be activated by thrombin, but can be 
efficiently activated by chymotrypsin (100). Residues in close proximity of  R169 appear 
to influence Ca2+ affinity and/or the Ca2+-dependent conformation of  PC through 
either direct or indirect mechanisms.
Probing this same region, residues K174, R177 and R178 were mutated to glutamic 
acid. The activation rates of  the mutants by thrombin were 12-fold faster than that 
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observed for wt-PC in the presence of  Ca2+, and unchanged in the absence of  Ca2+. 
Addition of  TM did not stimulate activation of  the PC variants, suggesting that residues 
174, 177 and 178 are involved in PC activation by the thrombin-TM complex (101).
Heavy chain: catalytic domain mutations
The well-studied catalytic domain of  APC, residues 170–419 (16–254: chymotrypsin 
numbering is given in parentheses from hereon), contains the catalytic triad, which 
is responsible for the proteolysis of  APC-substrates. Moreover this domain contains 
substrate binding regions, to which APC substrates must bind prior to their cleavage. 
Mutations in this domain are therefore likely to directly influence the catalytic efficiency 
and the binding of  substrates to the protease. The 3D structure of  the catalytic domain 
and its various loop regions is shown in Figure 5.
Mutations in 191-loop (37-loop), Ca2+-binding loop and autolysis loop
For the anticoagulant activity of  APC, especially the cleavage at R506 in FVa is 
required (73, 102). Protein-protein docking- and mutagenesis studies have revealed 
that multiple electrostatic contacts between APC and the R506 cleavage site in FVa 
mediate the efficient contact between FVa and APC (16, 102). The positively charged 
area in the catalytic domain of  APC includes the 191-loop, alternatively described as 
37-loop (residues 190–193 (36–39)), the Ca2+-binding loop (residues 225–235 (70–80)) 
and the autolysis loop (residues 302–317 (143–154)) (3, 103). The importance of  the 
electrostatic interactions made by these surface loops was shown by several mutagenesis 
studies.
Three 191-loop (37-loop) and/or Ca2+-binding loop mutants were constructed: 2R2A-
APC (RR229/230AA (RR74–75AA)), 3K3A-APC (KKK191–193AAA (KKK37–
39AAA)) and 5A-APC (combination of  both mutants) (73, 74, 102, 104–106). In an 
APTT-based assay the anticoagulant activities of  2R2A-APC, 3K3A-APC and 5A-APC 
were 14%, 5% and <3%, respectively, of  that of  wt-APC, with amidolytic activities 
being unaffected. These effects can largely be explained by reduced cleavage at R506 
in FVa (73, 74, 102), while these residues are also important for FVIIIa inactivation at 
both R336 and R562 in FVIIIa (107). In vivo, 5A-APC lacked antithrombotic activity in 
an acute arterial thrombosis model (75). Thus these engineered APC variants, and in 
particular the 5A-mutant, show reduced anticoagulant activity while the in vitro and in 
vivo cytoprotective effects were undistinguishable from wt-APC, with normal affinity 
for EPCR and PAR-1 (72–75).
The 191-loop (37-loop) is furthermore established as a heparin-binding loop (104, 
105). Mutation of  residues KKK191–193 (KKK37–39) results in reduced heparin 
stimulated inhibition by PCI. Activation and Ca2+-dependent inhibition of  191-loop 
(37-loop) variants by thrombin was identical to wt-PC. However activation of  these PC 
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variants by the thrombin-TM-complex was severely impaired (105). This indicates that 
the positively charged residues KKK191–193 (KKK37–39) contribute to PC activation 
by the thrombin-TM complex, to the anticoagulant function of  APC and are part of  a 
heparin-binding site. In line with this, a K193Q (K39Q) mutation has been described in 
a type II deficient patient with a history of  thrombo-embolic disease (108).
Mutation of  R229 to glutamine (R74Q) has been described in a family with type II PC 
deficiency, associated with thrombosis. The affected individuals have normal PC antigen 
and amidolytic activity levels, but ~50% decreased anticoagulant activity. These data, 
together with those from structure-function studies of  recombinant R229Q (R74Q) 
PC, indicate the importance of  R229 (R74) for anticoagulation and activation of  PC by 
the thrombin-TM complex (89, 90, 109–111).
The PC autolysis loop (residues 302–317 (143–154)) is involved in stabilisation of  the 
activation peptide in its Ca2+-dependent inhibitory conformation, leading to enhanced 
activation by the thrombin-TM-complex and decreased activation by thrombin (112, 
113). The hPC autolysis loop is five residues longer than the autolysis loops of  other 
vitamin K-dependent proteases and four residues longer than the homologous loop in 
bPC. Replacement of  the autolysis loop in hAPC by the shorter bovine form resulted 
in a four-fold increased catalytic activity. Replacement of  the hAPC autolysis loop by 
that of  hFXa resulted in higher Ca2+-affinity and increased PC activation by thrombin 
both in the absence (5-fold) and presence (2.5-fold) of  TM. Furthermore, from the 
reduced half-life of  these PC variants in plasma it was concluded that the autolysis loop 
is involved in inhibition by serpins. In both chimeras, substitution of  the autolysis loop 
results in increased inactivation rates of  FVa and FVIIIa, while conflicting results were 
reported for interaction with protein S (112, 113). Studies wherein individual residues 
of  the autolysis loop were mutated (114, 115) showed that APC residues R306 (R147), 
K308 (K149), K311 (K149c), R312 (R149d) and R314 (R151) are important for FVa 
cleavage at R506 and residues R306 (R147), K311 (K149c) and R314 (R151) are essential 
for FVIIIa inactivation by APC.
Mutations in 214-loop (60-loop)
bAPC is, in contrast to its human counterpart, nearly completely resistant to inactivation 
by AAT. Homology modelling and site- directed mutagenesis studies of  the serine 
protease domains of  bAPC and hAPC identified the 214-loop (residues 214–220) (60-
loop (residues 60–65)) as being probably involved in interaction with AAT, heparin 
and PCI (116). Three PC mutants, E215S/S216R (E60aS/S61R), S336E (S173E) and 
K217N/K218D (K62N-K63D) were generated (104, 116, 117). Mutant APC amidolytic 
activities were unaffected, except for S336E (S173E) which had a reduced Km, which 
suggests that a glutamate residue at position 336 (173) improves the fit of  the substrate 
in the catalytic cleft (104, 116, 117). K217N/K218D (K62N-K63D)-APC had slightly 
lower anticoagulant activity compared to wt-APC and showed undetectable binding 
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Figure 5: 3D structure of the APC serine protease domain 
The serine protease domain is represented as a ribbon diagram with helix and loop regions visible in dark 
blue. Relevant loops and residue side chains have been indicated. Yellow: H211 (H57), D257 (D102), S360 
(S195) active site residues; Red: K191 (K37), K192 (K38), K193 (K39) in the 191-loop (37-loop); Orange: 
R229 (R74), R230 (R75) in the Ca2+-binding loop; Light blue, E309 (E149A) in the autolysis loop; Wheat: 
E330 (E167) and E333 (E170) in helix 325–333 (162–170); Purple: E215 (E60a), S216 (S61), K217 (K62), 
K218 (K63) in the 214-loop (60-loop); Green: R222 (R67) and D237 (D82), both residues after mutation 
to C are involved in the formation of  an engineered disulphide bridge; Gray: E357 (E192). The position of  
the Na+-binding loop, at V221-E225 (V66-E70), is indicated.
to heparin (104, 117). Both E215S/S216R (E60aS/S61R)-APC and S336E (S173E)-
APC are resistant to AAT (116). E215S/S216R (E60aS/S61R)-APC was 2–3 times 
more efficiently inhibited by PCI than wt-APC in the absence as well as the presence 
of  heparin (116). Inhibition of  K217N/K218D (K62N-K63D)-APC by PCI was 
3–5 times more efficient in the absence of  heparin and two times less efficient in the 
presence of  heparin. These results indicate that residues E215 (E60a), S216 (S61) and 
S336 (S173) influence the interaction of  APC with heparin and/or AAT and residues 
K217 (K62) and K218 (K63) are important for heparin stimulation of  APC inhibition 
by PCI (104, 116, 117).
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Active site mutants
A much studied APC variant (17, 71, 73, 118) is S360A (S195A)-APC, wherein the 
active site serine S360 (S195) is mutated to alanine. Consequently, this APC is unable 
to proteolyse substrates (71). Remarkably, in plasma-based assays, S360A (S195A)-APC 
still has 15–25% of  the anticoagulant activity of  wt-APC. S360A (S195A)-APC had 
a dose-dependent effect on the activity of  the purified prothrombinase complex (17, 
119), in particular at low prothrombin and FXa concentrations, since the Kd’s for the 
interactions between FVaFXa and FVaS360A (S195A)-APC are similar (17). Inhibition 
of  FVa by S360A (S195A)-APC is independent of  protein S. S360A (S195A)-APC is 
able to inhibit FVIIIa, but 1–2 orders of  magnitude higher concentrations were required 
compared to FVa inactivation, which illustrates that APC may be of  lesser importance 
for the inactivation of  FVIII activity. Remarkably, S360A (S195A)-APC did not show 
any anticoagulant activity in a FVLeiden plasma (17, 71). It was shown that the affinity 
of  S360A (S195A)-APC for FVLeiden is 150-fold lower than the affinity for wt-FV and 
that the availability of  an R506 residue in FVa is critical for the non-enzymatic binding 
interaction of  FVa and S360A (S195A)-APC (17, 71). S360A (S195A)-APC is devoid 
of  cytoprotective effects (70, 73) and can not cleave PAR-1 (118). S360A (S195A)-APC 
does not form complexes with serpins and therefore has a longer half-life in plasma 
compared to wt-APC (71). Collectively these data indicate that for the expression of  
anticoagulant activity, binding of  APC, under certain conditions, is sufficient, however 
a functional active site is required for proteolysis of  APC substrates such as coagulation 
cofactors, inhibitors and PAR-receptors.
Other catalytic domain mutants
An interesting engineered APC variant is C222-C237 (C67-C82)-APC in which a 
disulfide bond was introduced between two antiparallel β-structures consisting of  
residues that form the Ca2+-binding loop of  APC (70, 120). Binding of  Ca2+ to this 
loop results in overall stabilisation of  the catalytic domain. As a result, PC changes to 
a thrombin-(hyper) activatable conformation in which recognition by the thrombin-
TM complex and the subsequent activation of  PC are enhanced (70, 120). Due to 
the engineered disulfide bond, C222-C237 (C67-C82)-PC is trapped in the thrombin-
(hyper) activatable conformation, even in the absence of  Ca2+, resulting in a 80-fold 
increased activation rate in the absence of  Ca2+ and TM. The amidolytic activity of  the 
mutant and its inactivation by PCI were unaffected (120). C222-C237 (C67-C82)-APC 
has strongly reduced anticoagulant activity in both purified and plasma-based clotting 
assays (70). Two-fold higher concentrations of  C222-C237 (C67-C82)-APC are required 
to reach cytoprotection that is comparable to wt-PC, likely due to lower EPCR affinity. 
These results show that occupation of  the Ca2+-binding loop is not necessary for the 
expression of  cellular activities. It is not known why the introduction of  a disulfide 
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bond abolishes the anticoagulant activity of  APC, but a changed conformation of  the 
APC catalytic domain may likely impair the interaction of  C222-C237 (C67-C82)-APC 
with FVa and FVIIIa (70).
Two glutamic acid residues at position 330 (167) and 333 (170), located in helix 325–
333 (helix 162–170) are not conserved in homologous regions of  other vitamin-K-
dependent proteins. Replacement of  these residues by alanine yielded variants that were 
indistinguishable from wt-APC except for their cytoprotective properties (118). E330A 
(E167A)-APC and E333A (E170A)-APC show normal interactions with EPCR, but 
display dramatically impaired cleavage of  PAR-1. Thus, both E330 (E167) and E333 
(E170) are required for the interaction of  APC with PAR-1 and mutation of  these 
residues results in a loss of  cytoprotective activity (118).
To investigate the role of  N-linked glycosylation on APC functions, four recombinant PC 
variants in which the asparagines at 97, 248 (93), 313 (150) and 329 (166) were mutated 
to glutamine, were generated (5, 121). Elimination of  the latter three glycosylation sites 
increased activation by the thrombin-TM complex and improved anticoagulant activity 
in both a modified APTT assay and in a thrombin generation assay (5, 121). Notably, 
the N329Q (N166Q) mutation influenced the cytoprotective function of  APC. In an 
endothelial barrier permeability assay, N329Q (N166Q)-APC was up to six-fold more 
efficient than wt-APC and in staurosporine-induced endothelial cell apoptosis, N329Q 
(N166Q)-APC completely inhibited apoptosis at a 30-fold lower concentration than 
wt APC (121). Possibly the absence of  a N-linked glycan chain at N329 enhances the 
access of  residues E330 and E333 to PAR-1 and EPCR-dependent PAR-1 activation by 
APC is up-regulated, resulting in increased cytoprotection (121).
E357 (E192) is involved in binding of  macromolecular substrates. Engineered E357Q 
(E192Q)-APC showed two- to three-fold improved FVa inactivation, but slightly 
reduced anticoagulant activity in plasma compared to wt-APC, likely due to an observed 
280-fold faster inhibition by AAT (122). In contrast to wt-APC, this variant is effectively 
inactivated by pancreatic trypsin inhibitor, TFPI and AAT in both the presence and 
absence of  heparin. These findings hint at an evolved function of  E357 (E192) in order 
to prevent fast inhibition by serpins, at the cost of  a reduced FVa inactivation (122).
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Conclusion
APC is a protease with both anticoagulant and cytoprotective functions. Several areas 
on the surface of  (A)PC are involved in the many interactions between (A)PC and its 
ligands (Figure 6). Mutagenesis studies proved the importance of  a number of  residues 
in the Gla-domain for the anticoagulant function of  PC. The correct Ca2+-dependent 
conformation of  this domain is essential for its binding to PL membranes and EPCR. 
Several studies have been performed to study the mechanism of  PL binding for Gla-
domains in general and for PC in particular. Detailed structure-function data have 
provided a rational basis for protein engineering of  PC, which has resulted in variants of  
PC with improved membrane binding, which may prove effective in the pharmacological 
use of  PC (76, 77, 86). Residues in 191-loop (37-loop) the Ca2+-binding loop and the 
autolysis loop of  the protease domain are important for electrostatic interactions 
between APC and FVa, the main physiological APC substrate in coagulation. Residues 
interacting with protein S are situated in the helical aromatic segment (residue 38), 
EGF domain (residue 71), linking peptide (residue 149) and autolysis loop. For the PC 
activation by thrombin and the thrombin-TM-complex, residues in close proximity to 
residue 169 are important, as well as residues in the Gla- domain (residue 16 and 26), 
191-loop (37-loop), 214-loop (60-loop), the Ca2+-binding loop and the autolysis loop. 
The interaction of  PC with heparin, PCI and AAT is mediated by residues in 191-loop 
(37-loop), 214-loop (60-loop) and residue 336 (173). The autolysis loop and residues 357 
(192) and 360 (195) are important for the interaction of  PC with serpins. Mutagenesis 
studies have indicated that the more recently discovered cytoprotective functions of  
APC can be linked to residues 149, 329 (166), 330 (167), 333 (170) and 360 (195), which 
are essential for cytoprotection. The effects of  a number of  other APC variants, which 
have been characterised for their anticoagulant properties, have not been investigated 
so far in the context of  their cytoprotective properties and this research is currently 
ongoing. Considering the interest from both the academia and the pharmaceutical 
industry in PC, it is desirable and likely that a completed structure- function description 
of  the cytoprotective properties of  APC will become available in the next years. This 
will aid in the engineering of  a yet safer variant of  APC devoid of  increased bleeding 
risks, for use in cell-protection in a number of  relevant clinical conditions of  which 
severe sepsis appears the most prominent.
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Figure 6: Mapping of APC interactions on its overall 3D structure 
The mosaic protein architecture of  APC is shown. The different domains are shown in their 
ribbon structure with the Vanderwaals protein surface overlaid as a mesh representation to better 
illustrate the volume and shape of  the protease. From N-terminus to C-terminus are shown: 
green, the Gla-domain, residues 1–37, residue numbers refer to the mature protein) including a 
helical aromatic segment, residues 38–45; red, EGF-1 and EGF-2 domains, residues 46–92 and 
93–136 respectively; yellow, a linking peptide (residues 137–157); blue, the trypsin-like serine 
protease domain, residues 170–419 (16–254). Indicated are interactions in the exosites and active 
site. Exosite regions have been described that facilitate the interactions between APC and FV(a)/
FVIII(a), thrombin-TM complex, PCI, heparin, PAR-1, protein S, EPCR and PL. Likewise, the 
interaction of  the APC active site with APC substrates is pharmacological pharmacological use 
of  PC (76, 77, 86). Residues in 191-loop (37-loop) the Ca2+-binding loop necessary for proteolysis. The 
activation peptide, residues 158–169, is not visible after its removal due to activation of  PC, 
interactions to this region (as with thrombin or the thrombin-TM complex) are not shown.
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Abstract
Introduction: Activated protein C (APC) is the central enzyme of  the anticoagulant 
protein C pathway. Low concentrations of  APC circulate in plasma and are believed to 
contribute to the maintenance of  anormal haemostatic balance.
Materials and Methods: We have used a structure-based virtual screening approach to 
discover small drug-like molecules that inhibit the interaction between APC and its 
substrate FVa through inhibition of  a predominant APC exosite,known to be involved 
in FVa substrate binding. We have combined in silico selection with functional screening 
and direct binding analysis to identify novel molecules and to ascertain and characterize 
the inhibition of  the interaction between APC and FVa.
Results: We have identified a number of  novel molecules that bind to APC and protein C 
with Kd values in the range of  10-3–10-5 M. Inhibition by these molecules is incomplete, 
which most likely reflects the extended surface that is involved in the interaction between 
APC and its substrates. Direct binding of  hit molecules to variant APC molecules 
that were mutated in the targeted binding site revealed that several of  the molecules 
presented a 100–500 fold lower affinity for the variant molecule, suggesting that these 
molecules indeed bind the exosite of  APC.
Conclusions: The protein-protein interaction inhibitors discovered here, could function 
as starting molecules for further development of  small molecules with anti-APC 
properties. Such molecules may be of  clinical interest, in particular in individuals where 
thrombin formation is compromised and the haemostatic balance is tipped towards 
bleeding tendencies, such as in haemophilia A.
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Introduction
Activated protein C (APC) is the central protease of  the anticoagulant protein C 
pathway and APC, together with its cofactor, protein S, is of  vital importance to the 
regulation of  the procoagulant activities of  the activated cofactor proteins factor VIIIa 
and factor Va (1). Failure to express the anticoagulant functions of  APC, such as in 
protein C deficiency, protein S deficiency or in carriership of  the FVLeiden mutation is 
associated with a life-long enhancement of  the risk of  thromboembolic disease (2, 3). 
The severity of  such conditions is most dramatically exemplified in patients who are 
homozygously deficient of  protein C. In these individuals life-threatening thromboses 
of  the microvasculature occur already in the neonatal phase, a clinical disease state 
named ‘purpura fulminans’.
APC is the activated form of  protein C, a serine protease zymogen that circulates 
in human blood at an average concentration of  70 nM (4) and it is estimated that 
picomolar amounts of  APC circulate in plasma, in levels proportional to the protein C 
levels (5). Protein C is a vitamin-K dependent protein which has a mosaic multi-domain 
structure in which a N-terminal γ-carboxyglutamic acid (Gla)-domain, is followed by 
two epidermal growth factor (EGF)-like domains, a linking peptide, a small activation 
peptide and a trypsin-like serine protease domain in which the active site triad (residues 
D257, H211 and S360, protein sequence numbering system according to (6)) are present 
(4, 6). Protein C is activated by the removal of  a 12-amino acid activation peptide, upon 
which the active serine protease APC is formed. APC then is able to inactivate the 
coagulation cofactors FVIIIa and FVa through limited proteolysis of  these cofactors, 
which results in a loss of  cofactor activity (7, 8), a process which is essential for the 
maintenance of  a normal haemostatic balance. More recently, it was shown that APC 
has important cellular functions and acts as a cytoprotective protein (9, 10).
The most common, genetically determined risk factor for increased in vivo generation 
of  thrombin and consequently thrombosis, is APC resistance, which is caused in 95% 
of  cases by a mutation in the FV gene, giving rise to FVLeiden, which harbors a R506Q 
mutation at a predominant APC cleavage site in FV. Due to this mutation, FVaLeiden 
is down-regulated less efficiently than normal FVa (11, 12). Moreover, FVLeiden has a 
reduced APC cofactor activity in the proteolytic down-regulation of  FVIIIa (13, 14). 
Remarkably, in the case of  coinheritance of  FVIII-, FIX- or FVII-deficiency and APC 
resistance, the phenotype of  doubly affected carriers is considerably milder than that 
of  factor deficient patients who are not APC resistant. In vitro experiments have verified 
that in case of  e.g. combined FVIII deficiency and FVLeiden, an increased generation 
of  thrombin is observed in the presence of  APC. Thus, the increased procoagulant 
tendency, due to reduced bioactivity of  APC results in an overall beneficial effect in these 
patients (15–20). These in vitro and in vivo observations suggest that a reduced function/
activity of  the protein C pathway is associated with a relative shift in the haemostatic 
balance towards a more procoagulant state. In this respect, APC is an attractive target 
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for inhibition to provide support of  in vivo thrombin generation, as has been put forward 
by Butenas and colleagues (16) and which was further elaborated on by De Nanteuil and 
coworkers (21). The latter identified an APC inhibitor with an IC50 of  820 nM, which 
showed reasonably good specificity for APC. The latter inhibitor however contained 
a hydrophilic benzamidine moiety which may raise hepatotoxicity issues. Both these 
studies (16, 21),used peptidic or peptide-like compounds for inhibition of  APC and 
were aimed at inhibition of  the proteolytic activity of  APC.
A relatively extensive amount of  structure function information is available for FV, 
FVIII and APC, and amino acid residues have been identified which are of  importance 
to the interaction between APC and its substrates in the anticoagulant response (for a 
recent review see (1)). Given the importance of  APC for cell viability, we decided to 
specifically target the exosites important for the anticoagulant functions of  APC, and 
in particular those that govern the formation of  a productive complex between APC 
and the cleavage sites at Arg506 and Arg306 in FVa, which are known to be of  lesser 
importance for the cellular APC functions, so as not to interfere with the cytoprotective 
properties of  APC. Thus, the current work was undertaken toinvestigate in model 
systems the possibility to pharmacologically induce acquired APC resistance in patients 
who are at risk for bleeding with small molecules. To provide such a proof-of-concept, 
we aimed at the discovery of  inhibitors of  protein-protein interaction (iPPI) through 
a structure-based virtual ligand screening approach. Our hypothesis is that specific 
inhibition of  the substrate-binding exosites in circulating APC, will result in the relative 
enhancement of  circulating levels of  cofactor proteins FV and FVIII without affecting 
the cytoprotective properties of  APC. We hypothesize that these iPPI’s could, after 
having been optimized, (partly) relieve the burden of  the existing deficiency and/or 
reduce the intensity of  protein-replacement therapy needed to maintain a haemostatic 
balance.
Materials and Methods
Proteins
Human FV from plasma of  a normal individual was prepared as described (7). 
FXa, a-thrombin, and prothrombin were purchased from Kordia Lab Supplies, The 
Netherlands. All coagulation factors were of  human origin, unless otherwise stated. 
The anti-human protein C antibodies 0370 and P0374 were from Dako (Denmark) and 
the APC inhibitory polyclonal antibody used was from Nordic Immunology (Tilburg, 
The Netherlands). Phospholipid vesicles were prepared as described (22). Synthetic 
lipids, 1,2 dioleoyl-sn-glycero-3-phosphoserine (DOPS), 1,2 dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1,2 dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) 
were obtained from Avanti Polar Lipids (Alabaster, Alabama, USA). Phospholipid 
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vesicles were prepared as described previously (23). The chromogenic substrates H-D-
Phe-Pip-Arg-p-nitroanilide (S-2238) and pyroGlu-Pro-Arg- p-nitroanilide (S2366) were 
obtained from Chromogenix (Milan, Italy). Ovalbumin was purchased from Sigma (St 
Louis, USA). Small chemical compounds were purchased from Chembridge (La Jolla, 
USA). DMSO (99.9% pure) was from Sigma, USA. Corn trypsin inhibitor (CTI) was 
from Hematologic Technologies, Essex Junction VT, USA and tissue factor (TF) was 
from Dade-Behring. 
Expression and Purification of  Recombinant Human Protein C
Two recombinant human protein C mutants, Y302A/F316A (YFAA variant) and 
K191A/K192A/K193A/R229A/R230A (5A variant) were produced via PCR-based 
site-directed mutagenesis of  the eukaryotic expression vector pRC/RSV (Invitrogen), 
expressed in HEK293 cells (CRL-1573ATCC), purified and characterized essentially as 
described earlier (24, 25). In order to produce the 5A variant, we first prepared a K191A/
K192A/K193A (3A variant) and a R229A/R230A (2A variant) and recombined the 
mutated DNA fragments into 1 expression vector containing all five desired missense 
mutations. We intended to similarly express a fourth mutant, L194A/L228A, however 
we did not succeed in the expression of  this variant since it could be shown that it was 
not secreted from the HEK293 cells and was degraded intracellularly (not shown). The 
purity and integrity of  the protein C preps were evaluated by SDS-PAGE. Protein C 
concentrations were quantified by measurement of  absorbance at 280 nm using an 
absorption coefficient of  14.5 (280 nm, 1%, 1 cm). Protein C was further quantified 
using a protein C ELISA, employing the anti-human protein C polyclonal antibody 
Dako 0370 (Dako, Denmark) as a catcher antibody and the horseradish peroxidase-
conjugated anti-human-protein C polyclonal DAKO P0374, as a detecting antibody. 
Dilutions of  normal pooled plasma were used to calibrate the assay, assuming that 
plasma contains 64.5 nM protein C (26).
Activation of  Protein C and Catalytic Activity against Small Substrates
Protein C variants were activated with bovine thrombin, and the thrombin was removed 
by ion exchange chromatography, as previously described (27). Complete removal of  
thrombin was ascertained by the measured absence of  a difference in amidolytic activity 
between measurement with S2238 of  the APC preparation, in the presence and absence 
of  hirudin. APC concentrations were determined from the absorbance at 280 nm and 
by the above-described protein C ELISA. 
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Druggable Pocket Definition 
The detection and the druggabilityofthe binding pockets at the surface of  human APC 
were assessed using the web server DoGSiteScorer (28),FTSite (29) and MetaPocket 
(30). The APC structure used for the assessment has as PDB code 1AUT.pdb.
Virtual Screening
The 50,000 compounds of  the ChemBridge ExpressPick Diversity set (Oct2007) 
were prepared as 3D single conformations using Frog (31) and then docked in the 
contiguous pockets present on the P’side of  the catalytic site of  APC, toward the area 
involved in FVa/FVIIIa contact sites using Surflex 2.1 (32). The logprocess command 
of  Surflex 2.1 was then used to rescore the docked poses to weigh the polar and crash 
contributions in the final docking scores using respectively a threshold of  1 for polar 
interaction and −2 for crash tolerances. A ranking was made based on this score, and the 
top 2000 compounds were then manually inspected. Among these 2000 compounds a 
list of  624 compounds was selected for experimental testing.
Inhibition of  APC activity in Plasma
To analyze that in its plasma environment APC inhibition contributes to overall FVa 
stability in plasma, and that this inhibition can enhance the lifetime of  FVa and hence 
of  thrombin formation, we performed an in vitro thrombin generation experiment in 
which we measured generation of  FVa and of  thrombin in plasma simultaneously. 
To this end, normal pooled plasma was triggered with 12 pM of  relipidated tissue 
factor (TF) and thrombin generation and FVa generation were followed in time by 
sampling from the plasma mixture into 20 mM Tris pH7.9, 150 mM NaCl, 20 mM 
EDTA (stopbuffer). Diluted samples in stopbuffer were next assayed for the presence 
of  thrombin using the chromogenic substrate S2238 (Chromogenix) as described earlier 
(23). Simultaneously, samples were assayed for the presence of  FVa activity as described 
before (7). Triggering of  coagulation in plasma was performed in the presence or 
absence of  an APC inhibitory polyclonal antibody (goat-anti-human-APC, GAHu/pC, 
Nordic Immunology, Tilburg, The Netherlands).
Functional Screening of  Small Molecules
Activity of  compounds was initially screened in mixes of  4 different compounds at 
a concentration of  125 μM each (final concentration). Upon positive test outcome 
the mixture was deconvoluted and the individual compounds were tested. The assay 
was carried out generally as described before (33): FV from plasma was diluted 1800-
fold in 25 mM Hepes pH 7.5, 150 mM NaCl and 5 mg/ml BSA (Buffer I) and was 
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activated with thrombin for 15 minutes at 37 °C in the presence of  10/90 DOPS/
DOPC phospholipid vesicles and calciumchloride. Next, DMSO only or hAPC was 
added after this had been preincubated with compounds in DMSO diluted in Buffer 
I, and the inactivation reaction was allowed to proceed for 10 minutes at37 °C, with 
the final concentration DMSO during the inactivation being 5,5% for all test samples. 
Finally, FVa inactivation was stopped by the addition of  prothrombin and FXa, to 
initiate prothrombin conversion by the prothrombinase complex for 150 seconds, after 
which the reaction was stopped by the addition of  EDTA. Final concentrations of  
FXa and prothrombin in the prothrombin activation mixture were 0,3 nM and 0,5 μM 
respectively. The amount of  thrombin formed in the presence or absence of  APC was 
quantitated with the chromogenic substrate S-2238 (Chromogenix, Milan, Italy) and 
from this the percentage of  remaining FVa was calculated and normalized against a 
similar percentage measured in the absence of  compound. The APC concentration (0.6 
nM) was chosen such that after the 10 min. inactivation, approximately 15% remaining 
FVa activity was present in the sample to which APC was added. In the initial screen, 
30% remaining FVa activity was arbitrarily regarded as a positive test outcome and 
this was encountered in 72 compound mixtures of  the 156 tested (46%). Next the 
deconvoluted 288 single compounds were tested individually and normalized ratios for 
remaining FVa were calculated. During every series of  measurements, several blank 
values (no compound present) as well as positive controls (assay performed in the 
presence of  the inhibitory goat-anti-protein C antibody) were included to ensure assay 
performance. All determinations were performed in triplicate.
Factor Va Assay
FVa activity was determined from the rate of  FXa-catalyzed prothrombin activation, 
as described previously (34). Briefly, prothrombin activation in a reaction mixture 
containing 0.5 μM prothrombin, a limiting concentration of  FVa (≤20pM), 5nM FXa, 
40 μM phospholipid vesicles (10:90, DOPS:DOPC, mol:mol), 0.5 mg/ml ovalbumin 
and 3 mM CaCl2, was incubated for 2 min at 37 °C, after which thrombin was measured 
from the rate of  S-2238 hydrolysis. We verified that the FVa activity assay was not 
influenced by percentages of  DMSO of  up to 5,5%.
APC-catalyzed Inactivation of  FVa
FVa inactivation by APC was determined by following the loss of  FXa-cofactor activity 
of  FVa in the prothrombinase complex as a function of  time as described earlier (34). 
Since it has been described (35–37) that the targeted exosite in APC is particularly 
important for cleavage at the predominant Arg506 cleavage site in FVa, analysis of  full 
time courses of  inactivation reveal possible cleavage-specific effects of  compounds 
that are more difficult to extract from single time point measurements as our screening 
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assay. The full time course analysis was performed using both plasma derived FVa as 
described for the screening assay above and two different recombinant variants of  
FVa: FV R506Q/R679Q (abbreviated as RQQ, in which the Arg506 and Arg679 APC 
cleavage sites were mutated) or FV R306Q/R679Q (abbreviated as QRQ in which 
Arg306 and Arg679 were mutated to Gln) were prepared and analysed as described 
(34). These model molecules can only be cleaved by APC at a single cleavage site, at 
Arg306 and Arg 506 respectively. In short, 20 pM of  the activated FV variants was 
incubated with 25 μM phospholipid vesicles (10% DOPS/90% DOPC; mol/mol) at 37 
°C in 25 mM Hepes (pH7.5),150mM NaCl and 3 mM CaCl2. Next, three aliquots of  90 
μl were taken from the reaction mixture to determine the FVa activity in the absence of  
APC in triplicate. Then, APC was added to the reaction mixture and the mixture was 
subsequently separated into several 90 μl aliquots, one for each time point measured. 
For the QRQ and RQQ variants, final APC concentrations of  0.1 nM and 5.0 nM were 
used, respectively. At different time points after the addition of  APC, the residual FVa 
activity was measured in a prothrombinase assay, in which limiting concentrations of  
FVa (≤20 pM), were analyzed. Prewarmed FXa (0.3 nM in the prothrombinase mixture) 
and prothrombin (0.5 μM) were added to the FVa aliquots and thrombin generation 
was allowed to continue during 2,5 min after which the reaction was stopped by >40-
fold dilution in ice-cold EDTA buffer (50 mM Tris, 175 mM NaCl, 40 mM EDTA,0.5 
mg/ml ovalbumin, pH 7.9). Thrombin was quantified using the chromogenic substrate 
S2238 (23). Data analysis was performed as detailed earlier (7). The concentration of  
DMSO was 0,9% in the prothrombinase mixture for all samples tested.
Surface Plasmon Resonance
Direct binding analysis was performed on a Biacore T200 surface plasmon resonance 
apparatus (GE healthcare, USA). To this end we used two different chips, CM5 and 
CM7 (GE Healthcare, USA), to which we immobilized the different APC or protein C 
variants by amine coupling as instructed by the manufacturer. The CM5 chip was coated 
with wild type APC, APC-5A and APC-YFAA such that final coverage of  the chip 
was ~4800 resonance units per flow cell. Flow cell 1 was not coated and was used as a 
reference cell. Via a similar method a CM7 chip was coated with APC and PC, at final 
immobilization levels of  18,000 resonance units. For binding analysis with the CM5 
chip, the Biacore was run at 100 μl/min, with 60 s contact time and 140 s dissociation 
time in 0.02 M Tris, pH 7.4, 0.15 M NaCl, 2 mM CaCl2, 1% v/v DMSO, 0.005% v/v 
Tween 20 (Biacore running buffer). Varying concentrations of  compound, as indicated 
in the results section, were injected. For regeneration we used 0.02 M Tris pH 7.4, 0.15 M 
NaCl, 2 mM CaCl2, 20% v/v DMSO, 0.1% v/v Tween 20 (Biacore regeneration buffer) 
and raw data were processed by application of  a solvent correction as instructed by the 
Biacore company for DMSO containing samples. Prior to every run, the apparatus was 
primed 5 times. Binding analyses with the CM7 chip were performed identical to those 
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with the CM5 chip, with the exception of  the flow rate, which was set to 50 μl/min and 
the regeneration buffer used was 0.02 M Tris pH 7.4, 0.15 M NaCl, 2 mM CaCl2, 20% 
v/v DMSO, 0.005% v/v Tween 20. Sensorgrams were analysed with the Bia-evaluation 
software (version 1.1.1, Biacore company AB, Sweden) using a 1:1 binding model for 
the interaction between small compounds and APC or PC. Kinetic parameters were 
obtained from SPR experiments performed with a compound concentration varying 
from 3.125 μM to 200 μM and each series was repeated at least two times. Sensorgrams 
for which the Bia-evaluation software indicated that the kinetic constants could not be 
uniquely determined were not included in the calculation of  Kd values.
Results
Druggability Assessment of  the Exosite on APC
The webservers DoGSiteScorer, FTSite and MetaPocket were used to detect and 
investigate the binding pockets on the surface of  APC using the energy minimized 
X-ray structure of  APC (PDB file: 1AUT.pdb after removal of  all non-protein atoms). 
The procedure has highlighted some critical druggable pockets as shown in Figure 1. 
The first relevant pocket area concerns regions that include the S1 pocket close to the 
catalytic triad (H211, D257, and S360), and the second major area involves binding 
cavities on the S’side of  the catalytic site including the S4’ area and an exosite known to 
be important for FVa binding (34–40). These complementary subpockets are contiguous 
and together possess druggable properties with a cumulated volume of  around 500 Å3 
and a surface area of  around 900 Å2. 
Docking Procedure into the APC Exosite and S4’ Pocket Area.
A docking procedure was designed to specifically identify inhibitors of  the APC/FVa 
interaction, applying structure-based virtual screening methodology onto the exosite 
region mentioned above. This has permitted the in silico selection of  a list of  624 
compounds. The selection rationale comprised the identification of  compounds that 
should be able to bind to the S4’ pocket and/or the exosite as discussed above. The 624 
selected compounds were next purchased and subjected to in vitro testing.
Chapter 3
60
Inhibition of  APC Activity in Plasma
As a model system for in vivo thrombin formation we performed a thrombin generation 
experiment in a human normal pooled plasma sample in which we measured 
simultaneously the generation of  thrombin and FVa (Figure 2). In the absence of  the 
inhibitory anti-APC antibody, thrombin formation presents with the commonly seen 
pattern that is characterized by a rapid rise in thrombin formation, which is followed by 
an equally rapid decline in thrombin activity. These phases coincide with the formation 
and activity of  the prothrombinase complex, which is dependent on the availability 
of  sufficient activated FV (FVa) which is followed by the second phase mainly caused 
by the inactivation of  free thrombin by the circulating plasma inhibitors antithrombin 
and α-2-macroglobulin (41). Since in the initiation phase of  thrombin formation, the 
reaction is dependent upon the availability of  FVa, the corresponding FVa generation 
curve follows that of  the formation of  thrombin. After the peak in thrombin 
formation however, although sufficient FVa is available, no further thrombin is formed. 
Figure 1. Structure of human APC co-crystallized with a peptide-like inhibitor in the catalytic 
site and analysis of predicted druggable pockets
Left: The structure of  APC is represented as ribbons and molecular surfaces with a view down the active 
site. The green patch represents the catalytic site occupied by a co-crystallized bound peptide-like inhibitor 
plunging deep into the S1 pocket with an arginine residue contacting Asp354 at the bottom of  the S1 
pocket. The blue patch represents the S4’ pocket and the exosite identified by binding pocket prediction 
analysis. Right: predicted druggable pockets at the surface of  APC shown as filled mesh in magenta, red and 
brown. Two major druggable pocket areas were identified with DoGSiteScorer, FTSite and MetaPocket. 
One region is the well-known catalytic site (shown as a magenta mesh surface) and the other seems to 
overlap with a known APC binding exosite for factor V (shown here as a red and brown mesh surface in the 
area of  Y302 and R222). This overall exosite appears to have the required features to bindmacromolecules 
and low molecular weight molecules. Numbering is according to protein C nomenclature as presented in 
(6).
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Importantly, FVa activity in plasma declines over time, a process which is at least partly 
dependent upon the presence of  APC since in the presence of  the APC antibody, 
FVa remains stable for the duration of  the experiment. Consequently, in the presence 
of  the antibody, a modest rise in overall thrombin formation is observed (Figure 2), 
the limited increase in thrombin generation is presumably caused by consumption of  
prothrombin since we observed that addition of  prothrombin, after its consumption 
from the reaction sample, results in renewed formation of  thrombin (data not shown).
Figure 2. The effect of APC inhibition on thrombin formation and FVa stability in plasma
Normal pooled plasma was extrinsically triggered using 12 pM of  relipidated TF and thrombin 
generation (circles) was followed by sampling at individual time points into an assay specific for thrombin. 
Simultaneously, the presence of  FVawasmonitored (triangles) by sampling into a FVa specific assay (see ref  
5). In addition, to the blood plasma was added compensation buffer (open symbols) or an equal volume 
containing an APC inhibitory antibody (closed symbols). 
Expression and Purification of  Recombinant Protein C Variants
Protein C variants were expressed under serum-free conditions at levels of  ~5 mg/l 
and purified with overall recoveries of  ~40%. On SDS-PAGE, all protein C variants, 
including the wild type protein C, migrated with a molecular weight of  approximately 
60 kDa. After reduction by addition of  ß-mercapto ethanol, the light chain as well as 
the β,and γ isoforms of  the heavy chain were seen (data not shown). Upon activation 
by thrombin, the heavy-chain isoforms for each of  the variants tested shifted to 
slightly lower migration positions, consistent with full activation (>95%) as judged by 
SDS-PAGE. To assess the correct function of  the proteins, we further determined 
activity:antigen ratios of  the different APC preps. For wildtype APC, 5A-APC and 
YFAA-APC these were very comparable, being 1.0; 0.7 and 1.6 respectively.
Chapter 3
62
Compound Screening
During the initial screen, mixtures of  4 compounds (at 125 μM) were selected for their 
ability to inhibit the inactivation of  FVa by APC, as determined from the residual FVa 
activities present after a fixed time of  inactivation by APC. Reaction conditions were 
set such that in the absence of  compound, approximately 15% remaining FVa activity 
was present in the test sample. Next, for reactions in the presence of  compounds, 30% 
remaining FVa activity was arbitrarily regarded as a positive test outcome and this was 
encountered in 72 compound mixtures of  the 156 tested (46%). Next, positive mixtures 
were deconvoluted and the 288 resulting single compounds were tested individually in 
triplicate with the same assay as described for the mixes. From this we selected the top 60 
compounds for further screening and these compounds were tested for their ability to 
inhibit FVa inactivation, as observed from a time course of  FVa inactivation (see Figure 
3 for a representative example of  time courses of  FVa inactivation in the presence of  
compounds with inhibitory activity towards APC). The analyses of  time courses were 
used to further narrow our selection and the best 20 compounds proceeded to further 
direct binding analysis by surface plasmon resonance (SPR). 
Figure 3. Time course of FVa inactivation, as determined for the 60 best compounds from 
initial screening
Shown are representative curves obtained for the time courses of  inactivation obtained in the 
absence (○,△), or presence of  100 μM compound G040021 (●) or A070015 (◆). FVa activitywas 
determinedwith the FVa assay as described in the methods section, with final concentrations 
used being: 2.5 nM thrombin, 20 pM FVa, 25 μM PL (10/90 DOPS/DOPC), 3 mM calcium 
ions, 30 pM APC, 0.3 nM FXa, 0.5 μM PT. 
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Furthermore, we analyzed the effects of  compounds on the inactivation of  FVa by 
APC and performed a series of  titrations for the top 3 compounds after the screening 
assay for individual compounds to ascertain a dose–response relationship between the 
amount of  compound present and the extent to which APC is functionally inhibited, 
thus verifying the methods that were chosen for hit selection. Figure 4 illustrates the 
outcome of  this analysis, which establishes that upon increase of  the concentration of  
compound present, APC is enhancingly inhibited. We observed that the FVa assay used 
was inhibited to a variable extent at the highest concentrations of  compound tested (200 
μM and 500 μM). At 200 μM inhibitions of  the assay were 34%, 7% and 8% and at 500 
μM inhibition was 85%, 14 and 63% for A070015, G040021 and G060016 respectively, 
while the DMSO concentration was constant over the complete range of  compound 
concentrations tested. For all hit molecules identified, we found that the compounds 
did not change the amidolytic activity of  APC towards the small chromogenic substrate 
S-2366, which implies that binding of  the small molecule did not alter the activity of  the 
catalytic site per se (as measured at 200 μM S-2366 and 5 nM APC in 50 mM Tris pH 
7.9, 150 mM NaCl, 20 mM EDTA, data not shown).
 
Figure 4. Dose–response curves of top 3 compounds after initial screening of single compounds
Increasing amounts of  compound are added to the FVa inactivation system as described under Materials 
and Methods. The ratio of  FVa activity present after inactivation by APC and that measured in the absence 
of  APC, while both having the same concentration of  compound present, is indicated as a function of  
the concentration of  compound present, with the %DMSO being constant over the complete range of  
compound concentrations tested. Indicated are means ± SD for three different measurements. Compounds: 
A070015 (●), G040021 () and G060016 ().
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Direct binding Analysis by SPR
The 20 best compounds selected after measurement of  time courses of  FVa inactivation 
were tested for their ability to bind to APC by surface plasmon resonance with a 
Biacore T200 apparatus using a CM7 chip. The analysis for the best binding compound, 
C060018, is shown in Figure 5A and data calculated from similar plots like given in 
Figure 5 are represented in Table 1. Given that the targeted exosites do not overlap with 
the activation peptide region in protein C, we also tested the binding of  compounds to 
immobilized PC (Figure 5B). Data shown are the result of  a hyperbolic fit to the final 
levels of  binding reached at the end of  the binding phase for compound concentrations 
between 3.125 and 200 μM. 
To verify that compounds were directed at the targeted exosites on the surface of  the 
SP domain of  APC, we performed a SPR analysis in which the differential binding of  
varying concentrations of  compounds (between 1 and 100 μM) was studied to wild 
type APC, 5A-APC and YFAA-APC simultaneously (Figure 6). To allow comparison 
between compounds, the Kd calculated for WT-APC binding (see Table 1) was set equal 
to 1 and the Kd values calculated for the other APC-variants were expressed relative 
to that of  WT-APC. For a number of  compounds (viz. G040021, G050016, G040020, 
G030014 and B110016) we observed that upon mutation of  the targeted binding site, 
the affinity as determined by SPR lowered by up to ~100-500 fold. Likewise, over 10-
fold increases in affinity were also observed (compounds A070015, C060018, E050019 
and D050021). While we interpret the change in measured Kd to reflect an alteration in 
binding between the immobilised protein and the small compound, it strongly supports 
the notion that the residues mutated in these particular APC variants are involved in 
the binding of  the small molecules. For three conditions we were unable to uniquely 
determine quantitative kinetic constants: G040018 binding to 5A-APC and for C020018 
binding to 5A-APC and to YFAA-APC.
Cleavage Site Specificity of  Compounds
The different cleavages in FVa have been shown to be mediated via different contacts 
between the overall large contact area between FVa and APC, in particular three 
positively charged surface loops of  APC, that surround the targeted area are involved 
in the interaction with the R506 cleavage site in FVa. To further analyse the possible 
specific effect of  our best inhibitory compounds, we used recombinant FVa molecules 
that can only be cleaved at a single cleavage site (Table 2) to study potential preferred 
effects by APC-catalyzed cleavage at either Arg506 or Arg306 cleavage in FVa. 
Table 2 presents the difference between the individual rates of  cleavage by APC of  
mutants RQQ and QRQ, as measured in the same experimental setup as described 
in the Methods section, in the presence and absence of  100 μM compound. It can be 
observed that the majority of  compounds (12 out of  20) influence both the Arg306 and 
Identification of novel small molecule inhibitors of activated protein C
65
Ch
ap
te
r 3
Figure 5.
A) SPR analysis of  compound binding to wildtype human APC. (Top) Sensorgrams representing the 
concentration-dependent binding of  compound C060018 to wild type human APC immobilized on a CM7 
sensor chip. The association time was 60 seconds and the dissociation time was 140 seconds. Sensorgrams 
were corrected for binding to the reference cell and for buffer effects. (Bottom) Non-linear affinity 
analysis of  the binding of  the compound with human wild type APC. The compound concentration range 
was 3.125–200 μM. B) SPR analysis of  compound binding towildtype human PC. (Top) Sensorgrams 
representing the concentration-dependent binding of  compound C060018 towild type human PC 
immobilized on a CM7 sensor chip. The association time was 60 seconds and the dissociation time was 
140 seconds. Sensorgrams were corrected for binding to the reference cell and for buffer effects. (Bottom) 
Non-linear affinity analysis of  the binding of  the compound with human wildtype PC. The compound 
concentration range was 3.125–200 μM. 
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Arg506 cleavage. However, we have detected 4 compounds that preferably influence 
the cleavage at Arg306 and 4 compounds that appear to preferably influence Arg506 
cleavage. Remarkably, the average rank from the activity screening for these compounds 
was 13,75 ± 2.14 and 8,75 ± 4.33 respectively (mean ± SEM), suggesting that the 
compounds that have a R506 specificity have higher activities than those that preferably 
inhibit R306 cleavage. Under the conditions chosen here, the most specific compounds 
presented with a modest 3–5 fold difference in inactivation between the two cleavage 
sites studied.
Figure 6. Binding of compounds as quantitated via SPR
The 20 best compounds after first screening were assayed for their affinity to bind to immobilised wild 
type human APC (WT, dark gray) as well as to 2 APC variants, APC-Y302A/F316A (YFAA, black) and 
APCK191A/K192A/K193A/R229A/R230A (5A, light gray). For reasons of  comparison, Kd values 
found are expressed relative to those for wild type APC binding. Values indicated are averages of  at least 
3 analyses.
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Discussion
In order for APC to proteolyse FVa it needs to form a productive complex with FVa, 
in the absence of  which proteolysis is not possible. In fact, APC has extensive contacts 
with FVa which by themselves are responsible for the (reversible) loss of  FVa cofactor 
activity prior to cleavage, even in the absence of  FVa proteolysis as was observed for 
an active-site mutated APC (27). The strategy used in the present study is to reduce the 
inactivation of  FVa by prevention of  its protein-protein interaction with APC. The goal 
was to identify small drug-like molecules that bind to APC and inhibit its anticoagulant 
properties through targeting of  the interaction patch on the surface of  APC that binds 
FVa, without targeting the catalytic site. Via this approach one could specifically block 
the anti-coagulant function of  APC but leave intact the cytoprotective properties of  
APC that depend on the availability of  a functional catalytic site. To this end we used 
various in silico tools (structural bioinformatics and virtual screening) to rationally 
discover molecules that bind to areas known to be involved in anticoagulant functions. 
In the first part of  the project we therefore scrutinized the regions of  APC that should 
interact with FVa by searching for druggable binding pockets in this area of  APC that 
could overlap with FVa binding sites. To this end, the use of  DoGSiteScorer, FTSite and 
MetaPocket helped us to characterize likely binding zones on the P’side of  the catalytic 
site (see Figure 1). We were able to evaluate the druggability of  pockets and subpockets 
identified in the region of  the S4’ pocket and of  an exosite contiguous to the S4’ pocket. 
Table 2 Fold-difference between the rates of inactivation at R306 and R506, as influenced by 
the presence of 100 μM compounds.
The average rates of  inactivation at FVa-R306 and FVa-R506, to which these differences are compared 
were determined as: 4,41 ± 0.77 * 106 M-1 s-1 for FVa-R306 and 5,89 ± 1.14 *107M-1 s-1 for FVa-R506 
(mean±SD, n=20). Used were the FVa variants RQQ and QRQ. A cleavage value N1 implies that the 
inactivation is inhibited, which implies that the proteolytic inactivation of  FVa is slower than normal.
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These combined contiguous pockets possess druggable properties, meaning that they 
are accessible and large enough to accommodate the binding of  a small molecule, and 
were therefore the subject of  our docking procedure with the goal of  identifying low 
molecular weight and non peptidic modulators of  the APC/FVa interaction. Several 
other studies have highlighted that such targetable exosites are indeed present in blood 
coagulation serine protease s, as was for instance shown for thrombin (42, 43), for FXa 
(44) or for FVIIa (45, 46). However, thus far it was not known if  a non-peptidic drug-
like molecule could bind to the selected APC exosites and influence APC function.
With the intention to specifically identify compounds with predicted binding modes 
that target the S4’ pocket and exosite, we selected 624 compounds after in silico 
screening through small-molecule docking and tested them for their ability to inhibit 
the inactivation of  FVa by APC. Several molecules demonstrated an effect in the 
inactivation of  FVa. We illustrate the predicted position for two molecules, as they either 
show a good inactivation profile across different experimental tests and/or because 
they were sensitive to our site directed mutant APC molecules. Compounds A070015 
and G040020 are expected to bind into the S4’ pocket and the exosite (see Figure 7). 
The data presented in Figure 2 illustrate the potential effect of  APC inhibition on in vitro 
thrombin formation and more importantly show that FVa in human plasma is stable, 
provided that its proteolytic downregulator APC is inhibited. In the absence of  an 
inhibitory antibody against APC, FVa activity readily diminished after full activation of  
FV, due to the in situ formed APC. In the presence of  the inhibitory antibody however, 
increased formation of  thrombin was observed and FVa activity remained stable after 
plasma activation. These observations open the possibility for potential therapy based 
on inhibition of  APC as the prolonged lifetime of  FVa may give rise to increased 
thrombin generation. These findings are in agreement with earlier attempts to design 
APC inhibitors that increase the thrombin potential in human plasma (16, 21, 47) and 
in particular in plasma from haemophiliacs. 
During the initial steps of  compound screening we identified a fairly large number of  
positive mixtures containing anti-APC activity (46% of  the 156 mixtures were regarded 
as positive). This high percentage has been influenced by several factors: first, we choose 
a threshold for selection which was twice as high as the assay outcome level measured 
in the absence of  any compound, this is a rather mild criterion which was instigated 
by our expectation that it would be difficult to detect good protein-protein interaction 
inhibitors that target the large interaction area between FVa and APC (here computed 
to be at least 1500 Å2 on the serine protease domain of  APC). When compared to the 
surface that can be covered by a small molecule (typically 300–500 Å2) the challenge 
taken up here by us becomes more conceivable. Second, given that molecules may act 
in synergy, it is possible that the coincidental mixture of  more than one weaker inhibitor 
of  APC has caused the overall inhibition to be overestimated. Infact, this has been 
tested in an experiment where we found that the amount of  inhibition by a mixture 
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of  50 μM each of  compounds G060016 and A070015 equaled that by 100 μM of  
either of  these compounds (data not shown). Third, the concentration chosen for initial 
screening (125 μM) may be considered as high, which will lead to the detection of  
moderately active hit molecules.
By means of  individual measurements (both functional and direct binding) we selected 
only the best molecules to be included for further analysis. Moreover, as seen in Figure 
4, we verified that the top 3 compounds after functional screening owed their activity to 
dose-specific effects rather than to a-specific inhibition of  APC, thereby also verifying 
the validity of  our screening assay. While we noticed an influence on the FVa assay, 
when using high concentrations of  compounds, such influence was negligible at the 
lower concentrations where it was (14%, 4% and 0% for A070015, G040021 and 
G060016 respectively when the assay was performed at 100 μM compound). To exclude 
the possibility of  APC inhibition through binding to the active site, we checked that the 
top 20 compounds did not interfere with proteolysis of  the small amidolytic substrate 
for APC, S2366.
The top 20 molecules after functional screening were analyzed for their ability to bind 
to APC and its zymogen protein C (see Table 1). The latter is not functional as an 
anticoagulant but should be accessible to a small compound in the exosites which has 
been targeted in our virtual screening approach. In agreement with this hypothesis, we 
Figure 7. Predicted pose for molecules A070015 and G040020
The overall orientation of  APC is as in Figure 1 with a view down the active site. Left, the predicted 
pose for molecule A070015 is shown, the binding of  this molecule is improved in our mutant, suggesting 
that our pose is most likely acceptable. Indeed, this compound should have a positive charge and the 
binding could be disfavored by the presence of  positive charges in APC, possibly at position R222. Right: 
The molecule G040020 is shown, several hydrophobic, aromatic and hydrogen bonds are expected to be 
damagedwhen binding to ourmutant APCmolecules, confirming that thismolecule should fit in this overall 
area of  APC. More detailed explanations about the positioning of  the molecules will require NMR and/
or X-ray experiments.
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observed no major differences between the Kd values obtained for binding to APC 
or to PC. Of  interest is the fact that there is little correlation between the observed 
rank after functional screening and the rank after direct binding analysis for the top 
20 molecules (Table1). This may imply that a larger binding surface is available for 
interaction between the compounds and APC but that a tight binding per se is not 
sufficient to disturb the interaction between APC and its substrates. This observation 
is significant since it exemplifies the non-trivial fact that the use of  a screening assay 
that probes the function of  a protein by calculation of  a ratio of  signal measured in 
the absence- or presence of  effector in a multi-component environment, as was the 
case here, is necessary when the goal of  screening experiments is the interference with 
the function of  a protein. In this respect it is worthwhile to mention that use of  a 
functional assay yields not only information on the desired activity of  a compound on 
the intended target protein, but also, the measurements in the absence of  APC (and in 
the presence of  compound) in our case yielded information on the potential influence 
of  compounds on the activity of  the homologous serine proteases FXa and thrombin, 
thus hinting at the specificity of  the compounds studied. Therefore, we believe that 
potential binding to off-targets, which are commonly seen in drug discovery campaigns 
(and which are also seen in many marketed drugs) cannot be excluded but will be 
noticed and is minimized if  a ratio of  two functional measurement is determined: one 
with- and one without the target. In fact several compounds were excluded from further 
study because they interfered with the assay, in the absence of  added APC.
We have sought to gain information on the binding area by use of  mutant APC 
molecules, which contain mutations in the targeted interaction site. Although clearly 
not for all, we have verified through this approach for 10 out of  the top 20 compounds 
that binding of  the compounds is indeed significantly altered when the compound is 
interacting with the mutant molecule (for 2 out of  the top 20 we were not able to 
determine direct binding parameters due to binding of  the molecules to the reference 
cell). We have observed for 6 compounds a ~100-500-fold loss in affinity for a given 
mutated APC, as was most clear for compounds G040020 and G030014 (Figure 7). 
From the 3D structure of  the docked compounds into the wild-type APC structure we 
can explain this loss of  affinity results from reduced or lost hydrophobic/aromatic and 
hydrogen bond interactions between the compound and the mutated binding site. On 
the other hand, increase in affinity, as was observed for 4 different compounds could be 
explained by an enlargement of  the binding site and reduced positive charge repulsion 
through the mutation which facilitates the binding of  compounds such as A070015, 
C060018, E050019 and D050021 (Figure 7). The targeted area has been described 
to be involved particularly in the cleavage of  FVa at position Arg506. Therefore, we 
measured the individual rates of  FVa inactivation at either Arg306 or Arg506, the two 
predominant cleavage sites in FVa, by use of  recombinant FVa molecules that can 
only be cleaved at a single position. We observed a predominant effect for cleavage at 
Chapter 3
72
Arg506 in FVa for 4/20 compounds tested. Moreover, we observed 4/20 molecules to 
affect preferably Arg306 as well. From this we conclude that apparently, regions on the 
surface of  APC, that are obscured by the binding of  these compounds can likewise be 
involved in binding at Arg306 as they can be in binding at Arg506. This is in line with 
earlier observations by us and others who have concluded that a large interaction area is 
involved in the interaction between APC and FVa and that the epitopes important for 
cleavage at Arg306 or Arg506 do not fully overlap (27, 34–38, 48). The affinities of  the 
molecules found can be described as of  rather modest affinity and are lower than those 
found for peptide-like compounds (21) or for APC RNA aptamers (49) or ssDNA 
aptamers (47) who found affinities of  800 nM, 100 nM and 0.43 nM respectively. Yet, 
the biological function of  a protein-protein interaction can be efficiently modulated 
even if  small molecule binders are not of  high affinity and there are many advantages 
to work with low molecular weight compounds as in general their bioavailability is much 
higher than for peptides and aptamers.
Taken together we show here, for the first time, that it is possible to discover small protein-
protein interaction inhibitors through a structure-based virtual screening approach of  
the interaction between coagulation factor Va and APC. The molecules discovered have 
weak to moderate binding affinities but are able to inhibit the inactivation of  the natural 
substrate FVa, in a system that contains FVa and APC but also albumin. This work 
could provide a basis on which these molecules may be further developed into orally 
available small molecules that could be used to increase in vivo thrombin generation by 
specific inhibition of  the anticoagulant properties of  APC. 
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Abstract
Activated protein C (APC) is a serine protease that has both anticoagulant and 
cytoprotective properties. The cytoprotective effects are protease activated receptor 
1 (PAR-1) and endothelial protein C receptor (EPCR) dependent and likely underlie 
protective effects of  APC in animal models of  sepsis, myocardial infarction and 
ischemic stroke. S360A-(A)PC, a variant (A)PC that has no catalytic activity, binds 
EPCR and shifts pro-inflammatory signaling of  the thrombin-PAR-1 complex to anti-
inflammatory signaling.
In this study we investigated effects of  human (h)wt-PC, hS360A-PC, hwt-APC and 
hS360A-APC in acute (mouse model of  acute myocardial ischemia/reperfusion (I/R) 
injury) and chronic inflammation (apoE-/- mouse model of  atherosclerosis). 
All h(A)PC variants significantly reduced myocardial infarct area (p<0.05) following 
I/R injury. IL-6 levels in heart homogenates did not differ significantly between sham, 
placebo and treatment groups in I/R injury. None of  the h(A)PC variants decreased 
number and size of  atherosclerotic plaques in apoE-/- mice. Only hS360A-APC slightly 
affected phenotype of  plaques. IL-6 levels in plasma were significantly (p<0.001) 
decreased in hwt-APC and hS360A-PC treated mice. In the last group levels of  
monocyte chemotactic protein 1 (MCP-1) were significantly increased (p<0.05). 
In this study we show that both hwt and hS360A-(A)PC protect against acute 
myocardial I/R injury, which implies that protection from I/R injury is independent 
of  the proteolytic activity of  APC. However, in the chronic atherosclerosis model hwt 
and hS360-(A)PC had only minor effects. When the dose, species and mode of  (A)PC 
administration will be adjusted, we believe that (A)PC will have potential to influence 
development of  chronic inflammation as occurring during atherosclerosis as well.
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Introduction
Protein C (PC) circulates as an inactive zymogen that can be activated by thrombin 
bound to the endothelium associated transmembrane receptor thrombomodulin. When 
PC is bound to the endothelial protein C receptor (EPCR), its activation is enhanced 
by 20-fold (1). Activated protein C (APC) is a serine protease that, together with its 
cofactors protein S and factor V (FV), regulates thrombin formation by proteolysis 
of  the active coagulation factors V (FVa) and VIII (FVIIIa) (2-5). The anticoagulant 
PC pathway is vital to normal haemostasis, as indicated by the increased risk for 
thromboembolic events in heterogeneous PC deficiency (6, 7) and the life threatening 
thrombotic complications observed, even in the presence of  aggressive anticoagulant 
therapy, in homozygous PC deficiency (8, 9).
APC has initially been identified and characterized as an anticoagulant protein; however 
recent interest has focused more on the cytoprotective functions of  APC. APC has 
anti-inflammatory, anti-apoptotic and endothelial barrier stabilizing effects in different 
cell types, that are protease activated receptor 1 (PAR-1) and EPCR-dependent (10, 11). 
These cellular effects, rather than the anticoagulant activity of  APC, likely explain the 
protective effects of  APC observed in animal studies of  sepsis, lung injury, myocardial 
infarction and ischemic stroke (12-16). 
The active site of  APC contains the conserved catalytic triad: residues H211, D257 
and S360. Mutation of  the active site serine to alanine (S360A) yields a protein that 
is not able to cleave substrates, but still retains some anticoagulant activity through its 
ability to compete with activated coagulation factors X and IX for binding to FVa and 
FVIIIa, respectively (17, 18). The cell surface receptor PAR-1 is involved in mediation 
of  the cell-protective properties of  APC. S360A-APC, however fails to cleave PAR-1 
and is therefore regarded as being devoid of  cytoprotective effects (19). Thrombin is 
also able to cleave PAR-1 and in contrast to APC cleaved PAR-1, thrombin cleaved 
PAR-1 causes permeability-enhancing and pro-inflammatory effects via Gq and G12/13 
mediated signaling (20). Interestingly, it has been shown that binding of  APC, PC as 
well as S360A-PC to EPCR, is associated with PAR-1 coupling to a G(i/o) family 
of  G-proteins, resulting in initiation of  protective signaling after cleavage of  PAR-1 
by either APC or thrombin (21). Thus, this implies that protective PAR-1 signaling 
can also be initiated by PC and by proteolytically inactive S360A-(A)PC. Therefore 
we hypothesize that not only human wild type (hwt)-APC, but also hwt-PC, hS360A-
PC and hS360A-APC may initiate cytoprotective signaling in vivo via EPCR-dependent 
modulation of  PAR-1 signaling. 
In the present study we have investigated the cytoprotective effects of  human hwt-
PC, hS360A-PC, hwt-APC and hS360A-APC in two different cardiovascular relevant 
mouse models: myocardial ischemia/reperfusion (I/R) injury and atherosclerosis. 
hAPC is very similar to murine (m) APC (69% sequence identity) (22). It is known that 
mAPC is significantly more potent than hAPC as an anticoagulant in mice (15), but we 
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hypothesize that anticoagulation is not necessary for protection in our models. Previous 
studies have shown that hAPC has positive effects on lesion volume, inflammation, 
vascular permeability and neurological function in murine models studying I/R injury 
and stroke (23-27). 
Inflammation plays a key role in the pathogenesis of  both myocardial I/R injury and 
atherosclerosis models in the current study, although the sequence of  immune cell 
infiltration and the characteristics of  the immune cell infiltrate are markedly different. 
After acute myocardial I/R, neutrophils migrate into the infarct zone within 24 hours, 
where they release granular enzymes and reactive oxygen species and cause vascular 
plugging (28). In atherosclerosis, mainly T-cells and monocytes are recruited into 
the plaque, where monocytes mature into macrophages and finally foam cells. These 
immune cells release cytokines within the plaque and promote the expression of  
matrix metalloproteinases that break down collagen and thereby make plaques more 
vulnerable (29). We hypothesize that hwt-(A)PC and hS360A-(A)PC will protect against 
acute inflammation in the myocardial I/R injury model and chronic inflammation in the 
atherosclerosis model.
Materials & Methods
Expression and purification of  recombinant human (S360A)-PC
Recombinant hS360A-PC was obtained by PCR-based site-directed mutagenesis 
of  hwt-PC cDNA. The cDNA of  hwt-PC and hS360A-PC were inserted into the 
eukaryotic expression vector pRc/CMV (Invitrogen), transfected into HEK293 cells 
(CRL-1573 ATCC) and recombinant h(S360A)-PC was purified and characterized as 
described earlier (30, 31). The purity and integrity of  h(S360A)-PC was evaluated by 
SDS-PAGE (Figure 1). h(S360A)-PC concentrations were quantified by measurement 
of  absorbance at 280 nm using an absorption coefficient of  14.5 (280 nm, 1%, 1cm) 
and by ELISA, employing the horse anti-human PC polyclonal antibody PAHPC-H 
(HTI), as a catcher antibody and the horseradish peroxidase-conjugated anti-human PC 
polyclonal Dako P0374 as a detecting antibody (18). 
Activation of  h(S360A)-PC and catalytic activity against small substrates
hwt-PC and hS360A-PC were activated with a 1 ml HiTrap NHS-Activated HP column 
(GE Healthcare) to which 50 Units of  carrier-free Protac (Pentapharm) had prior been 
conjugated. Up to 0.5 mg of  h(S360A)-PC was incubated for 2 hours on the column 
at room temperature, and was next eluted and concentrated with a 10K Macrosep 
Advance Centrifugal Device (Pall Life Sciences). Complete activation of  the hwt-PC was 
ascertained by measuring the amidolytic activity of  APC with S-2366 (Chromogenix) 
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directly and after 60 minutes incubation in the presence of  additionally added (0.05 
units/ml final concentration) Protac. We confirmed the absence of  Protac from the 
APC preps generated. For both hwt- and hS360A-PC, completion of  activation was 
verified by SDS PAGE analysis (Figure 1). APC concentrations were determined from 
the above-described PC ELISA. 
Figure 1. SDS page gel of human wt- and S360A-(A)PC
Reduced samples of  human wt-PC (lane 1), wt-APC (lane 2), S360A-PC (lane 3) and S360A-APC (lane 4) 
were loaded on a 10% SDS PAGE gel and afterwards stained with Coomassie Brilliant Blue.
Mice
All animal experiments were approved by the Animal Ethics Committee of  Maastricht 
University. All mice were housed and bred according to institutional guidelines and 
were fed a normal chow diet. For the myocardial I/R experiment male C57BL/6 mice 
(Charles River Laboratories) of  8 weeks old and 25 g were used (n=13 per group). For 
the atherosclerosis experiments, 21-week old male ApoE-/- mice were used (Charles 
River Laboratories/in house breeding facility Maastricht University). Treatment, twice 
weekly, with intraperitoneal (i.p.) injections of  saline (n=20) or 0.2 mg/kg of  hwt-PC 
(n=13), hS360A-PC (n=12), hwt-APC (n=16) or hS360A-APC (n=16) started at week 
21 and was continued for 8 weeks. The 0.2 mg/kg dose has been proven protective in 
models of  myocardial I/R injury (23), hepatic I/R injury (25) and stroke (15, 32, 33).
Procedure myocardial I/R
Myocardial I/R was performed as described earlier (34). In short, mice were anaesthetized 
with isoflurane and were ventilated during the ischemic period. Ischemia was induced 
by ligation of  the left anterior descending (LAD) artery for 60 minutes followed by 2 
hours of  reperfusion. hwt-PC, hS360A-PC, hwt-APC or hS360A-APC (0.4 mg/kg) or 
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placebo (saline) were administered intravenously (i.v.) both 15 minutes after induction 
of  ischemia and 5 minutes after induction of  reperfusion. After reperfusion, the animals 
were anaesthetized as described earlier. Heart tissue was collected for determination of  
infarct size (n=6 per group) or interleukin (IL)-6 levels (n=7 per group). 
Myocardial I/R: determination of  infarct size
Infarct size was determined by Evans Blue/triphenyl tetrazolium chloride (TTC) staining 
(35). In brief, after reperfusion, the LAD was re-ligated and Evans Blue dye was injected 
i.v. and was allowed to circulate for 2 min to identify the area at risk (AAR). After 
excision of  the heart, it was cut into 0.5-mm-thick slices and TTC was added to mark 
the viable cells within the AAR red. The non-viable cells remained pale and defined the 
area of  infarction (AOI). Pictures of  the slices were taken and were analyzed by Adobe 
Photoshop CS2 to determine infarct sizes (AOI/AAR ratios).
 
Myocardial I/R: determination of  IL-6 levels
Hearts of  mice were excised, lyophilized and the resulting dry heart powder was 
dissolved in glucopyranoside. After determination of  protein levels with DC Protein 
Assay Kit II (Bio-Rad), tissue homogenates were diluted to 5 mg/ml protein and IL-6 
levels per mg heart homogenate were determined with mouse IL-6 ELISA Ready‐set‐
go (eBiosciences).
Atherosclerosis: tissue processing, histology, and morphometry
At the end of  the experimental period, at 29 weeks of  age, mice were anaesthetized 
with pentobarbital (100 mg/kg, i.p.). Blood was taken in EDTA via cardiac 
puncture, followed by perfusion of  the arterial tree under physiological pressure 
with PBS containing sodium nitroprusside (Sigma-Aldrich) and subsequently by 1% 
paraformaldehyde. The aortic arch including its main branch points was removed, fixed 
overnight in 1% paraformaldehyde, longitudinally embedded in paraffin, and sectioned. 
Twenty consecutive sections (4 μm) representing the central area of  the aortic arch with 
an intact morphology of  the arch and branch points were selected. For histological 
analysis of  atherosclerosis, 4 sections (20 μm apart) were stained with hematoxylin and 
eosin (H&E) and the atherosclerotic lesions were classified as “initial” or “advanced” 
according to the Virmani classification (36). Plaque area was determined using a Leica 
DM3000 light microscope and a 10/0.3 NA on 20/0.5 objective (Leica Microsystems) 
coupled to a computerized morphometry system (Qwin 3.5; Leica, Wetzlar, Germany). 
Images were captured using a Leica DFC 425c camera. Morphometric parameters were 
determined as described previously (37).
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Atherosclerosis: flow cytometry
Blood and spleen were collected, processed and fluorescently stained with either 
antibody mix 1 (CD3-FITC, CD4-PerCp, CD8-eFLUO450, CD25-APC, Foxp3-
PE and B220-PE-Cy7) or antibody mix 2 (CD11b-PE-Cy7, Ly6C-APC, Ly6G-PE, 
CD3-FITC, B220-APC-eFLUO780 and NK1.1-PerCp-Cy5.5) or isotype control IgG 
(all BD Biosciences or eBioscience). Cells were analysed using a FACS-Canto II (BD 
Biosciences) flowcytometer.
Atherosclerosis: (immuno)histochemistry
Aortic arch sections were immunolabeled with anti-Mac3 monoclonal antibody (mAb) 
(1:30; BD Biosciences PharMingen) to detect macrophages, anti-CD3 (1:200; Dako) 
to detect T lymphocytes and anti-CD45 mAb (1:5000; BD Biosciences) to detect 
leukocytes. Antibody staining was visualized by diaminobenzidine or Vectastain red. 
Sirius red staining was performed for analysis of  collagen content.
Atherosclerosis: analysis of  cytokine and cholesterol levels
Enzyme-linked immunosorbent assays (ELISAs) were used to quantify concentrations 
of  cytokines IL-6, IL-10 and MCP-1 (all R&D systems) in plasma. Cholesterol levels in 
plasma were measured using the Cholesterol CHOD-PAP method (Roche).
Statistical Analysis
Data analysis was performed with GraphPad Prism 5. Data were presented as mean +/- 
SEM. Differences between groups were tested using One-way ANOVA and Dunnett’s 
multiple comparison post hoc test. P<0.05 was considered statistically significant.
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Results
Expression and purification of  recombinant h(S360A)-PC 
hwt-PC and hS360A-PC were expressed under serum-free conditions at levels of  5 
mg/liter and purified with overall recoveries of  ~40%. SDS-PAGE gel analysis under 
reducing conditions, revealed the presence of  the light chain as well as the α, β and 
γ isoforms of  the heavy chain (Figure 1). Upon activation by Protac, a fast-acting PC 
activator isolated from the venom of  the copperhead snake Agkistrodon contortrix, the 
heavy chain isoforms shifted to a slightly lower migration position, consistent with 
full activation (95%) as judged by SDS-PAGE (Figure 1). The purified hS360A-
APC preparation contained no measurable (<0.03%) amidolytic activity toward the 
chromogenic substrate S-2366.
hwt- and hS360A-(A)PC reduce infarct area in a myocardial I/R mouse model
To examine the effects of  APC treatment on myocardial I/R injury, mice were subjected 
to 1 hour ischemia by ligation of  a suture around the LAD artery, followed by 2 hours 
of  reperfusion. Mice received a first dose (0.4 mg/kg) of  hwt-PC, hS360A-PC, hwt-
APC, hS360A-APC or placebo (saline) 15 minutes after induction of  ischemia and a 
second dose of  the same treatment 5 minutes after induction of  reperfusion. Next, 
infarct areas in the different groups were determined by Evans Blue/TTC staining 
(Figure 2A). Figure 2B shows that the infarct area in the placebo-treated mice was 
26.1%. Remarkably, hwt-PC, hS360A-PC, hwt-APC and hS360A-APC treatment all 
significantly reduced myocardial infarct area (P<0.05) to values of  11.1% to 14.3%. 
hwt- and hS360A-(A)PC have no effect on IL-6 levels in a myocardial I/R mouse model
Interleukin 6 (IL-6) is a cytokine with pro-inflammatory and pro-coagulant properties 
that stimulates hepatocytes to produce several acute-phase proteins, like C reactive 
protein. Increased levels of  IL-6 were found in coronary heart disease patients and 
were associated with prognosis (38). We measured IL-6 levels in tissue homogenates 
of  heart tissue from mice that underwent myocardial I/R. We observed no significant 
difference in IL-6 levels between mice that received placebo and mice in the different 
h(A)PC treatment groups (Figure 2C).
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hwt- and hS360A-(A)PC do not influence plaque area in ApoE-/- mice
Having observed that all hPC and hAPC forms conferred cytoprotection in the 
acute inflammatory myocardial I/R model, we subsequently investigated the effect 
of  hAPC administration on plaque development in a chronic inflammatory mouse 
model of  atherosclerosis. ApoE-/- mice were treated twice weekly with placebo, or 
hwt-PC, hS360A-PC, hwt-APC or hS360A-APC (0.2 mg/kg) for 8 weeks, after which 
atherosclerotic plaque development in the aortic arch was determined. Representative 
images of  hematoxylin and eosin (H&E) stained initial and advanced plaques are shown 
in Figure 3A-B. On average, we detected 1 initial plaque and 3 advanced plaques in 
 
Figure 2. Treatment with wt- or S360A-(A)PC decreases infarct area
Mice were subjected to 1h ischemia and 2h reperfusion. Treatment (0.4 mg/kg) or placebo (saline) were 
administered i.v. 15 min after induction of  ischemia and a second time 5 minutes after induction of  
reperfusion. A) Representative picture of  the Evans Blue/TTC staining after 2h reperfusion. The normal 
tissue (non infarcted area) is stained dark blue, whereas the ischemic area (area at risk (AAR)) is stained 
brick red and the non-viable infarct area (area of  infarction (AOI)) did not stain and remained pale. B) 
Infarct area (percentage AOI of  AAR) as determined by Evans Blue/TTC staining. C) IL-6 concentrations 
were determined in heart tissue homogenates (5 mg/ml protein content) by ELISA and IL-6 per mg heart 
homogenate was calculated. All graphs show mean +/- SEM, statistical significance was tested using one-
way analysis of  variance with Dunnett post hoc test, *** P<0.001.
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the mice from all groups analyzed (Figure 3C). We did observe a (non-significant) 
reduction in the total number of  plaques for the hS360A-PC group. The number of  
advanced plaques was greatest in the placebo group and slightly decreased in the groups 
receiving treatment. Surprisingly, in the four treatment groups, total plaque area was not 
significantly different from the placebo group (Figure 3D). The areas of  the individual 
initial plaques were comparable between groups (Figure 3E), with the placebo, hS360A-
PC and hS360A-APC groups presenting with the lowest inter-individual variation. 
Figure 3. Treatment with wt- or S360A-(A)PC does not alter plaque area or # of plaques
ApoE-/- mice were injected with saline or 0.2 mg/kg of  wt-PC, S360A-PC, wt-APC or S360A-APC. 
Images of  an initial (A) and an advanced (B) plaque after hematoxylin and eosin (H&E) staining. C) 
Atherosclerotic lesions were classified as initial (black bars) or advanced (white bars) and numbers of  both 
type of  plaques per mouse were determined. D) Total plaque area in the aortic arch as determined by H&E 
staining. E) Surface area of  individual initial plaques. F) Surface area of  individual advanced plaques. All 
graphs show mean +/- SEM, statistical significance was tested using one-way analysis of  variance with 
Dunnett post hoc test, * P<0.05.
Surprisingly, the areas of  individual advanced plaques were significantly increased in 
the hwt-APC and hS360A-APC groups compared to the placebo group (Figure 3F), 
although the data points of  plaque sizes in the five different groups show considerable 
overlap. So, overall no clear effect of  hwt- or hS360A-(A)PC on plaque development 
was observed.
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Effect of  h(A)PC variants on plaque phenotype and the immune system
Subsequently the plaque phenotype was further characterized. Collagen content (Figure 
4A/E) and infiltration of  macrophages (Figure 4B/F), leukocytes (Figure 4C/G) and 
T cells (Figure 4D/H) were determined in all plaques. hS360A-APC treated mice had, 
compared to placebo treated mice, significantly lower collagen content in their plaques 
(P<0.05), while they had increased leukocyte (P<0.01) and T cell (P<0.01) infiltration. 
Interestingly, also the hwt-APC treated group presented with significantly lower collagen 
content in their plaques (P<0.05). In the hwt-PC and hwt-APC groups, we noted a trend 
towards increased T cell and leukocyte counts. Infiltration of  macrophages in plaques 
had a low variation and was not different between the placebo and different treatment 
groups. So, the plaque phenotype was slightly changed by hS360A-APC treatment and 
not by other treatments.
Figure 4. Only S360A-APC treatment influences plaque phenotype
Images of  plaques stained for collagen (A), macrophages (B), leukocytes (C), and T cells (D). E) After 
sirius red staining, the percentage of  collagen was determined by dividing the area of  collagen by the total 
plaque area. F) After Mac-3 staining, the percentage of  macrophages as a percentage of  the total number 
of  cells per plaque was calculated. G) After CD45 staining, the percentage of  leukocytes as a percentage of  
the total number of  cells per plaque was calculated. H) After CD3 staining, the percentage of  T cells of  the 
total number of  cells per plaque was calculated. All graphs show mean +/- SEM, statistical significance was 
tested using one-way analysis of  variance with Dunnett post hoc test, * P<0.05, ** P<0.01.
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The effects of  hAPC treatment on the innate and adaptive immune system were assessed 
by flow cytometric analysis of  immune cells isolated from both blood and spleen. No 
significant differences were observed between quantities of  B cells, granulocytes, NK 
cells, NKT cells and different types of  monocytes (Ly6Chigh/low/-) and T cells (CD4+, 
CD8+, CD25+ and Foxp3+) (Figure 5-7). 
Figure 5. Effect of wt- and S360A-(A)PC treatment on immune cells in blood
Percentages of  A) NK cells (NK1-1+, CD3-), B) NKT cells (NK1-1+, CD3+), C) Granulocytes (CD11b+, 
Ly6G+) and D) monocytes (CD11b+, Ly6G-) were determined by flow cytometric analysis of  mice blood. 
E) Monocytes were further characterized as Ly6C high (), Ly6C low () or Ly6C- (◊). Graphs A-D show 
mean +/- SEM.
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Figure 6. Effect of wt- and S360A-(A)PC treatment on immune cells in blood
Percentages of  A) total T cells (CD3+), B) CD8+ T cells, C) CD4+ T cells, D) regulatory T cells (FOXP3+, 
CD25+) and E) B cells (B220+) were determined by flow cytometric analysis of  mice blood. All graphs show 
mean +/- SEM.
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Effect of  h(A)PC variants on plasma levels of  cytokines IL-6, IL-10 and MCP-1
We next determined the levels of  cytokines IL-6, IL-10 and MCP-1 and of  cholesterol 
in the plasma from the animals included in this study and to this end prepared plasma 
pools by mixing equal volumes of  plasma for each of  the animals studied per group. 
Mice treated with hS360A- PC had significantly lower IL-6 levels (P<0.001) and 
increased MCP-1 levels (P<0.05), see Figure 8A/C. In the hwt-APC group, the IL-6 
levels were also lower than in the placebo group (P<0.01). The latter group was highest 
Figure 7. Effect of wt- and S360A-(A)PC treatment on immune cells isolated from spleen
Percentages of  A) total T cells (CD3+), B) CD8+ T cells, C) CD4+ T cells, D) regulatory T cells (FOXP3+, 
CD25+) and E) B cells (B220+) were determined by flow cytometric analysis of  cells isolated from mice 
spleen tissue. All graphs show mean +/- SEM, statistical significance was tested using one-way analysis of  
variance with Dunnett post hoc test, * P<0.05.
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of  all groups determined here, for both the IL-6 and the IL-10 measurements. A non-
significant trend was observed for the lowering effect of  hS360A-PC on IL-10 levels 
(Figure 8B). Cholesterol levels were slightly but significantly higher in mice treated with 
hwt-PC, hS360A-PC and hS360A-APC compared to placebo treated mice (Figure 8D).
Figure 8. Effects of wt- and S360A-(A)PC treatment on cytokine and cholesterol levels 
A) Interleukin (IL) 6 levels measured with ELISA in mouse plasma pools. B) IL-10 levels measured with 
ELISA in mouse plasma pools. C) Monocyte chemotactic protein-1 (MCP-1) levels measured with ELISA 
in mouse plasma pools. D) Cholesterol levels in mouse plasma pools measured with cholesterol CHOD-
PAP method. All graphs show mean +/- SEM, statistical significance was tested using one-way analysis of  
variance with Dunnett post hoc test, * P<0.05, ** P<0.01, *** P<0.001.
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Discussion
Several elegant studies have previously provided experimental evidence that wt-APC 
protects against acute myocardial I/R injury via both anti-inflammatory and anti-
apoptotic effects (Table 1). In this study we show that not only hwt-APC, but also hwt-
PC, hS360A-PC and hS360A-APC significantly reduce infarct area in a myocardial I/R 
model. This finding, which is a phenomenological observation at this point, deserves 
further mechanistic explanation. It has been shown (39, 40, 41) that EPCR and PAR-
1 are associated with caveolin-1 within endothelial lipid rafts. When EPCR is bound 
to the gamma-carboxyglutamic (Gla)-domain of  either wt-(A)PC or S360A-(A)PC, 
it dissociates from caveolin-1 and alters the G-protein mediated signaling of  PAR-1 
from pro-inflammatory (Gq and/or G12/13) to anti-inflammatory signaling (pertussis 
toxin–sensitive Gi-protein). In this caveolin-unbound state, cleavage of  PAR-1 by 
thrombin or APC and resulting Gi activation, initiates a barrier protective and anti-
inflammatory response, which includes activation of  Rac1 and inhibition of  RhoA and 
NFκB signaling cascades. We speculate that these mechanisms likely contributed to the 
protective effects observed for the hPC and hAPC forms tested by us, including the 
proteolytically inactive hS360A-(A)PC variant. Despite the mutation of  the active site, 
S360A-(A)PC is still able to bind EPCR via its Gla-domain (42, 43) and can thereby 
influence PAR-1 signaling pathways.
Additionally it was shown that both PC and APC significantly decrease LPS-induced 
reactive oxygen species (ROS) generation by macrophages. Remarkably these effects 
were EPCR-independent and only in APC-treated cells accompanied by inhibited NFκB 
activation (44). Alternatively, these antioxidant effects of   (A)PC may be related to 
inhibition of  NADPH oxidase or by regulation of  transcription factor Sp1 (45). PC and 
APC reduced copper-induced LDL peroxidation via interaction of  their Gla-domains 
with phospholipids on the surface of  LDL particles, and protected unsaturated fatty 
acids against oxidation (44). Both increased ROS generation and lipid peroxidation are 
observed during I/R injury and have been described to play an important role in the 
pathophysiology of  myocardial injury (46, 47). The observation that also zymogen PC 
provides in vitro antioxidant activity implies that the antioxidant properties are at least 
partly independent of  the catalytic side and in line with our finding that both hwt- and 
hS360A-(A)PC have protective properties in acute myocardial I/R injury. There are 
several possible explanations for the observation that zymogen PC induced a similar 
reduction in infarct size as APC, while in fact its antioxidant capacities are those of  
APC (44). Firstly, activation of  PC on endothelial cells generates APC with 4-fold 
higher cytoprotective barrier protective properties than exogenous APC (42). This 
discrepancy cannot be explained by differences in the local APC concentrations and 
possibly originates because protective signaling by APC is mechanistically linked to PC 
activation (42). Additionally, both zymogen PC and S360A-(A)PC have the advantage 
that these are not inhibited by circulating serpins and therefore have a longer half  life 
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in vivo (17), which would make these proteins better suited for potential application 
in a clinical therapeutic context, like for organ/tissue protection. Additional beneficial 
properties can be attributed to S360A-PC, since this molecule, unlike its wild-type 
homolog, is unlikely to result in bleeding side effects after in vivo thrombomodulin-
mediated activation by thrombin. 
Although S360A-(A)PC still has residual anticoagulant activity because of  its ability 
to limit thrombin formation through competition with FXa and FIXa for resp. FVa 
and FVIIIa, it is unlikely that these anticoagulant properties of  S360A-(A)PC have 
contributed to the reduced myocardial infarct area observed in S360A-(A)PC treated 
mice. It has been shown before (14, 48) that the use of  in vivo thrombin inhibition by 
heparin administration or the selective thrombin generation inhibitor dansyl glutamyl-
glycyl-arginyl chloromethyl ketone-treated activated factor X (DEGR-FXa), failed to 
reduce myocardial I/R injury and I/R-induced spinal cord injury. Likewise, another 
study by Wang and coworkers (49) compared the effects of  the cytoprotective-selective 
5A-APC variant (<10% anticoagulant but normal cytoprotective activity) and the 
anticoagulant-selective E149A-APC variant (>3-fold increased anticoagulant activity 
but defective cytoprotective activities) in a murine focal ischemic stroke model. Despite 
its reduced anticoagulant activity, 5A-APC significantly decreased infarct- and edema 
volume and improved neurological outcome, while E149A-APC administration resulted 
in significantly worsened neurological outcome and increased infarct- and edema 
volume. Additionally, E149A-APC treatment was associated with an increased risk of  
bleeding as indicated by 5-fold increased hemoglobin levels in the ischemic brain.   
In contrast to the study of  Loubele (14) and coworkers we did not find a significant 
effect of  h(A)PC treatment on IL-6 levels in heart homogenates after acute myocardial 
I/R injury. One possible explanation for the difference is the fact that IL-6 levels in 
placebo treated mice were 5-fold lower in the present study, leaving less room for a 
further decrease by h(A)PC treatment. The discrepancy may also arise from the fact that 
we used h(A)PC and Loubele and co-workers mAPC. Previous research has shown that 
hAPC was significantly less potent in murine stroke models as compared to mAPC (24). 
The observed difference cannot be explained by a difference in proteolytic activity, but 
the lower affinity of  hAPC for mPAR-1 than for the human isoform of  this receptor 
probably plays a role (50). Differences in sequence (69% sequence identity between 
hAPC and mAPC (22)) or post-translational modifications can possibly explain these 
different affinities. 
While we hypothesized that administration of  h(A)PC would also influence plaque 
development in the long term chronic atherosclerosis mouse model, we found that 
none of  the h(A)PC variants significantly protected against the development of  
atherosclerosis in this mouse model of  chronic inflammation. hwt-APC and hS360A-
APC even slightly increased plaque area of  advanced plaques, but the differences 
between these groups and the other groups were relatively small. Probably the lack 
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of  effect of  h(A)PC on reducing plaque development can be explained by the in vivo 
bioavailability after injection. Previously it was shown that i.p. administration of  0.1 
or 0.8 mg/kg mAPC produces a transient rise in APC levels in circulation for 3 hours, 
with a plateau after around 20 min (32, 51). This transient rise in (A)PC concentration 
in circulation, that was achieved twice a week in our model, was apparently not enough 
to initiate protective signaling that lasted long enough to provide long term protection 
against atherosclerosis development during the time span of  our study. 
We have however observed a clear effect of  hS360A-PC and hwt-APC administration 
on IL-6 levels in plasma. The decrease in concentration of  the pro-inflammatory 
cytokine IL-6 after hS360A-PC and hwt-APC treatment can possibly be explained by 
inhibited IL-6 release by neutrophils as a result of  h(A)PC treatment (52). Conflicting 
reports on the role of  IL-6 in the development of  murine atherosclerosis have 
appeared; some studies show that IL-6 promotes atherosclerosis while other studies 
show that IL-6-/- mice are more atherogenic than control mice, so it is not clear what 
the exact contribution of  IL-6 to atherogenesis is (53-58). In hS360A-PC treated mice 
we found an increased level of  MCP-1. Remarkably, this was not accompanied by 
increased percentages of  leukocytes and macrophages in plaques and therefore likely 
had no effects on plaque development. In hS360A-APC treated mice the phenotype 
of  the atherosclerotic plaques was slightly changed. Plaques contained significantly less 
collagen, while the infiltration of  both leukocytes and T-cells was increased. Both an 
increase in activated immune cells and a decrease of  collagen in plaques are associated 
with a more unstable plaque phenotype (59, 60). 
Analysis of  other cardiovascular studies which have studied the in vivo effects of  (A)
PC in a cardiovascular context (Table 1) reveals that administration of  APC has mainly 
been studied in models of  acute diseases like I/R injury and stroke. In most of  these 
experimental models administration of  APC improved primary and secondary outcome 
variables, like survival, lesion/edema volume, cardiac/neurological function and lowered 
the concentration of  inflammation markers. For comparison between experiments it is 
important to realize that administration of  0.2 mg/kg APC i.v. and 0.8 mg/kg APC i.p. 
result in similar APC plasma pharmacokinetic profiles (32). Wang et al. (23) show that an 
APC mutant that is not able to cleave PAR-1 (E170A-PC) does not have any protective 
effect, while an APC mutant with greatly impaired anticoagulant function (3K3A-APC) 
was as effective as wt-APC in decreasing lesion volume and improving neurological 
function. This result in itself  suggests that mainly the cytoprotective PAR-1-dependent 
effects of  APC, rather than the anticoagulant functions of  APC, are important for 
protection in cardiovascular disease. However, the current study showed that hS360A-
APC was as effective as hwt-APC in decreasing lesion volume in myocardial I/R injury, 
although this variant had strongly decreased anti-coagulant activity and was not able to 
cleave PAR-1. We hypothesize that hS360A-APC was protective because it can bind 
through its Gla-domain to EPCR and thereby promotes protective PAR-1 signaling 
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via endogenous mAPC and thrombin (21). Both these serine proteases are known 
to be formed during I/R damage (61, 62). Alternatively, hS360A APC may reduce 
ROS formation and bind through its Gla-domain to phospholipids on LDL particles, 
resulting in reduced lipid peroxidation as discussed above for PC and APC. Both effects 
can contribute to decreased lesion volume in acute myocardial I/R injury.
We have studied the effects of  4 different h(A)PC variants in mouse models for 
cardiovascular disease: in an acute I/R injury model and in a chronic atherosclerosis 
model. We have shown that treatment with both hwt and hS360A-(A)PC decreases 
infarct area in our acute murine myocardial I/R injury model. However, no significant 
effects were observed for the development of  atherosclerotic plaques, a chronic slow 
process. Trends were observed that indicate that h(A)PC may be able to reduce in 
particular IL-6 and collagen levels, but under the conditions used in our experiments 
these did not lead to significant differences in total plaque area or plaque phenotype. 
Comparison of  our data with those in literature learns that the (A)PC dose, mode of  
administration and species of  administered (A)PC varied among different studies. We 
therefore propose that for future experiments in chronic disease models using mice, it will 
be preferable to include at least mAPC, which is administered preferably intravenously 
and more frequently than in the current study. If  possible a slow-release device would 
be a preferred method, but this will require that the (A)PC preparations are stable for 
extended periods of  time at body temperature. Nonetheless, while recognizing that 
such controlled study has not been provided yet, we regard our current study as valuable 
information that will enable the needed further study. In conclusion, this study showed 
that both hwt and hS360A-(A)PC protect in an acute murine myocardial I/R injury 
model and have the potential to influence development of  chronic inflammation as 
occurring during atherosclerosis as well.   
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Abstract
Histones are cationic nuclear proteins that package and order DNA into structural units 
called nucleosomes. Extracellular histones are cytotoxic and major mediators of  death 
in murine sepsis. Circulating nucleosomes and histones are elevated in patients with 
inflammation, sepsis and traumatic injury. Activated protein C (APC), an anticoagulant 
protein that can cleave histones in vitro and in vivo, reduces histone cytotoxicity. 
We investigated in vitro cleavage of  histone H3 by human wildtype (wt)-APC and 
by the human APC variant 5A-APC (1), which has minimal anticoagulant activity. 
We determined effects of  Ca2+ and phospholipids on H3 cleavage and cytotoxicity. 
Furthermore, we identified APC cleavage sites in H3.
H3 cleavage by APC is most efficient in the presence of  physiological Ca2+ 
concentrations and phospholipid vesicles containing both phosphatidylethanolamine 
and phosphatidylserine. Surprisingly, 5A-APC cleaved H3 significantly better than wt-
APC. Both wt-APC and 5A-APC cleaved histone H3 at R26 and R52, resulting in two 
H3 fragments of  12.49 kDa (K27-A135) and 9.66 kDa (R53-A135). Both fragments 
lack in vitro cytotoxic properties towards endothelial cells.
5A-APC therefore can potentially be used for treatment of  patients with acute and 
chronic pathologic conditions characterized by increased histone levels in circulation. 
The advantages of  this variant over wt-APC are that 5A-APC cleaves histones more 
efficiently and that higher concentrations can be safely administered without risk for 
bleeding complications. 
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Introduction
Histones are cationic nuclear proteins that package and order DNA into structural units 
called nucleosomes. Nucleosomes consist of  a core octamer containing two copies each 
of  histones H2A, H2B, H3 and H4 surrounded by a superhelix of  146 bp DNA (2). 
Both the nucleosome core particle and the DNA are bound by linker protein histone 
H1 to form a higher-order chromatin structure, called chromatosome, which stabilizes 
the nucleosome (3). 
In murine models it was shown that extracellular histones are major mediators of  
death in sepsis and that mainly histone H3 and histone H4 are cytotoxic (4). Increased 
concentrations of  extracellular histones and nucleosomes were found in circulation 
of  patients with systemic inflammation, sepsis and traumatic injury (5-7) and were 
shown to correlate with disease severity and mortality (8). Extracellular histones and 
nucleosomes can originate from apoptotic and necrotic cells (6) and from neutrophil 
extracellular traps (NETs) that are formed after neutrophil activation (9, 10). NETs are 
composed of  granular and nuclear constituents and are produced to trap, disarm and kill 
bacteria extracellularly (10). It was already known for a long time that histones possess 
bactericidal activity (11). Extracellular histones not only kill bacteria but also host cells 
such as endothelial cells and thereby contribute to endothelial dysfunction, organ failure 
and death during sepsis (4, 12). The exact molecular mechanism of  histone-mediated 
cytotoxicity is not clear yet. Histones are able to interact directly with membrane 
phospholipids and may form channels in both plasma and nuclear membranes, causing 
loss of  membrane barrier function (13-15). The tertiary structure of  histones and the 
degree of  positive charge play important roles in this activity, which is enhanced in the 
presence of  anionic phospholipids (13). Another line of  evidence shows that histones 
can activate Toll-like receptor (TLR) 2 and TLR4, leading to cytokine production that 
results in sterile inflammation, tissue injury and death in mouse models (16).
In critically injured trauma patients, the association between increased histone levels 
and mortality was abrogated by concomitant elevation of  activated protein C (APC) 
levels (8). Xu et al. (4) showed that APC can target and cleave histones both in vitro and 
in vivo and thereby reduce their cytotoxicity. APC is best described as an anticoagulant 
serine protease that, together with its cofactors protein S and factor V (FV), regulates 
thrombin formation by proteolysis of  the active coagulation factors V (FVa) and VIII 
(FVIIIa) (17, 18). It is known that three loops of  a positively charged exosite on the 
surface of  APC are important for FVa and FVIIIa binding and cleavage. These loops 
are the 191 loop (residues 190-193), the calcium binding loop (residues 225-235) and 
the autolysis loop (residues 302-317) (19, 20). Mutation of  three residues in the 191 
loop and two residues in the calcium binding loop (KKK191-193AAA and RR229-
230AA) yields a mutant (5A-APC), firstly described by Mosnier et al. (1), that was found 
to possess minimal anticoagulant activity but that retains normal cytoprotective activity.
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In the present study we describe the proteolytic cleavage of  histone H3 by wt-APC and 
5A-APC and the effect of  such cleavage on histone-mediated cytotoxicity to endothelial 
cells. We furthermore describe the effect of  calcium and phospholipid vesicles on the 
efficiency of  histone H3 cleavage by APC and identify the cleavage sites of  APC in 
histone H3. 
Materials & Methods
Expression and purification of  recombinant human PC
Recombinant human 5A-PC (containing alanine substitutions of  residues K191, K192, 
K193, R229 and R230) was obtained by PCR-based site-directed mutagenesis of  wt-PC 
cDNA. The cDNA of  wt-PC and 5A-PC were inserted into the eukaryotic expression 
vector pRc/CMV (Invitrogen), transfected into HEK293 cells (CRL-1573 ATCC) and 
recombinant 5A-PC was purified and characterized as described earlier (21,22). 
The purity and integrity of  wt-PC and 5A-PC preparations was evaluated by SDS-
PAGE. Wt-PC and 5A-PC concentrations were quantified by measurement of  
absorbance at 280 nm using an absorption coefficient of  14.5 (280 nm, 1%, 1cm) and 
by ELISA, employing the horse anti-human PC polyclonal antibody PAHPC-H (HTI, 
VT, USA) as a catcher antibody and the horseradish peroxidase-conjugated anti-human 
PC polyclonal (Dako P0374, Glostrup, Denmark) as a detecting antibody (23). 
Activation of  PC and catalytic activity against small substrates
Wt-PC and 5A-PC were activated with a 1 ml HiTrap NHS-Activated HP column 
(GE Health care, Little Chalfont, United Kingdom) to which 50 Units of  carrier-free 
Protac (Pentapharm, Basel, Switzerland) were conjugated. Up to 0.5 mg of  (5A) PC 
was incubated for 2 hours on the column at RT, and was next eluted and concentrated 
with 10K Macrosep Advance Centrifugal Devices (Pall Corporation, Port Washington, 
NY). Complete activation was ascertained by measuring the amidolytic activity of  APC 
with S-2366 (Chromogenix, Milan, Italy) directly and after 60 minutes incubation in 
the presence of  additionally added (0.05 units/ml final concentration) Protac. For both 
wt-PC and 5A-PC, completion of  activation was verified by SDS PAGE analysis. APC 
concentrations were determined from the absorbance at 280 nm and by the above-
described PC ELISA.
Preparation of  phospholipid vesicles
Small unilamellar phospholipid vesicles were prepared as described (24). Synthetic 
lipids 1,2 dioleoyl-sn-glycero-3-phosphoserine (DOPS), 1,2 dioleoyl-sn-glycero-3-
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phosphocholine (DOPC) and 1,2 dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) 
were obtained from Avanti Polar Lipids (Alabaster, Alabama).
Cell culture
The human endothelial cell line EA.hy926, kindly provided by Dr. Dariusz Leszczynski 
(STUK - Radiation and Nuclear Safety Authority, Helsinki, Finland), was maintained 
in Dulbecco’s modified eagle’s medium (Lonza, Basel, Switzerland) supplemented with 
penicillin, streptomycin, L-glutamine, 10% fetal bovine serum and HAT supplement 
(all Life Technologies, Carlsbad, CA) in a humidified atmosphere at 37 °C and 5% CO2.
Histone H3 cleavage by APC
40 μg/ml Purified calf  thymus histone H3 (Roche, Basel, Switzerland) was incubated 
for 30 minutes at 37 °C in buffer (25 mM Hepes, 150 mM NaCl, pH: 7.7) containing 
0-1000 nM wt-APC, 0-500 nM 5A-APC, 0-5 mM CaCl2 and 0-200 μM phospholipid 
vesicles (DOPC, 20:80 DOPS:DOPC (mol:mol) or 20:60:20 DOPS:DOPC:DOPE 
(mol:mol:mol)). Next, cell cytotoxicity and histone H3 cleavage were analyzed with 
respectively flow cytometry and SDS-PAGE followed by Western blotting (see method 
histone H3 determination). 
Flow cytometry
EA.hy926 cells were cultured in 24 well plates (1 x105 cells/well) to produce confluent 
monolayers, washed with PBS and incubated for exactly 30 minutes with (cleaved) histone 
H3 (prepared as described before) at 37°C. Afterwards buffer containing detached dead 
cells was collected in a fresh tube and the remaining cells were detached with 0.05% 
trypsin/EDTA during exactly 5 minutes and transferred to the same tube. Cells were 
pelleted, diluted to 1 x 106 cells/ml and incubated for 10 min on ice in buffer (10 mM 
Hepes, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, pH: 7.4) containing 
2.5 μg/ml propidium iodide (PI) (Life Technologies, Carlsbad, CA). Percentages of  PI 
positive cells and mean fluorescence of  PI were determined with a flow cytometer (BD 
AccuriTM C6, Franklin Lakes, New Jersey) and BD CFlow plus software. 
Western blotting
Ten times diluted samples of  (cleaved) histone H3 (prepared as described above) 
were analysed via SDS-PAGE gel electrophoresis (6-15%) and transferred to PVDF 
membranes (Pall Corporation, Port Washington, NY) by a semi-dry blotting technique. 
After blocking, the membranes were overnight incubated at 4 °C with a rabbit polyclonal 
histone H3 antibody mapping an epitope at the C-terminus (1:1000, sc-8654-R, Santa 
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Cruz Biotechnology, Heidelberg, Germany), followed by incubation with a biotinylated 
goat anti-rabbit IgG antibody (1:1000, Vector Laboratories, Burlingame, CA) for 30 
minutes at RT and finally with StreptABComplex/AP solution (1:3000, Dako, Glostrup, 
Denmark) for 30 minutes at RT. Protein bands were detected by BCIP/NBT (Sigma-
Aldrich, St. Louis, Missouri) and density of  histone H3 bands was quantified by ImageJ 
software (x86, Wayne Rasband) and percentages of  the total intensity of  all bands per 
lane were calculated.
Prediction of  cleavage sites and histone H3 fragments
The bovine histone H3.1 sequence was retrieved from the uniprot database (ID: 
P68432). The sequence contained 135 amino acids (after the initiator methionine being 
removed). The molecular weight (MW) of  fragments after APC-catalyzed cleavage was 
estimated from Western blot analysis. We defined an algorhythm to predict the sequence 
of  detectable histone H3 fragments based on the following assumptions: 1) APC is able 
to cleave C-terminal of  lysine (K) or arginine (R) when consecutive P1 to P1’ amino 
acids are: KK, KS, RE, RG, RH, RK, RM, RN or RR (25-27); 2) the fragments must 
contain the known epitope of  the histone H3 antibody used for Western blotting (at least 
10 amino acids from D106 to A135); 3) there are no post-translational modifications in 
the histone structure. Potential cleavage sites in the bovine histone H3.1 were identified. 
The molecular weights of  potential histone H3 fragments were calculated and compared 
to the estimated MW of  fragments obtained via Western blot analysis. 
N terminal sequencing by Edman degradation
A sample containing different histone H3 cleavage products was transferred from a 
SDS-PAGE gel to a PVDF membrane, stained with Coomassie Blue and two bands 
were cut out for N terminal sequencing analysis. The analysis was performed by 
Alphalyse (Odense, Denmark) on an ABI Procise 494 sequencer. The cyclic procedure 
was performed in 3 steps. In step 1 PITC reagent was coupled to the N-terminal amino 
group under alkaline conditions. In step 2 the N-terminal residue was cleaved in acidic 
media. In step 3, the PITC coupled residue was transferred to a flask, converted to a 
PTH-residue and identified by HPLC chromatography. The next cycle was then started 
for identification of  the next N-terminal residue. If  the sample contained more than 
one protein or N-terminal variants of  the same protein then residues will be shown 
as X/Y/Z. Due to differences in the chemical reaction for certain amino acids the 
identification of  some residues may be uncertain and was shown in parentheses (X/Y).
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Statistical analyses
Analysis of  data was performed in GraphPad Prism 5. Results in Figure 2 are expressed 
as mean ± SEM and independent samples T tests were used to analyze differences 
between groups. For analysis of  correlation in Figure 3 Coefficients of  determination 
(R2), Pearson correlation coefficients (r) and two tailed P-values were calculated. In all 
cases P-values <0.05 were regarded as statistically significant.
Results
Histone H3 cleavage is more efficient by 5A-APC than by wt-APC and influenced by 
calcium
Histone H3 cleavage by wt-APC was followed over time by Western blotting (Figure 
1A). Uncleaved, full length histone appears as a ~15 kDa band (t=0), corresponding to 
its calculated weight of  15.25 kDa. Within 1 minute of  incubation, 94% of  full-length 
histone H3 was cleaved and within 3 minutes all full-length histone H3 disappeared and 
different cleavage products appeared. Finally, after 1 hour of  incubation two histone H3 
cleavage products with estimated MW of  12.32 kDa and 9.70 kDa remained and can be 
considered as end products. 
Cleavage of  histone H3 by wt-APC was compared with cleavage by the 5A-APC mutant, 
which has minimal anticoagulant activity but normal cytoprotective capacity. Figure 
1B shows that 5A-APC cleaves histone H3 more efficiently compared to wt-APC. At 
concentrations of  50 and 200 nM, after a fixed time interval of  30 minutes incubation, 
wt-APC has cleaved approximately 50% of  full-length histone H3, while 5A-APC has 
cleaved all full-length histone H3. When higher concentrations (500 nM) of  wt-APC 
are used, histone H3 was cleaved completely within 30 minutes of  incubation and the 
Western blot of  final reaction products was comparable to that of  5A-APC.
Next we investigated the effect of  calcium on histone H3 cleavage by APC. Calcium-
ions are important for procoagulant and anticoagulant processes in general and for the 
maintenance of  the Ca2+-dependent conformation of  APC, for phospholipid binding 
of  APC and hence for APCs anticoagulant activity in particular (28). We found that 
CaCl2 concentrations of  1 mM and 2.5 mM, which are in a range of  what is considered 
as “physiological”, are optimal for histone H3 cleavage by wt-APC (Figure 1C) and 
5A-APC (not shown). In either the absence of  CaCl2 or in the presence of  higher CaCl2 
concentrations (>5 mM) APC cleaved histone H3 less efficient.
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Cleavage of  histone H3 decreases its cytotoxicity to endothelial cells
To investigate the effect of  histone H3 cleavage on its cytotoxicity, histone H3 cleavage 
products were incubated for 30 minutes with endothelial cells, followed by determination 
of  cell viability by flow cytometry. In the absence of  histone H3, APC did not influence 
cell viability of  endothelial cells in any of  the experimental conditions used (not 
shown). Figure 2A shows that 30 min pre-incubation of  histone H3 with different 
concentrations of  either wt-APC or 5A-APC dose-dependently decreased cytotoxicity 
of  histone H3 and resulted in increased remaining cell viability of  endothelial cells. In 
agreement with the increased cleavage of  histone H3 by 5A-APC observed by Western 
blotting, we observed that 5A-APC destroys H3 cytotoxicity more efficiently than wt-
APC (Figure 2A). 
Figure 2B shows that pre-incubation of  histone H3 with APC in the presence of  1 mM 
and 2.5 mM CaCl2 reduces histone-mediated cytotoxicity. The percentage of  viable 
cells increased significantly from 44.73% in the absence of  calcium to 73.74% in the 
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Figure 1. Histone H3 cleavage by wt and 5A-APC 
A) 5 µg/ml histone H3 was incubated for 0-60 min at 37 °C with 85 nM wt APC and 5 mM CaCl2. The estimated 
MW of bands: 1) 15.25 kD, 2) 14.55 kDa, 3) 13.77 kDa, 4) 13.00 kDa, 5) 12.32 kDa and 6) 9.70 kDa. B) 40 
µg/ml histone H3 was incubated for 30 min at 37 °C with 50-500 nM wt APC or 50-500 nM 5A-APC. C) 40 
µg/ml histone H3 was incubated for 30 min at 37 °C with 200 nM wt APC and 0-5 mM CaCl2. All samples were 
analyzed with SDS-PAGE followed by Western blot using a rabbit polyclonal histone H3 antibody mapping an 
epitope at the C-terminus. Western blots are representative images of at least 3 experiments. 
 
Figure 2B shows that pre-incubation of histone H3 with APC in the presence of 1 mM and 2.5 
mM CaCl2 reduces histone-mediated cytotoxicity. The percentage of viable cells increased 
significantly from 44.73% in the absence of calcium to 73.74% in the presence of 1 mM 
CaCl2 (P=0.0270) and 68.15% in the presence of 2.5 mM CaCl2 (P=0.0199). This is in 
agreement with the increased cleavage of hist ne H3 observed in the presence of these CaCl2 
concentrations. In the absence of APC addition of CaCl2 does not have any effect on cell 
viability. 
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Figure 1. Histone H3 cleavage by wt and 5A-APC
A) 5 μg/ml histone H3 was incubated for 0-60 min at 37 °C with 85 nM wt APC and 5 mM CaCl2. The 
estimated MW of  bands: 1) 15.25 kD, 2) 14.55 kDa, 3) 13.77 kDa, 4) 13.00 kDa, 5) 12.32 kDa and 6) 9.70 
kDa B) 40 μg/ml histone H3 was incubated for 30 min at 37 °C with 50-500 nM wt APC or 50-500 nM 
5A-APC. C) 40 μg/ml histone H3 was incubated for 30 min at 37 °C with 200 nM wt APC and 0-5 mM 
CaCl2. All samples were analyzed with SDS-PAGE followed by Western blot using a rabbit polyclonal 
histone H3 antibody mapping an epitop  at the C-terminus. Western blots are represe ative i ges of  at 
least 3 experiments.
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presence of  1 mM CaCl2 (P=0.0270) and 68.15% in the presence of  2.5 mM CaCl2 
(P=0.0199). This is in agreement with the increased cleavage of  histone H3 observed in 
the presence of  these CaCl2 concentrations. In the absence of  APC addition of  CaCl2 
does not have any effect on cell viability.
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Figure 2. Effect of APC, CaCl2 and phospholipids on histone H3 cytotoxicity to endothelial cells
In all conditions 40 µg/ml histone H3 was pre-incubated for 30 min at 37 °C with different concentrations of 
APC, CaCl2 and phospholipids. Samples were afterwards incubated for 30 min with EA.hy926 cells, followed by 
flow cytometric analysis of cell viability with propidium iodide (PI). A) Pre-incubation of histone H3 with 0-
1000 nM wt APC or 0-500 nM 5A-APC. *P<0.05 for comparison of wt APC and 5A-APC. n=2-9 per condition. 
B) Pre-incubation of histone H3 with 0 or 200 nM wt APC and 0-5 mM CaCl2. *P<0.05 compared to 0 mM
CaCl2. n=2-7 per condition. C) Pre-incubation of histone H3 with 2.5 mM CaCl2 and 0-200 µM phospholipids 
PC, 20:80 PS:PC or 20:60:20 PS:PC:PE in the absence of APC. *P<0.05 compared to 0 µM phospholipids. n=3 
per condition. D) Pre-incubation of histone H3 with 2.5 mM CaCl2 and 0-200 µM phospholipids PC, 20:80 
PS:PC or 20:60:20 PS:PC:PE in the presence of 200 nM wt APC. *P<0.05 compared to 0 µM phospholipids. 
n=3 per condition.
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Figure 2. Effect of APC, CaCl2 and phospholipids on histone H3 cytotoxicity to endothelial cells
In all conditions 40 μg/ml histone H3 was pre-incubated for 30 min at 37 °C with different concentrations 
of  APC, CaCl2 and phospholipids. Samples were afterwards incubated for 30 min with EA.hy926 cells, 
followed by flow cytometric analysis of  cell viability with propidium iodide (PI). A) Pre-incubation of  
histone H3 with 0-1000 nM wt APC or 0-500 nM 5A-APC. *P<0.05 for comparison of  wt APC and 
5A-APC. n=2-9 per condition. B) Pre-incubation of  histone H3 with 0 or 200 nM wt APC and 0-5 mM 
CaCl2. *P<0.05 compared to 0 mM CaCl2. n=2-7 per condition. C) Pre-incubation of  histone H3 with 2.5 
mM CaCl2 and 0-200 μM phospholipids PC, 20:80 PS:PC or 20:60:20 PS:PC:PE in the absence of  APC. 
*P<0.05 compared to 0 μM phospholipids. =3 per condition. D) Pre-incubation of  histone H3 with 2.5 
mM CaCl2 and 0-200 μM phospholipids PC, 20:80 PS:PC or 20:6 :20 PS:PC:PE in the presence of  200 nM 
wt APC. *P<0.05 compared to 0 μM ph spholipids. n=3 per condition.
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Effect of  phospholipid vesicle composition on histone H3 cleavage by APC 
It is known that histones interact with membrane phospholipids (13, 29) and Xu et al. 
(4) have shown that APC cleaves histone H3 and histone H4 better in the presence 
of  liposomes containing phosphatidylethanolamine (PE). We here investigated the 
effect of  phospholipid vesicle composition on the cytotoxicity of  histone H3 towards 
endothelial cells in the presence and absence of  APC. Histone H3 was pre-incubated 
with different concentrations of  phospholipid vesicles containing only PC, 20:80 
(mol:mol) phosphatidylserine (PS): phospatidylcholine (PC) or 20:60:20 (mol:mol:mol) 
PS:PC:PE in the presence or absence of  200 nM wt-APC. In the absence of  APC, none 
of  the phospholipid vesicle compositions induced any histone H3 cleavage (not shown, 
as judged by Western blot analysis). Nevertheless, all phospholipid compositions dose-
dependently protected endothelial cells against histone H3 cytotoxicity. Figure 2C 
shows that PC has only a minor, non-significant, effect on H3 cytotoxicity, 20:80 PS:PC 
has an intermediate effect that was significant at a concentration of  200 μM (P=0.003), 
and 20:60:20 PS:PC:PE phospholipids were most effective in reducing H3 cytotoxicity 
with effects reaching significance at both 50 μM (P=0.0012) and 200 μM (P=0.0022). 
Thus, the presence of  phospholipid vesicles, even in the absence of  APC, can protect 
endothelial cells against the cytotoxic effects of  histone H3.
The residual cell viability in the absence of  added lipid vesicles increased from ~25% to 
~75% by addition of  200 nM wt-APC. Addition of  20:80 PS:PC or 20:60:20 PS:PC:PE 
phospholipid vesicles resulted in increased histone H3 cleavage by APC (not shown) 
and an additional stimulation of  cell protection (Figure 2D). Phospholipids that contain 
only PC do not significantly enhance the effect of  APC on cell viability (at 200 μM 
PC, P=0.1156), while 20:80 PS:PC phospholipids enhance the effect of  APC at 50 
μM (P=0.0171) and 200 μM (P=0.0027). Phospholipid vesicles that contain both PS 
and PE significantly increase cell viability at concentrations of  25 μM (P=0.0093), 
50 μM (P=0.0032) and 200 μM (P=0.0025). So, both in the absence and presence of  
APC 20:60:20 PS:PC:PE phospholipid vesicles protect endothelial cells best against 
the cytotoxic effects of  histone H3, while overall protection in the presence of  APC 
exceeds that seen in its absence.
Histone H3 cleavage products with estimated MW of  12.32 kDa and 9.70 kDa are not 
cytotoxic to endothelial cells
The effect of  histone H3 cleavage on its cytotoxicity was further analysed as is 
represented in Figure 3. We performed semi-quantitative analysis of  Western blots by 
comparison of  band intensities of  full-length histone H3 (Figure 3A) and the cleavage 
end products of  12.32 kDa (Figure 3B) and 9.70 kDa (Figure 3C), for all available 
different conditions tested in different experiments that included wt-APC in either the 
presence or absence of  CaCl2. Next, we correlated the Western blot band intensities to 
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cell viability of  endothelial cells in culture determined by flow cytometry 30 minutes 
after addition of  fragments. In flow cytometry measurements in the absence of  histone 
H3, APC did not influence cell viability (not shown). Figure 3A shows that there is a 
significant negative correlation between the amount of  full-length histone H3 present 
and cell viability of  endothelial cells (P>0.0001, Pearson r = -0.8076, R2 = 0.6523). 
The decrease of  the full-length histone H3 band, as is observed during APC-catalyzed 
proteolysis of  H3, is accompanied by an increase in both the 12.32 kDa and 9.70 kDa 
histone H3 bands. The band intensity of  both of  these fragments on Western blot 
showed a significant positive correlation with cell viability of  endothelial cells (12.32 kDa 
fragment: P>0.0001, Pearson r = 0.8435, R2 = 0.7114; 9.70 kDa fragment: P>0.0001, 
Pearson r = 0.8235, R2 = 0.6782). From this we conclude that both histone H3 cleavage 
products do not possess cytotoxicity towards endothelial cells.
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Figure 3. Cleavage of histone H3 correlates with its cytotoxicity to endothelial cells 
40 µg/ml histone H3 was incubated for 30 min at 37 °C with different concentrations of wt APC and CaCl2. 
Incubated H3 samples were analyzed i) on cleaved products using SDS-PAGE and Western blot analysis and ii) 
on cytotoxicity by 30 min incubation with EA.hy926 cells followed by flow cytometric analysis of cell viability. 
ImageJ software was used to quantify the density of three different histone H3 bands (see arrows figure 1A): 
full-length histone H3 band (A), 12.32 kDa histone H3 band (B) and 9.70 kDa histone H3 band (C). Coefficients 
of determination (R2) and Pearson correlation coefficients (r) were calculated in GraphPad Prism 5. 
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Figure 3. Cleavage of histone H3 correlates with its cytotoxicity to endothelial cells
40 μg/ml histone H3 was incubated for 30 min at 37 °C with different concentrations of  wt APC and 
CaCl2. Incubated H3 samples were analyzed i) on cleaved products using SDS-PAGE and Western blot 
analysis and ii) on cytotoxicity by 30 min incubation with EA.hy926 cells followed by flow cytometric 
analysis of  cell viability. ImageJ software was used to quantify the density of  three different histone H3 
bands (see arrows figure 1A): full-length histone H3 band (A), 12.32 kDa histone H3 band (B) and 9.70 
kDa histone H3 band (C). Coefficients of  determination (R2) and Pearson correlation coefficients (r) were 
calculated in GraphPad Prism 5.
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Prediction of  APC cleavage sites in histone H3
Based on our assumptions, the developed algorhythm identified 13 potential cleavage 
sites in histone H3 (R8, K9, R17, R26, K27, K36, R49, R52, K56, R63, R72, R128 and 
R131) and 38 potentially detectable histone H3 fragments. The MW of  these fragments 
(Table 1) was compared with the estimated MW of  fragments that were obtained after 
Western blot analysis (Figure 1: 14.55, 13.77, 13.00, 12.32 and 9.70 kD). The fragments 
that matched the predicted MW of  the fragments best were marked in dark grey and 
other possible fragments that had a maximum MW deviation of  0.2 kDa were marked 
in light grey in table 1. 
Table 1: Molecular weights of predicted histone H3 fragments based on our algorhythm.
 
Fragment Molecular 
Weight (kDa)
Fragment Molecular 
Weight (kDa)
Fragment Molecular 
Weight (kDa)
G132-A135 0.41 E50-R128 9.22 K27-A135 12.49
R129-R131 0.43 R53-R131 9.25 K18-R128 12.62
R129-A135 0.84 E50-R131 9.64 K18-R131 13.04
E73-R128 6.29 R53-A135 9.66 S10-R128 13.37
E73-R131 6.72 E50-A135 10.06 K18-A135 13.46
E73-A135 7.13 K37-R128 10.75 K9-R128 13.50
K64-R128 7.43 K37-R131 11.18 S10-R131 13.80
K64-R131 7.86 S28-R128 11,52 K9-R131 13.93
S57-R128 8.25 K37-A135 11.59 S10-A135 14.21
K64-A135 8.27 K27-R128 11.65 K9-A135 14.34
S57-R131 8.67 S28-R131 11.95 A1-R128 14.41
R53-R128 8.82 K27-R131 12.07 A1-R131 14.84
S57-A135 9.08 S28-A135 12.36 A1-A135 15.25
The bovine histone H3.1 sequence was retrieved from the uniprot database (ID: P68432). Based on the 
assumptions described in the methods section, potential cleavage sites in the histone H3 sequence were 
identified and the molecular weight of  possible fragments after APC cleavage was calculated. Uncleaved, 
full length histone H3 (A1-A135) has a molecular weight (MW) of  15.25 kDa. Based on semi-quantitative 
Western blot analysis we estimated the MW of  APC cleavage products 2 t/m 6 (see figure 1) to be 14.55, 
13.77, 13.00, 12.32 and 9.70 kD. The fragments that matched our predicted MW best are marked in dark 
grey and other possible fragments that deviated maximum 0.2 kDa from our predicted MW were marked 
in light grey.  
To further verify the identity of  APC-cleavage sites we performed N-terminal sequencing 
to determine the first five N-terminal amino-acids of  the two end products of  histone 
H3 cleavage (indicated as bands 5 and 6 in Figure 1). In both fragments 3 consecutive 
amino-acids could be determined with 100% certainty (Figure 4). Both of  these amino-
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acid sequences were only present at one position in the histone H3 sequence, so the 
cleavage sites could be exactly determined.
The location of  these cleavage sites is at the R26-K27 and at the R52-R53 peptide bond. 
The resulting histone H3 fragments were based on the bovine histone H3.1 sequence 
retrieved from the uniprot database (ID: P68432) determined at 12.49 kDa (K27-A135, 
indicated as band 5, Figure 1) and 9.66 kDa (R53-A135, indicated as band 6) and were 
correctly identified by our algorhythm. Other predicted cleavage sites based on our 
algorhythm are R8/K9, R17, R128 and R131, resulting in the histone H3 fragments 
K18-R131 (13.04 kDa, indicated as band 4), S10-R131/K9-R131 (13.80/13.93 kDa, 
indicated as band 3) and A1-R128 (14.84 kDa, indicated as band 2). 
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Figure 4: APC cleaves histone H3 at arginine (R)26 and R52 
Edman N terminal sequencing was used to determine the first five N terminal amino acids of the histone H3 
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sequences of both histone H3 fragments are highlighted in grey.   
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Discussion
We have shown that APC-catalysed cleavage of  histone H3 is accelerated in the 
presence of  CaCl2 concentrations with an apparent optimal CaCl2 concentration at the 
near physiological concentration range of  1 to 2.5 mM. This optimum in proteolysis is 
reminiscent of  that found for the cleavage of  FVa by APC (30) which also shows an 
optimum at ~2 mM. Calcium ions are in general important for pro- and anticoagulant 
processes and in case of  APC for the maintenance of  the overall structure and its 
phospholipid binding capacities (28).
We observed that phospholipids not only accelerate cleavage of  histone H3 by APC, 
but surprisingly also reduced the cytotoxicity of  histone H3 in the absence of  APC. 
The latter activity may be explained by sequestration of  histone H3 by phospholipid 
vesicles since it has been shown that histones can interact directly with membrane 
phospholipids and are able to transverse lipid bilayers of  large unilamellar vesicles and 
multilamellar vesicles (13, 15).
In this study we used small unilamellar vesicles that are apparently able to interact 
with histones and thereby prevent the cytotoxic effects of  histones, as evidenced from 
increased endothelial cell survival. The best protective effect was reached when the 
phospholipid vesicles did not only contain the neutral phospholipid PC, but also the net 
negative phospholipid PS and the neutral phospholipid PE. It has been described before 
that positively charged histones bind the anionic phospholipid PS with high avidity 
(31). Specific phospholipid-dependent enhancement of  APC activity has likewise been 
reported before. Part of  this stimulatory effect will presumably be due to the fact that 
both the substrate (histone H3) and the enzyme (APC) bind to the phospholipid surface, 
promoting their interaction and reaction (32). For FVa inactivation it was described that 
optimal APC-catalyzed proteolysis requires calcium and PS containing phospholipid 
vesicles (30, 32, 33), moreover Smirnov et al. (34) and Norstrøm et al. (35) showed that 
PE has an essential role for optimal expression of  the anticoagulant activity of  APC in 
both purified systems and plasma. 
We observed that 5A-APC, a non-anticoagulant engineered APC variant, cleaves histone 
H3 with significantly higher efficiency than wt-APC. 5A-APC is a variant wherein five 
positively charged amino-acids (lysine 191-193 and arginine 229-230) in an exosite of  
APC that is known to be important for electrostatic interaction with FVa, were mutated 
to alanine (36). We hypothesize that since histones are highly positively charged proteins, 
neutralization of  the positively charged exosite has resulted in enhanced interaction of  
5A-APC with histone H3, overall resulting in a more efficient histone H3 cleavage.
We identified, via N-terminal sequencing R26 and R52 as cleavage sites of  APC in histone 
H3, resulting in end products K27-A135 (12.49 kDa) and R53-A135 (9.66 kDa). Using 
bioinformatics we had correctly predicted these fragments. Other predicted cleavage 
sites based on our algorhythm were R8/K9, R17, R128 and R131, resulting in the 
histone H3 fragments K18-R131 (13.04 kDa), S10-R131/K9-R131 (13.80/13.93 kDa) 
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and A1-R128 (14.84 kDa). Peptidylarginine deiminase 4 (PAD4) citrullinates histone 
H3 residues R2, R8, R17 and R26 during NETosis (37, 38, 39). The degree of  histone 
citrullination depends on local PAD4 and calcium concentrations and on the structure, 
charge and flexibility of  amino acids flanking the arginine residues (40). Citrullination 
can theoretically increase susceptibility to proteolytic degradation by unfolding proteins. 
On the other hand citrullination can decrease proteolysis by loss of  the positive charge 
of  arginine residues (40). Due to these conflicting effects it is unknown what the net 
effect of  histone citrullination on its proteolysis by APC will be.
We here confirm the existence of  an APC-cleavage site at R26 cleavage site, as was 
already predicted by Xu et al. (4) for the highly homologous mouse histone H3 and 
provide evidence for an additional cleavage site at R52. At present we can only speculate 
on the relative importance of  these two sites. However, we have shown that the 12.49 
kDa and the 9.66 kDa histone H3 fragments were not cytotoxic to endothelial cells, 
so cleavage of  histones by APC at both sites can have potential therapeutic efficacy in 
patients suffering from acute and chronic pathologic conditions that are characterized 
by increased histone and nucleosome levels in circulation. We hypothesize that 5A-APC 
is superior to wt-APC as therapeutic agent to treat patients suffering from sepsis and 
traumatic injury because 5A-APC cleaves histones more efficiently and, perhaps even 
more importantly, 5A-APC exhibits only minimal anticoagulant activity, a feature of  
great value in patients at risk for bleeding.
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Abstract
Sepsis is a leading cause of  death worldwide with an estimated incidence of  at least 
19 million cases per year and a mortality rate of  20-30%. Extracellular histones are 
cytotoxic compounds mediating death in murine sepsis and circulating nucleosome 
levels predict mortality in human inflammation and sepsis. 
In this study we measured plasma histone H3 (H3) levels in 43 sepsis patients and 
determined correlation with disease severity, organ failure, mortality and coagulation- 
and tissue homeostasis parameters. 
Median H3 levels were significantly increased in non-survivors compared to survivors 
3.15 (IQR: 69) μg/ml, versus 0.57 (1.74) μg/ml, P=0.038). H3 levels are positively 
correlated with lactate dehydrogenase (LDH) activity (Pearson’s r=0.873, P=0.000), 
lactate levels (r=0.403, P=0.011) and Sequential Organ Failure Assessment (SOFA) 
score (r=0.373, P=0.023) and negatively correlated with antithrombin levels (r=-0.347, 
P=0.025) and platelet counts (rho=-0.377, P=0.013). 
We conclude that circulating H3 levels correlate with sepsis-induced organ failure and 
serve as a predictive biomarker of  mortality in sepsis. 
Extracellular histone H3 levels are associated with sepsis-induced organ 
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Introduction
Sepsis is a syndrome caused by a deregulated host response to infection. Extrapolated 
from incidence rates in the United States, worldwide there are currently at least 19 
million cases of  sepsis per year (1). Despite advances in supportive therapy for organ 
failure and the use of  potent antibiotics, mortality rates are still 20-30% for sepsis 
patients and even higher for severe sepsis and septic shock patients (2). 
In murine models it was shown that extracellular histones are major mediators of  death 
in sepsis and that mainly histones H3 and H4 are cytotoxic (3). Histones are highly 
alkaline nuclear proteins that form nucleosomes and, thus, organize the structure of  
chromatin. A nucleosome comprises two copies of  histones H2A, H2B, H3 and H4 
and is surrounded by a superhelix of  146 bp DNA (4). Histones can be released into 
the extracellular compartment during apoptosis and necrosis (5), as well as during 
NETosis (6, 7) where they cause endothelial dysfunction and eventually organ failure (3, 
8).  Predominantly H3 and H4 exhibit cytotoxic activity but the molecular mechanism 
underlying their cytotoxicity is still not fully understood. Histones can interact directly 
with phospholipid bilayers of  cellular membranes, promote channel formation and 
cause loss of  membrane barrier function (9-11). Alternatively, H3 and H4 can activate 
Toll-like receptors (TLR) 2 and 4 resulting in MyD88 signaling, NF-κB activation 
and downstream cytokine production, leukocyte recruitment, microvascular leakage, 
inflammation, tissue injury and finally death in murine models (12-14).
Elevated levels of  circulating nucleosomes have been reported in patients with systemic 
inflammation and sepsis (5, 15, 16) and correlate with mortality in traumatic injury 
patients (17). In addition, extracellular histones have been implicated in the pathogenesis 
of  sepsis, thrombosis, peritonitis, lung injury, autoimmune diseases and brain, liver and 
kidney disease (18). 
In this study we determined circulating H3 concentrations in the plasma of  a group 
of  43 intensive care unit (ICU) sepsis patients. We determined correlations between 
H3 levels and mortality, disease severity and organ failure and between H3 levels and a 
number of  variables reflecting coagulation status and tissue homeostasis.
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Materials & Methods
Study design
43 sepsis patients admitted to the Intensive Care Unit (ICU) of  the Academic Medical 
Center (AMC) in Amsterdam, The Netherlands, were included between May 1st and 
December 31th 2013. The inclusion criteria were: age > 18 years and a positive score for 
sepsis according to the Bone criteria (19): clinical suspicion of  infection and at least 2 
SIRS criteria: 1) a body temperature greater than 38 °C or less than 36 °C; 2) a heart rate 
greater than 90 beats/minute; 3) tachypnea, manifested by a respiratory rate greater than 
20 breaths/minute or hyperventilation, as indicated by a PaCO2 of  less than 32 mmHg; 
4) an alteration in the white blood cell count, such as a count greater than 12.000/mm3, 
a count less than 4.000/mm3, or the presence of  more than 10% immature neutrophils. 
The exclusion criteria were: no informed consent, patients receiving > 48 hours of  
antibiotic treatment for a suspected infection prior to ICU admission and previous 
participation in this study. The group of  sepsis patients was subdivided into sepsis, 
severe sepsis and septic shock patients. Severe sepsis patients meet the aforementioned 
criteria and in addition present with sepsis-induced organ dysfunction, hypoperfusion 
abnormality (lactic acidosis, oliguria, acute alteration of  mental status) or hypotension. 
Septic shock patients have severe sepsis with hypotension despite adequate fluid 
resuscitation. 
Upon ICU admission routine physiological measurements were performed and Acute 
Physiology and Chronic Health Evaluation III (APACHE III, range 0-299) and adjusted 
Sequential Organ Failure Assessment (SOFA) scores (range 0-20) were calculated. 
For calculation of  the adjusted SOFA score, the scores that assess cardiovascular, 
coagulation, liver, renal and respiration systems were included. The central nervous 
system score was excluded, as this score is unreliable in sedated ICU patients. Within 24 
hours of  ICU admission arterial blood from each patient was withdrawn in vacutainer 
tubes containing 3.2% citrate (BD, Franklin Lakes, New Jersey) and immediately 
centrifuged for 15 min at 1500g at 4 °C. Plasma samples were stored at -80 °C to 
perform supplemental analyses at later time points. All laboratory tests were performed 
in a blind manner, without knowledge of  the patient status. The study was approved 
by the Medical Ethics Review Committee of  the AMC Amsterdam (NL 34294.018.10) 
and all participants or their representatives signed informed consent before enrollment 
in the study.
Semi-quantitative H3 determination
Ten times diluted plasma samples were separated via SDS-PAGE gel electrophoresis (6-
15%) and transferred to PVDF membranes (Pall Corporation, Port Washington, NY) by 
semi-dry blotting. After blocking, the membranes were overnight incubated at 4 °C with 
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a rabbit polyclonal H3 antibody directed against an epitope at the C-terminus (1:1000, 
sc-8654-R, Santa Cruz Biotechnology, Heidelberg, Germany), followed by incubation 
with a biotinylated goat anti-rabbit IgG antibody (1:1000, Vector Laboratories, 
Burlingame, CA) for 30 minutes at RT and finally with StreptABComplex/AP solution 
(1:3000, Dako, Glostrup, Denmark) for 30 minutes at RT. Protein bands were detected 
by BCIP/NBT (Sigma-Aldrich, St. Louis, Missouri) and density of  all H3 bands was 
quantified by ImageJ software (x86, Wayne Rasband). The densities of  H3 bands in 
patient plasma samples were compared with the density of  known concentrations of  
purified H3 (Roche, Basel, Switzerland) that were used as a reference to calculate H3 
concentrations in patient samples. 
Calibrated Automated Thrombinography (CAT)
Thrombin generation in clotting plasma was monitored by calibrated automated 
thrombinography (CAT), where conversion of  a low affinity fluorogenic substrate 
(Z-Gly-Gly-Arg-7-amido-4-methylcoumarin (Bachem, Bubendorf, Switzerland)) 
by thrombin was followed over time in a Fluoroskan Ascent microtiter plate reader 
(Thermo Labsystems, Helsinki, Finland) with 390-nm excitation and 460-nm emission 
(20). CAT thrombin generation curves and the endogenous thrombin potential (ETP), 
were calculated using Thrombinoscope software (Thrombinoscope B.V., Maastricht, 
The Netherlands). Thrombin formation was routinely initiated by the addition of  5 
pM of  recombinant tissue factor, 16 mM CaCl2, 30 μM phospholipid vesicles (20:60:20 
DOPS:DOPC:DOPE (mol:mol:mol)) and 50 μg/ml corn trypsin inhibitor. Pooled 
normal human plasma (34 donors: 14 females, 20 males), which was collected in the 
same way as the sepsis plasma samples, was used for normalization of  measured values 
of  the sepsis patients. 
Patients that were on anticoagulant medication (acenocoumarol, heparin) before ICU 
admittance (n=6), patients that received heparin at ICU before blood sampling (n=5) 
and patients that received both anticoagulant medication before ICU admittance and 
heparin at ICU before blood sampling (n=4) were excluded from thrombin generation 
measurements.  
Lactate dehydrogenase (LDH) activity assay
Plasma samples were 25 times diluted in buffer (25 mm HEPES buffer, 150 mm NaCl, 
5 mg/ml bovine serum albumin, pH 7.7) and a LDH activity assay kit (Sigma-Aldrich, 
St. Louis, Missouri) was used to measure LDH activity.
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Antithrombin determination
For the quantitative determination of  antithrombin in plasma samples of  sepsis patients 
the ACTICHROME® Antithrombin chromogenic activity kit (American Diagnostica 
Inc., Stamford, CT) was used. As describe before (21), thrombin was added to a plasma 
dilution containing antithrombin in the presence of  excess heparin. After an initial 
incubation, residual thrombin was determined with a thrombin-specific chromogenic 
substrate. The residual thrombin activity was inversely proportional to the antithrombin 
concentration. Pooled normal human plasma (34 donors: 14 females, 20 males), which 
was collected in the same way as the sepsis plasma samples, was used as an antithrombin 
reference.
Prothrombin determination
Prothrombin concentrations in plasma samples of  sepsis patients were determined 
using Ecarin (Pentapharm, Basel, Switzerland), a metalloprotease isolated from the 
venom of  the saw-scaled viper (Echis carinatus), that specifically activates prothrombin 
independent of  calcium, phospholipids and FXa/FV. Plasma samples were diluted in 
buffer (25 mm HEPES buffer, 150 mm NaCl, 5 mg/ml bovine serum albumin, 5 mM 
CaCl2, pH 7.7), Ecarin was added (final concentration 0.33 U/ml) and samples were 
incubated for 15 minutes at 37 °C. Next, samples were diluted in ice cold stopbuffer (20 
mM Tris, 150 mM NaCl, 20 mM EDTA, pH 7.9) and amidolytic thrombin activity was 
measured with the chromogenic substrate S-2238 (Chromogenix, Milan, Italy). Pooled 
normal human plasma (34 donors: 14 females, 20 males), which was collected in the 
same way as the sepsis plasma samples, was used as a normal prothrombin reference.
Statistical analyses
Analysis of  data was performed with IBM SPSS Statistics 20. Normality of  continuous 
variables was tested with the Shapiro-Wilk test. For nominal variables, significance of  
differences between groups was tested with the Fisher’s exact test. For ordinal variables 
the non-parametric Kruskall Wallis and Mann Whitney U test were used to test for 
significance of  difference between groups. To test for correlations between variables 
Pearson’s correlation coefficient (r) and Spearman’s non parametric correlation 
coefficient rho where calculated. Both coefficients gave comparable results, so only 
Pearson’s correlation coefficients are shown in Table 4. In all cases P-values <0.05 were 
regarded as statistically significant.
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Results
Study population 
Baseline characteristics of  the 43 sepsis patients included in the study are shown in 
Table 1. The percentages of  males and females were comparable and most patients 
(91%) were of  Caucasian origin. The average age of  the patients was 60 years and their 
average BMI was 27.9 kg/m2. The study population had mean APACHE III and SOFA 
scores of  respectively 83.7 and 9.7 and an average mortality rate of  28%. The majority 
of  patients had a primary infection of  the respiratory tract (42%), abdomen (26%), 
cardiovascular system (9%) or urinary tract (9%). Infection was caused in 21% of  cases 
by gram negative bacteria, in 9% of  cases by gram positive bacteria and in 16% of  
cases by both gram negative and gram positive bacteria. In 51% of  cases, the infection 
causative microorganism was not identified. 
In Table 2 patients with sepsis, severe sepsis and septic shock are compared. 
Hospitalization time at the ICU, mortality rate, APACHE III score and SOFA score 
gradually increased with disease severity and were significantly increased in septic shock 
patients (all P=0.000). In Table 3 characteristics of  survivors and non-survivors of  
sepsis are shown. Median APACHE III and SOFA scores were respectively 73 and 8 in 
survivors of  sepsis and were significantly increased to resp. 116 and 13 in non-survivors 
of  sepsis (P=0.003 and P=0.000).
H3 levels, coagulation status and tissue homeostasis 
The majority of  sepsis patients had plasma H3 levels below 10 μg/ml, while 6 patients 
had higher H3 levels of  22, 64, 90, 93, 115 and 126 μg/ml. H3 levels were comparable 
in sepsis, severe sepsis and septic shock patients (Figure 1A, Table 2). Median H3 levels 
were significantly increased from 0.57 μg/ml in non-survivors of  sepsis to 3.15 μg/ml 
in survivors of  sepsis (P=0.038, Figure 1B, Table 3). 
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Table 1: Baseline characteristics of the study population
Average (range) or n (%)
Male, n (%) 24 (56%)
Age (years) 60 (19-92)
BMI (kg/m2) 27.9 (19.2-50.8)
Race (white/black/asian), n (%) 39/3/1 (91/7/2%)
Time at ICU (days) 6.5 (2-36)
Mortality at ICU (yes/no) 12/31 (28/72%)
Sepsis/severe sepsis/septic shock, n (%) 15/14/14 (35/33/33%)
APACHE III score 83.7 (26-153)
SOFA score 9.7 (3-17)
Primary site of  infection, n (%):
- respiratory tract
- intra-abdominal
- cardiovascular
- urinary tract
- skin or soft tissue
- central nervous system 
- unknown
43 (100%)
18 (42%)
11 (26%)
4 (9%)
4 (9%)
3 (7%)
1 (2%)
2 (5%)
Primary cause of  infection, n (%):
- gram negative bacteria
- gram positive bacteria
- gram negative + positive bacteria
- yeasts or fungi
- unknown
43 (100%)
9 (21%)
4 (9%)
7 (16%)
1 (2%)
22 (51%)
The general characteristics of  septic patients included in this study are shown, together with disease 
severity scores and mortality of  patients. For all patients the primary site and cause of  infection are shown. 
Abbreviations: APACHE: Acute Physiology and Chronic Health Evaluation; BMI: body mass index; ICU: 
intensive care unit; SOFA: Sequential Organ Failure Assessment.
In septic shock patients and non-survivors of  sepsis a hypocoagulable state was observed. 
Septic shock patients had significantly increased PT (P=0.000), reduced platelet count 
(P=0.002) and decreased levels of  prothrombin (P=0.017) and antithrombin (P=0.002) 
compared to sepsis patients. Non-survivors presented with significantly increased CAT 
lag time (P=0.044), decreased platelet count (P=0.020) and decreased antithrombin 
levels (P=0.014). In these patients a trend towards decreased prothrombin levels 
(P=0.096) and elevated PT (P=0.060) was observed.
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Table 2: Characteristics and biochemical data of septic patients
Sepsis, 
n=15 
(34.9%)
Severe sepsis, n=14 
(32.6%)
Septic shock, n=14 
(32.6%) 
Variables
Median 
(IQR)
Median 
(IQR)
P-value
Median 
(IQR)    
P-value
Male, n (%) 12 (80%) 8 (57%) 0.245 4 (29%) 0.009**
Age (years)# 58 (25) 60 (18) 0.940 64 (23) 1.000
BMI (kg/m2)# 24.7 (7.8) 31.3 (9.6) 0.061 25.1 (8.0) 0.568
Time at ICU (days) 3 (1) 4.5 (4) 0.000*** 6 (8) 0.000***
Mortality at ICU, n (%) 0 (0%) 3 (21%) 0.100 9 (64%) 0.000***
APACHE III score 57 (35) 67 (20) 0.161 117 (27) 0.000***
SOFA score# 5.5 (3) 8.5 (6) 0.013* 13 (4) 0.000***
Histone H3 (μg/ml) 0.53 (1.61) 0.69 (7.05) 0.159 1.95 (9.36) 0.179
Lactate (mmol/l) 2.5 (4.0) 1.7 (1.1) 0.116 7.1 (7.6) 0.001**
LDH activity (nmole/min/ml) 259 (162) 353 (232) 0.227 464 (620) 0.056
CAT: lag time (ratio) 1.56 (0.62) 1.95 (0.47) 0.210 1.70 (1.53) 0.730
CAT: ETP (ratio)# 1.33 (0.59) 1.49 (0.71) 0.586 1.02 (0.66) 0.503
CAT: peak height (ratio) 
(normalized)#
1.31 (0.52) 1.32 (0.37) 0.940 1.10 (1.59) 0.666
Platelet count (×109/l) 164.0 (73.0) 206.5 (162.8) 0.906 101.5 (96.0) 0.002**
Prothrombin (%) 76 (31) 60.5 (38) 0.043* 54 (42) 0.017*
Antithrombin (%)# 87 (37) 86 (14) 0.692 61 (34) 0.002**
APTT (s) 38 (16) 36 (28) 0.904 47 (25) 0.281
PT (s) 12.1 (1.6) 16.0 (6.9) 0.042* 20.7 (36.4) 0.000***
Sepsis patients were divided in patients with sepsis, severe sepsis (sepsis with sepsis-induced organ 
dysfunction) and septic shock (severe sepsis with hypotension despite adequate fluid resuscitation). For all 
continuous variables median and interquartile range (IQR) are shown. Variables with a normal distribution 
of  data within all 3 groups are marked with #. Significance of  differences between the sepsis group and 
both other groups was calculated with the Fisher’s exact test, the Kruskall Wallis test and posthoc Mann 
Whitney test. *P<0.05, **P<0.01, ***P<0.001. Abbreviations: APACHE: Acute Physiology and Chronic 
Health Evaluation; APTT: activated partial thromboplastin time; BMI: body mass index; CAT: calibrated 
automated thrombinography; ETP: endogenous thrombin potential; ICU: intensive care unit; LDH: lactate 
dehydrogenase; PT: prothrombin time; ratio: values of  patients are normalized against healthy controls; 
SOFA: Sequential Organ Failure Assessment.
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Table 3: Characteristics and biochemical data of septic patients
Survivors, n=31
 (72.1%)
Non-survivors, n=12
(27.9%)
Variables Median (IQR) Median (IQR) P-value
Male, n (%) 18 (58%) 6 (50%) 0.238
Age (years) 58 (21) 65.5 (14) 0.129
BMI (kg/m2) 26.1 (8.9) 27.4 (9.8) 0.899
Time at ICU (days) 4 (3) 4.5 (7) 0.162
APACHE III score# 73 (32) 116 (54) 0.003**
SOFA score# 8 (4) 13 (3) 0.000***
Histone H3 (μg/ml) 0.57 (1.74) 3.15 (69.00) 0.038*
Lactate (mmol/l) 2.1 (4.0) 8.5 (12.6) 0.001**
LDH activity (nmole/min/ml) 269.5 (179.0) 551.5 (1978.0) 0.001**
CAT: lag time (ratio) 1.58 (0.81) 1.95 (1.19) 0.044*
CAT: ETP (ratio) 1.34 (0.52) 1.31 (0.86) 0.989
CAT: peak height (ratio)# 1.32 (0.78) 1.16 (0.96) 0.857
Platelet count (×109/l)# 164 (90) 107.5 (107) 0.020*
Prothrombin (%) 67 (31) 54 (42) 0.096
Antithrombin (%)# 83 (30) 65.5 (27) 0.014*
APTT (s) 39 (24) 35 (81) 0.832
PT (s) 14.1 (7.7) 17.1 (19.8) 0.060
Sepsis patients were divided in survivors and non-survivors. Interquartile ranges (IQR) are shown 
for all continuous variables. Variables with a normal distribution of  data within both groups are 
marked with #. Significance of  differences between both groups was calculated with the Fisher’s 
exact test and Mann Whitney test. *P<0.05, **P<0.01, ***P<0.001. Abbreviations: APACHE: 
Acute Physiology and Chronic Health Evaluation; APTT: activated partial thromboplastin 
time; BMI: body mass index; CAT: calibrated automated thrombinography; ETP: endogenous 
thrombin potential; ICU: intensive care unit; LDH: lactate dehydrogenase; PT: prothrombin 
time; ratio: values of  patients are normalized against healthy controls; SOFA: Sequential Organ 
Failure Assessment. 
To assess tissue homeostasis, lactate and LDH activity levels were measured. In septic 
shock patients maximum lactate levels measured within the first day of  ICU admission 
were significantly increased (P=0.001) and a trend towards increased LDH activity levels 
was observed (P=0.056). Both LDH activity (P=0.001) and lactate (P=0.001) levels in 
plasma were significantly elevated in non-survivors compared to survivors of  sepsis. 
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Figure 1: Histone H3 levels in sepsis patients 
Boxplots with interquartile ranges are shown for histone H3 levels measured in (A) sepsis, severe sepsis and 
septic shock patients, (B) survivors and non-survivors of sepsis. Significance of differences is calculated with the 
Mann Whitney test, *P<0.05. 
 
H3 levels correlate with LDH/lactate, platelet count, SOFA and antithrombin levels  
Table 4 shows significant correlations between H3 levels, disease severity scores and 
variables reflecting coagulation status and tissue homeostasis. We were most interested in 
correlations of H3 with other parameters, since little is known so far about possible 
associations between the presence of extracellular histones and other parameters. Significant 
correlations of H3 with LDH activity (Pearson’s r= 0.873, P= 0.000), lactate (r= 0.403, P= 
0.011), platelet count (r= -0.377, P= 0.013), SOFA (r= 0.373, P= 0.023) and antithrombin 
levels (r= -0.347, P= 0.025) are shown in Figure 2 and highlighted in grey in Table 4. 
Additionally, there were correlations between disease severity scores, several coagulation 
parameters and lactate/LDH activity. Thus, increased levels of H3 in sepsis patients were 
associated with increased sepsis-related organ failure and with increased lactate/LDH activity 
and decreased antithrombin levels and platelet count. 
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Figure 1: Histone H3 levels in sepsis patients
Boxplots with interquartile ranges are shown for histone H3 levels measured in (A) sepsis, 
severe sepsis and septic shock patients, (B) survivors and non-survivors of  sepsis. Significance 
of  differences is calculated with the Mann Whitney test, *P<0.05.
H3 levels correlate with LDH/lactate, platelet count, SOFA and antithrombin levels 
Table 4 shows significant correlations between H3 levels, disease severity scores and 
variables reflecting coagulation status and tissue homeostasis. We were most interested 
in correlations of  H3 with other parameters, since little is known so far about possible 
ass ciatio s between t e presence of  extracellular histones and other parameters. 
Significant correlations of  H3 with LDH activity (Pearso ’s r= 0.873, P= 0 000), lactate 
(r= 0.403, P= 0.011), platelet count (r= -0.377, P= 0.013), SOFA (r= 0.373, P= 0.023) 
and antithrombin levels (r= -0.347, P= 0.025) are shown in Figure 2 and highlighted in 
grey in Table 4. Additionally, there were correlations between disease severity scores, 
several coagulation parameters and lactate/LDH activity. Thus, increased levels of  H3 
in sepsis patients were associated with increased sepsis-related organ failure and with 
increased lactate/LDH activity and decreased antithrombin levels and platelet count.
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Figure 2: Correlations between histone H3 and other variables. 
XY scatterplots and trendlines of significant correlations between histone H3 levels and other variables (see 
Table 4) are shown. 
Figure 2: Correlations between histone H3 and other variables.
XY scatterplots and trendlines of  significant correlations between histone H3 levels and other variables 
(see Table 4) are shown.
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Table 4: Significant correlations between pairs of variables measured in sepsis patients
Variable 1 Variable 2 Pearson’s r P-value N
Histone H3 LDH activity 0.873 0.000 42
APACHE III score SOFA score 0.748 0.000 37
CAT: ETP CAT: peak height 0.738 0.000 25
Lactate PT 0.597 0.000 38
APACHE III score Lactate 0.567 0.000 39
SOFA score Lactate 0.547 0.001 34
SOFA score Platelet count -0.510 0.001 37
Lactate Platelet count -0.435 0.006 39
LDH activity Antithrombin -0.408 0.007 42
SOFA score Antithrombin -0.420 0.010 37
Histone H3 Lactate 0.403 0.011 39
Histone H3 Platelet count -0.377 0.013 43
LDH activity Platelet count -0.376 0.014 42
Antithrombin Platelet count 0.372 0.015 42
Antithrombin Lactate -0.382 0.018 38
APACHE III score PT 0.363 0.018 42
APACHE III score Prothrombin -0.357 0.020 42
Histone H3 SOFA score 0.373 0.023 37
Histone H3 Antithrombin -0.347 0.025 42
APACHE III score Antithrombin -0.344 0.026 42
LDH activity Lactate 0.358 0.027 38
SOFA score PT 0.364 0.029 36
APACHE III score Platelet count -0.324 0.034 43
Pearson’s correlation coefficient (r) and P-values were calculated to test for significant 
correlations. A P-value <0.05 was regarded as statistically significant. Abbreviations: APACHE: 
Acute Physiology and Chronic Health Evaluation; APTT: activated partial thromboplastin time; 
CAT: calibrated automated thrombinography; ETP: endogenous thrombin potential; LDH: 
lactate dehydrogenase; PT: prothrombin time; SOFA: Sequential Organ Failure Assessment.
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Discussion
In this study we determined associations between extracellular H3 levels, and disease 
severity and mortality in ICU sepsis patients. We also determined associations with 
biomarkers that reflect coagulation status and tissue homeostasis. We found extracellular 
H3 levels to correlate with mortality, sepsis-related organ failure, lactate/LDH activity, 
antithrombin levels and platelet count and we conclude that H3 levels may potentially 
be used as a novel marker to predict mortality in these patients. 
In septic shock patients and non-survivors of  sepsis, we observed a hypocoagulable 
state, characterized by decreased antithrombin and prothrombin levels, decreased 
platelet count, prolonged PT and CAT lag time, all pointing towards an upregulation 
of  haemostatic processes and consumption of  coagulation proteins. We confirm that 
non-survivors present with significantly increased CAT lag times and lactate/LDH 
levels and that septic shock patients have decreased platelet counts, as well as decreased 
prothrombin and antithrombin levels (22-28). Here we add the levels of  circulating 
extracellular histones to these observations.
The hypocoagulable state in septic shock patients is preceded by systemic activation 
of  the coagulation system and development of  disseminated intravascular coagulation 
(DIC) is frequently observed. During DIC, small blood clots form inside blood vessels 
throughout the body, resulting in the consumption of  platelets and coagulant and 
anticoagulant factors (29). At the same time, concentrations of  anticoagulant proteins, 
like antithrombin, can be decreased due to impaired synthesis in the liver as a result 
of  the acute phase response to inflammation and due to proteolytic degradation by 
elastases released by activated neutrophils (30). 
In response to infection, activated neutrophils can form neutrophil extracellular traps 
(NETs) and can therefore, together with dying cells, become a source of  extracellular 
histones in circulation. We observed a correlation between H3 levels and SOFA scores 
in ICU sepsis patients and significantly increased H3 levels in plasma of  non-survivors 
compared to survivors of  sepsis. Extracellular histones possess direct cytotoxic effects 
by formation of  pores in cell membranes (9-11) and can activate NLRP3 inflammasome 
(31), leading to caspase-1-dependent pro-inflammatory cytokine secretion, controlling 
host responses to infection and injury (32). Furthermore circulating histones can induce 
TLR2- and 4-dependent MyD88 signaling in immune cells and platelets, resulting in 
activation of  NF-κB and MAPK target genes and downstream cytokine production, 
leukocyte recruitment, endothelial cell death, microvascular leakage, inflammation, 
thrombin generation, platelet aggregation and clotting, and as a consequence cause 
tissue injury and death in the context of  sepsis and DIC (3,12-14,33-35). 
Formation of  (micro)thrombi and fibrin deposition in blood vessels can lead to hypoxia 
and necrosis of  organ tissue and plays a pathologic role in the development of  organ 
failure and subsequent mortality in sepsis (29). Due to hypoxia, organs have to increase 
their anaerobic glycolysis, resulting in increased lactate production. Other causes for 
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increased lactate/LDH levels can be increased aerobic glycolysis and a decreased 
clearance of  lactate by the liver (36, 37). Previous research (22, 27, 28) has shown that 
increased lactate levels or the failure to clear lactate or LDH within the first 24-48 hours 
after ICU admittance are strong predictors of  mortality in sepsis patients, in agreement 
with the significantly increased lactate/LDH activity levels observed in non-survivors 
(P=0.001), compared to survivors of  sepsis in our study. 
The development and progression of  sepsis is a multi-factorial process. We show that 
extracellular histone levels, lactate/LDH activity and coagulation parameters in sepsis 
patients all reflect ongoing systemic inflammation, coagulation and organ failure and 
the extent of  these can be used to estimate organ failure and predict outcome in sepsis 
patients. While therapy aimed at improvement of  organ function, and restoration of  
the normal haemostatic balance are already being used, recent development from our 
laboratory and those of  others (3, 6, 12-14, 34, 35, 38, 39) have indicated that also the 
targeting of  extracellular histones may provide cytoprotection to patients whose organ 
functions are at risk.
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Abstract
Extracellular histones are considered to be major mediators of  death in sepsis. Although 
sepsis is a condition that may benefit from low-dose heparin administration, medical 
doctors need to take into consideration the potential bleeding risk in sepsis patients who 
are already at increased risk of  bleeding due to a consumption coagulopathy. Here, we 
show that mechanisms that are independent of  the anticoagulant properties of  heparin 
may contribute to the observed beneficial effects of  heparin in the treatment of  sepsis 
patients. We show that nonanticoagulant heparin, purified from clinical grade heparin, 
binds histones and prevents histone-mediated cytotoxicity in vitro and reduces mortality 
from sterile inflammation and sepsis in mouse models without increasing the risk of  
bleeding. Our results demonstrate that administration of  nonanticoagulant heparin is a 
novel and promising approach that may be further developed to treat patients suffering 
from sepsis.
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Introduction
Sepsis and septic shock are serious clinical problems with high mortality rates for which 
no adequate treatment currently exists (1). Neutrophils respond to infection with the 
formation of  neutrophil extracellular traps (NETs) (2, 3) intricate networks containing 
DNA as the major structural component and proteins like histones and neutrophil 
elastase, which have antimicrobial properties. Extracellular histones, however, also 
exhibit cytotoxic activity toward host cells, including the endothelium (4, 5) Histone 
release can thus trigger a feedback cascade, resulting in more cell death and additional 
release of  histones (6). Consequently, extracellular histones are considered interesting 
therapeutic targets for sepsis treatment (4).
Histones are positively charged, and NET-mediated cytotoxicity can be reduced with 
polysialic acid, a negatively charged polymer (5). We hypothesized that heparin, a 
negatively charged polysaccharide, blocks histone cytotoxicity and reduces mortality 
from sterile inflammation and sepsis. Low dose unfractionated heparin (UFH) has been 
tested in a clinical trial as a complementary treatment of  sepsis (7). The study rationale 
linked infection, inflammation, and coagulation in sepsis and sought to inhibit the 
coagulation part with low doses of  heparin so as not to increase the risk of  bleeding in 
a patient who is already at risk due to sepsis-associated consumption coagulopathy (7, 
8). Nevertheless, although this study failed to demonstrate a significant benefit on 28-
day mortality rate, we hypothesize that the minor beneficial effects of  heparin observed 
might be attributed to a mechanism independent of  the anticoagulant properties of  
heparin. We reasoned that removing the anticoagulant fraction from UFH would yield 
an antithrombin affinity-depleted heparin (AADH) that neutralizes histone-mediated 
cytotoxicity and effectively treats sepsis without increasing risk of  bleeding. Heparins 
have the highest negative charge density of  any known biological molecule (9) and have 
a strong affinity for histones (10, 11). It is, however, not known whether binding of  
heparin to histones also protects against the cytotoxic effect of  histones on endothelial 
cells and/or in vivo. Here, we investigated the effects of  UFH and AADH on histone 
cytotoxicity. We present data showing that complex formation of  histones with heparin 
reduces their cytotoxicity in an in vitro cell-based cytotoxicity assay. Furthermore, by use 
of  in vivo mouse models of  sterile inflammation, a cecal ligation and puncture (CLP) 
model for sepsis and bacterial lipopolysaccharide (LPS) challenge, we show that AADH 
increases the survival rate in all 3 animal models.
Study design
AADH was produced by fractionation of  UFH via affinity chromatography using an 
antithrombin-column, and its anticoagulant properties were quantitated via calibrated 
automated thrombography (CAT). The cytotoxic effects of  purified histones, in the 
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presence of  UFH and AADH, were tested in vitro via a flow cytometry-based histone 
cytotoxicity assay employing EA.hy926 cells. Direct binding interaction between 
histones and AADH was determined using surface plasmon resonance and confocal 
laser scanning fluorescence microscopy. In vivo, the activities of  UFH and AADH were 
tested in C57Bl6/J mice through a concanavalin A (ConA) challenge model for fatal 
sterile inflammation, through a CLP model and an LPS challenge model. Survival was 
used as the primary endpoint in these assays; liver viability assessment was performed to 
correlate disease severity to organ damage in the animals tested (CLP) and neutrophil lung 
infiltration, tissue leakage, and bronchoalveolar lavage cytokine levels were determined 
in the LPS model. Anticoagulant properties of  administered UFH and AADH were 
assessed via CAT and tail bleeding time measurements. The experiments were approved 
by the animal care committees of  the Spanish National Research Council and of  the 
Ludwig-Maximilians-University Munich.
Materials and Methods
Collection and handling of  mouse plasma samples
After intraperitoneal (i.p.) injection with urethane, the abdominal cavity of  C57BL6/J 
mice was opened and cardiac puncture was performed. Blood was drawn into a syringe 
containing acid-citrate-dextrose (ACD) buffer (9:1 volume). Plasma was prepared by 
centrifugation, twice at 800xg for 10 minutes at RT after which the supernatant plasma 
was collected. As a reference plasma samples of  healthy untreated C57BL6/J mice were 
pooled: control plasma pool (n=6), AADH3 (n=6), SAL3 (n=5), AADH6 (n=6), SAL6 
(n=6).
Production of  AADH
Heparin sodium salt (2 mg per run, Sigma-Aldrich, St. Louis, MO, USA) was dissolved 
in running buffer (140 mM NaCl, 20 mM Tris, pH 7.4) and loaded onto a 5 ml HiTrap 
NHS-activated HP column (GE Healthcare, Little Chalfont, UK) to which 12 mg of  
bovine antithrombin had been covalently immobilized. Antithrombin affinity depleted 
heparin (AADH) did not bind to the column and was found in the flow through. The 
AADH was then concentrated and switched to 140 mM NaCl, 20 mM Tris, pH 7.4 
buffer by use of  a PD-10 column (GE Healthcare, Little Chalfont, UK) and filtered 
over a 0.2 μM filter (Whatman, Maidstone, UK). We monitored the purification by 
thrombin generation assay, described below, and we have selected those fractions that 
showed no significant effect on aPTT or anti-FXa levels.
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Thrombin generation
Thrombin generation was measured in triplicate via calibrated automated thrombography 
(CAT) essentially as described before (12). Thrombin generation in mouse plasma was 
performed as previously described (13) in the presence of  varying concentrations of  
UFH and AADH.
Cell culture
The permanent human endothelial cell line EA.hy926 was kindly provided by Dr. 
Dariusz Lezczynski (STUK - Radiation and Nuclear Safety Authority, Helsinki, Finland). 
EA.hy926 were cultured as described (14).
Histone cytotoxicity assay
EA.hy926 (1 x 105 cells/well) were grown to confluence. Cells were washed twice with 
PBS and next incubated for 1 hour at 37 °C in serum-free DMEM containing 40 μg/
ml histone H3 (Roche Applied Science, Penzberg, Germany; 100 μg/ml histone mix, 
Sigma-Aldrich, St. Louis, MO, USA was equally active) in combination with varying 
concentrations of  UFH (LEO Pharma BV, Amsterdam, The Netherlands) or AADH. 
After 1 hour incubation the cells were washed and detached using 0.05% trypsin-EDTA. 
The cells were diluted to 1*106 cells/ml in 10 mM Hepes, 150 mM NaCl, 5 mM KCl, 
1 mM MgCl2 and 2.5 mM CaCl2 pH 7.4 buffer containing 0.25 μg/ml Annexin A5-
FITC (PharmaTarget BV, Maastricht, The Netherlands), 2.5 μg/ml propidium iodide 
(Invitrogen Life Technologies, Carlsbad, CA, USA) and incubated for 10 minutes in 
the dark on ice. Cell viability was measured by flow cytometry on an Epics XL MCL, 
Beckman coulter flow cytometer, using FL1 PMT at 505-545 nm for FITC and FL3 
PMT at 605-635 nm for propidium iodide.
Western Blotting and precipitation
Samples were denatured in standard gel sample buffer containing 1.25% mercaptoethanol 
at 95°C for 10 minutes, separated via electrophoresis in 15% SDS-polyacrylamide 
gels and transferred to PVDF membranes (Pall Life Sciences, Pensacola, FL, USA) 
by semi-dry blotting. After blocking the membranes were incubated overnight at 4°C 
with primary antibody for histone H3 (1:1000, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), followed by incubation with biotin-conjugated secondary antibody (1:1000, 
Vector Laboratories, Burlingame, CA, USA) for 30 minutes at RT and finally incubated 
with StreptABComplex/AP solution (1:3000, Dako Cytonation, Glostrup, Denmark) 
for 30 minutes at RT. Protein bands were detected by BCIP/NBT (Sigma-Aldrich, 
Steinheim, Germany) and histone H3 density was quantified by ImageJ software (x86, 
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Wayne Rasband, National Institutes of  Health, USA). For precipitation of  the AADH-
histone complex, 100 μg histone H3 was mixed with 57 μg AADH and incubated at 4°C 
for 30 minutes, next the reaction volume was centrifuged for 5 min at 20,000g and the 
pellet and supernatant were separately collected.
Surface Plasmon resonance
Histone H3 was coupled to a CM5 sensor chip using HBS-EP (10mM HEPES, pH 
7.4, 150mM NaCl, 3mM EDTA, 0.005% Tween-20) buffer at 25°C. Histone H3 was 
diluted in 10 mM Sodium-acetate buffer pH 5.0 to a concentration of  50 μg/ml and 
immobilized to the chip with ~4400 response units. 
SPR binding experiments were performed at 25°C at a flow rate of  50 μl/min and using 
HBSEP as running buffer. A single-cycle kinetics experiment was done with 5 different 
concentrations of  AADH (100, 50, 10, 5 and 1 nM), an association time of  300 sec and 
a final dissociation time of  1200 sec.
Cytokine measurement
Cytokine levels of  IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IFNγ and TNF were 
determined in mouse plasma samples by mouse cytokine IR array (9-plex) (Quansys 
biosciences, Logan, UT, USA).
Concanavalin A (ConA) sterile inflammation model
Eight to twelve weeks old C57Bl6/J mice were injected i.p. with a single dose of  570 μg 
AADH or buffer and after 60 minutes received an intravenous injection of  30 mg/kg 
ConA, for the following 24 hours the condition of  mice was continuously monitored, 
while survival as final parameter was registered.
Cecal ligation and puncture (CLP), prophylactic regimen
Mice were anesthetized with an i.p. injection of  ketamine (125 mg/kg body weight (b.w.); 
Sanofi-Cefa GmbH Düsseldorf, Germany) and xylazine (12.5 mg/kg b.w.; Phoenix 
Scientific, Encinitas, CA, USA). After positioning on a heating plate, longitudinal skin 
midline incision was performed and abdominal cavity was opened in the midline. After 
identifying the cecum, cecum was ligated and punctured with a 22G needle. Fascia, 
abdominal musculature and skin were closed by applying simple running sutures. Mice 
were treated with 570 μg AADH or buffer by i.p. injection 12 hours before CLP, right 
after CLP, and 12 hours after CLP.
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Cecal ligation and puncture (CLP), treatment regimen
Mice were anesthetized and treated as described for the prophylactic regimen above. 
Treatment was performed once with 570 μg AADH or buffer by i.p. injection 4 hours 
post CLP. Group size is: sham: n=15, CLP group, no treatment n=15; CLP group + 
AADH treatment n=10.
Isolation and activation of  neutrophils
Human neutrophils were isolated from a healthy donor using density gradient separation 
with histopaque-1077. Cells were resuspended in phenol-red free RPMI 1640 medium 
(1.75 x 106 cells/ml) and seeded onto glass coverslips in 12 well tissue culture plates. To 
induce NETosis cells were stimulated with 50 nM PMA for 2 hours at 37 °C.
Scanning electron microscopy (SEM)
After incubation with PMA, neutrophils on glass coverslips were fixed overnight with 
2.5% glutaraldehyde at 4°C. The specimens were postfixed using 1% osmiumtetroxide 
and dehydrated in graded ethanol series. For SEM, the specimens were dehydrated, 
critical point dried, mounted with silver paint on specimen tubs, and coated with 
gold. The surface of  the membrane was examined in a SEM (Philips CM100 electron 
microscope) at 10 kV.
Labeling of  AADH with fluorescein (FITC)
AADH (70 μM) was incubated with 0.28 M 5-(((2(carbohydrazino)methyl)thio)
acetyl) aminofluorescein (Invitrogen Life Technologies, Carlsbad, CA, USA) and 0.9 
M NaCNBH
3
 in acetate buffer in the dark for 4h at 37°C followed by 2 days at RT. 
Afterwards the AADH-FITC was dialyzed in a slide-A-lyzer dialysis cassette with a 
MWCO of  2 kDa (Thermo scientific, Rockford, IL, USA) at least four times against 
buffer (140 mM NaCl, 20 mM Tris, pH: 7.4) to get rid of  unbound label.
Fluorescence microscopy
After incubation with PMA, cells on glass coverslips were washed with PBS, fixed with 
4% PFA for 15 min at RT and incubated at RT for respectively 30 min with AADH-
FITC, for 2.5 h with rabbit monoclonal anti-histone H2B clone EP957Y (Millipore, 
Billerica, MA, USA), for 1 h with biotinylated Goat Anti-Rabbit IgG Antibody (Vector 
laboratories, Burlingame, CA, USA), for 15 min with Alexa Fluor® 680 streptavidin 
and for 15 min with propidium iodide (both Invitrogen Life Technologies, Carlsbad, 
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CA, USA). Finally the glass slides were imaged with a Leica TCS SPE confocal laser 
scanning fluorescence microscope (Leica DMRBE, Mannheim, Germany).
Tail bleeding time
Tail bleeding time measurements were performed as described earlier (15), with some 
modifications. Mice were anesthetized with an i.p. injection of  ketamine (100 mg/kg) 
and xylazine (20 mg/kg). Mice were injected with either saline (control), 114 μg UFH 
or 570 μg AADH. After 1 hour or 3 hours, the tip of  the tail at 5 mm diameter was cut 
and immediately immersed in PBS pH 7.4 pre-warmed at 37°C. Both the mice and pre-
warmed tubes with PBS were placed into an incubator at 37°C to maintain the mice at 
that temperature during the measurements. The total bleeding time was defined as the 
addition of  bleeding periods during monitoring. Monitoring of  the bleeding times was 
stopped at 10 minutes by cauterizing the tail to prevent excessive loss of  blood.
Liver viability assessment
After CLP, as described above for the prophylactic regimen, animals were sacrificed 
18 hours post ligation/puncture. The liver was harvested and sections prepared for 
TUNEL staining, allowing quantitation of  alive/death cells in the organ.
Acute lung injury model
C57Bl/6 mice were treated with LPS 20 mg/kg i.p. and 570 μg of  AADH 1 hour 
after the LPS challenge. After 6 hours mice were euthanized for sample harvesting. 30 
min before euthanasia, 5 μl FITC-Ly-6G (Gr1) (eBioscience) and 100 μl Fluorescein 
isothiocyanate–Dextran (30 mg/ml FITC-Dextran; 70 kDa, Sigma-Aldrich) were 
applied by tail vein injection to label intravasal neutrophils and to assess plasma leakage, 
respectively. The trachea was dissected and cannulated (Portex FineBore Polythene 
Tubing, 0.28 mm inner diameter (ID)/0.61 mm outer diameter (OD), Smiths Medical 
International, Keene, NH). 5x 0.5 ml PBS was injected and withdrawn. Thereafter, the 
ribcage was opened by a midline incision and the pulmonary vasculature was rinsed with 
15 ml ice-cold PBS with 0.5 mM EDTA after cutting the inferior cava vein to facilitate 
exsanguination. The lungs were removed, minced and digested with liberase (1:20; 25 
mg Liberase RI/ml aqua, Roche Mannheim Germany). Digested lungs were passed 
through a cell strainer (70 μm; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
and the resulting single cell suspension was centrifuged for 5 min at 300g. The pellets 
were resuspended in 1 ml Hank’s balanced salt solution with 0.3 mmol/l EDTA and 
0.1 % BSA. The bronchoalveolar lavage (BAL) fluid was centrifuged for 5 min at 300 g.
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Flow cytometry. 
Cell pellets were labeled with PerCP-Cy5.5 anti-mouse Ly-6G, PE anti-mouse CD115, 
APC-Cy7 anti-mouse CD45 and APC anti-Mouse F4/80 (all eBioscience). Neutrophils 
were identified by their typical appearance in the forward scatter-side scatter and as 
CD45 + CD115 – and PerCP- Gr1 + cells. Within the lung, FITC-Gr1 antibody was 
used to distinguish between interstitial neutrophils (CD45 +, CD115 –, PerCP- Gr1 +, 
FITC-Gr1 -) and intravasal neutrophils (CD45 +, CD115 –, PerCP- Gr1 +, FITC-Gr1 
+). All studies were performed on a FACS Canto II (Becton Dickinson, San Jose, CA) 
and data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Lung Permeability
FITC-Dextran (70 kDa, Sigma-Aldrich) was used to assess vascular leakage. 100 μl 
FITC-Dextran (30 mg/ml) were administered by tail vein injection 30 min prior to 
euthanasia and dye extravasation was used to assess change in vascular permeability. The 
fluorescence of  100 μl BAL supernatant (FluoBAL) and of  50 μl serum (FluoSerum) 
was measured and clearance volume was expressed in microliter VPerm = [(FluoBAL / 
100 μl) * BAL volume] / (FluoSerum / 50 μl).
Lung histology
After completion of  the experiment, one part of  the right lung was fixed in formalin, 
embedded in paraffin wax and stained with Mayer’s haematoxylin and eosin for 
histological examination. We scored histological sections based on a scheme outlined 
in the table below which is compliance with recommendations from the American 
Thoracic Society outlining standardized guidelines for models of  ALI in animals (16). 
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Protein concentration and cytokine measurements of  the BAL 
The protein content of  the BAL supernatants was assessed using the Bio-Rad Protein 
Assay based on the method of  Bradford (Bio-Rad Laboratories Germany). Measurement 
of  absorbance at 595 nm was performed with a microplate reader (infinite 200, Tecan 
Group Switzerland). TNF and IL6 in the BAL were assessed using a commercially 
available ELISA (R&D Systems). 
Statistical Analyses
Results are expressed as mean ± SD. 1-Way ANOVA followed by Newman-Keuls post 
tests were used as appropriate to determine significance between groups or Dunnett 
post test in case of  comparison to the control value. A P-value less than 0.05 was 
regarded as statistically significant, as indicated by *. Comparison of  survival curves 
was done through calculation using the Log-rank (Mantel-Cox) and Gehan-Breslow-
Wilcoxon test to calculate significance using GraphPad Prism 5.0 software (GraphPad 
Software, Inc.). Significance is indicated by **.
Results and discussion
Antithrombin affinity chromatography yielded a fraction of  UFH, AADH, with 
strongly decreased anticoagulant activity (Figure 1A) as determined by CAT (12), which 
shows that AADH has retained 0.2% to 0.5% of  the anticoagulant activity of  UFH. 
Both UFH and AADH inhibited dose-dependently the cytotoxic activity of  purified 
histones in cell culture (Figure 1C-D). To analyze whether AADH binds to histones, 
direct binding of  AADH to histones was verified by surface plasmon resonance (Figure 
1B). Binding affinity between histone H3 and AADH was characterized by an apparent 
dissociation constant of  86 nM. We further demonstrated in vitro, employing isolated 
human neutrophils, that addition of  AADH to neutrophils that have produced NETs 
(5) (Figure 2A) results in colocalization of  AADH with extracellular DNA fibers and 
histones (Figure 2B-C). Thus, both UFH and AADH possess cytoprotective properties, 
conferred by complexation of  histones, because we verified that heparin-histone 
complexes are devoid of  cytotoxic properties (Figure 3A). 
To further test our hypothesis on the cytoprotective activities of  AADH and translate 
our in vitro findings into an in vivo system, we next evaluated the effects of  AADH on 
the overall mortality rate in a mouse model of  fatal liver injury using ConA-triggered 
activation of  T cells to mimic sterile inflammation (Figure 3B). It has been described that 
extracellular histones are the major mediators of  death in this model (17). We measured 
plasma levels of  histone H3 by semiquantitative western blotting (17) and showed that 
ConA injection increased circulating histone H3 levels in all animals (Figure 3C). In 
treated animals, appearance of  histones was delayed and from our in vitro studies and 
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reported in vivo cytotoxicity of  extracellular histones, we conclude that histones detected 
in the treated group are at least partly complexed to AADH. Injection of  ConA caused 
significant differences in 24-hour survival between the AADH treated and control 
groups (P< 0.0005) (Figure 3B), with only a moderate effect of  AADH on thrombin 
formation (supplemental Figure 3D). We verified that the moderate anticoagulant 
effect seen is independent of  any antithrombin-mediated activities of  AADH and can 
be attributed to heparin cofactor II stimulation, the plasma concentration of  which 
does not allow complete inhibition of  thrombin formation (18). Together, our in vitro 
and in vivo results strongly indicate that AADH treatment results in complexation and 
Figure 1. In vitro heparin characterization
A) In vitro effects of  varying amounts of  UFH and AADH on thrombin generation in normal pooled 
mouse plasma as measured by CAT (13). B) Surface plasmon resonance–analysis of  AADH binding to 
immobilized histone H3 with collected data points in blue and data fit in black. Saturation of  binding was 
verified by analysis of  the binding data (insert). Variable amounts of  UFH (C) or AADH (D) and histone 
H3 (H3) were added to EA.hy926 cells and cell viability was quantitated with flow cytometry. Each bar 
represents the average 6 SD of  at least 5 independent experiments. Statistical significance (P<0.05) was 
tested using one-way analysis of  variance with Dunnett post hoc test. *Indicates significant difference 
compared with control samples.
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inactivation of  circulating histones with a concomitant improvement of  survival, in 
agreement with the observation that AADH abolished cytotoxic effects of  histones on 
endothelial cells by complexation (Figure 3A).
Figure 2. In vitro visualization of NETs
A) Scanning electron micrograph of  phorbol myristate acetate (PMA) stimulated human neutrophils. B-C) 
Fluorimaging analysis of  PMA–stimulated human neutrophils stained with propidium iodide (red), FITC-
labeled AADH (green), or anti-histone H2B antibody (blue). B) A detail showing colocalization (yellow, 
arrow) of  histones, DNA, and AADH on extracellular DNA fibers. C) Representative presentation of  
a larger field with NETs, where colocalization (yellow) was observed for histones, DNA, and AADH. 
Arrows indicate several of  the colocalization sites. Bar represents 20 mm for histology. 
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In contrast to UFH, AADH treatment of  unchallenged mice with a dose 5 times 
that of  UFH caused only moderate anticoagulation of  blood plasma (Figure 4A) and 
no significant prolongation of  tail bleeding time (Figure 4B). Furthermore, AADH 
treatment had no significant effects on plasma levels of  the cytokines interleukin-6, 
interleukin-10, and tumor necrosis factor at 3 and 6 hours after ConA challenge (data 
not shown).
Figure 3.
A) Histones, complexed histones, supernatant of  the precipitation reaction and only AADH are added to 
EA.hy926 cells and cell viability is quantitated with flow cytometry. As a control, cells to which control 
buffer was added were taken. B) Twenty-four–hour survival in mice challenged through intravenous 
injection of  30 mg/kg ConA following intraperitoneal injection of  570 μg AADH (n=15, dashed line) or 
saline (n=16, solid line). Found differences are significant (P=0.0005, with hazard ratio = 8.384 and 95% 
confidence interval (CI) of  ratio 2.371-21.79). C) Plasma of  saline- or AADH-treated mice was collected 
3 or 6 hours after ConA challenge and pooled (n=6). Histone H3 content was characterized by Western 
blotting. For comparison, a pooled mouse plasma sample from mice not challenged with ConA is shown. 
Relative densities as determined by densitometry using ImageJ are indicated. D) From the same samples as 
in Figure 3C, thrombin generation was measured by CAT as described (13). 
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To further investigate the potential therapeutic value of  AADH, we injected AADH in 
a mouse CLP model known to mimic human sepsis (19) and an LPS injection model 
that mimics TLR-mediated septic shock (19). As observed in the ConA model, AADH 
is able to significantly increase survival both when given prior to cecal puncture as well 
as when given 4 hours after puncture (Figure 4C) and when given 1 hour after LPS 
challenge (Figure 5A). Protection of  organs is likely to contribute to overall survival 
as was concluded from a liver viability assessment after CLP (Figure 4D) and lung 
tissue histological analysis (Figure 5B-C). Administration of  AADH appears to reduce 
neutrophil influx, protects against intrapulmonary protein leakage and capillary-alveolar 
leakage, and is accompanied by reduction of  cytokine release (Figure 5D-G).
Figure 4. 
A) Blood of  saline, 570 μg AADH or 114 μg UFH-treated control mice (an equivalent of  20 U UFH) was 
collected 1 or 3 hours after injection and equal plasma volumes were pooled (n=6). Thrombin generation 
in platelet-poor plasma was measured by CAT as described. B) Tail bleeding times in mice as measured 1 
and 3 hours after injection of  respectively 114 μg UFH or 570 μg AADH. C) Seventy-two–hour survival 
in CLP-challenged C57Bl/6 mice treated by intraperitoneal injection with 570 μg AADH 12 hours before, 
directly after, and 12 hours after CLP (prophylaxis, n=10, dashed black line) or only 4 hours after CLP 
(n=10, dashed gray line). Saline-treated, CLP-challenged mice are shown as a solid black line (n = 15), 
whereas survival of  sham-treated animals is shown as a dotted gray line (n=15). Differences between 
AADH-treated and nontreated groups are significant (for both the prophylactic and treatment regimes, 
with P=0.0031 and P=0.0275, respectively, and hazard ratios = 5.471 and 3.345, 95% CI of  ratio 1.774-
16.87 and 1.143-9.787, respectively. D) Quantitative analysis of  liver viability as detailed in the methods 
section with timing and doses as described for the prophylactic regimen. Shown are the percentages of  alive 
/ apoptotic cells from liver sections for untreated (n=8) or treated mice (n=8).
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Figure 5. Effect of AADH in a mouse model of LPS-induced sepsis
C57Bl/6 mice were treated with LPS 20 mg/kg i.p. and 570 mg AADH after 1 hour of  the LPS challenge. 
Mice were euthanized 8 hours after LPS challenge. (A) Survival in mice receiving LPS and vehicle (solid 
line) and mice receiving LPS plus AADH (dashed line) (n=9/group). The difference between groups is 
significant, with P=0.0375 and hazard ratio = 5.4328 and 95% CI of  ratio 1.088-17.22. (B) Representative 
histological hematoxylin and eosin-stained sections of  lungs from mice receiving saline (B1), LPS + vehicle 
control (B2), or LPS + AADH (B3). (C) Quantification of  histological analysis, n=4 per bar. Concentration 
of  TNF (D) and IL6 (E) in the BAL as assessed by ELISA. (F) Quantification of  neutrophils in the 
bronchoalveolar lavage (BAL) (white bars, left y-axis) of  adherent, intravascular (black bars, right y-axis), 
and interstitial (gray bars, right y-axis) neutrophils. Discrimination between neutrophils in either location 
was made based on an antibody to Ly6G injected 5 minutes prior to euthanasia (n=6-8 for each bar). (G) 
Assessment of  lung plasma leakage based on the exudation of  the plasma tracer FITC dextran (n=6-8). 
Statistical significance was tested using one-way analysis of  variance with Dunnett post hoc test. *Indicates 
significant difference (P<0.05) compared with the LPS-challenged group.
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We conclude that AADH, a low anticoagulant fraction of  UFH, has therapeutic 
potential to treat sepsis and other hyperinflammatory conditions in which excessive 
neutrophil activation with release of  histones is part of  the host response. Given the 
huge clinical experience with UFH and the anticipated safe profile of  AADH, we expect 
low thresholds for commencing clinical studies in the near future.
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Chapter 1 introduces the subject of  this thesis. An overview of  the extrinsic and intrinsic 
coagulation pathways is given, followed by a detailed description of  the anticoagulants 
activated protein C (APC) and heparin. Next to their anticoagulant functions, these 
biomolecules possess cytoprotective activities via anti-inflammatory, anti-apoptotic, 
endothelial barrier stabilizing and histone neutralizing properties. To improve the in vivo 
efficacy of  APC and heparin, engineered variants with strongly diminished anticoagulant 
properties were designed. The cytoprotective effects of  these variants were tested in 
murine disease models of  atherosclerosis, myocardial ischemia/reperfusion injury and 
sepsis. 
Structure-function relationship of APC
APC is an anticoagulant serine protease that controls thrombin formation via 
proteolysis of  active coagulation factors V (FVa) and VIII (FVIIIa). Proteolysis of  FVa 
and FVIIIa is most efficient in the presence of  phospholipids and cofactors protein S 
and FV (Figure 1A, chapter 2). The protective effects of  APC administration in animal 
models of  sepsis, stroke, myocardial infarction and lung injury can however not be 
explained by the  anticoagulant effects of  APC, but rather by its cytoprotective effects 
that are dependent on the presence of  the protease activated receptor 1 (PAR-1) and 
the endothelial protein C receptor (EPCR). Recently, it was shown that cell-receptors 
like Tie2, S1P1, CD11b/CD18, ApoER2 (LRP8) and epidermal growth factor (EGF) 
receptor are also involved in APC signaling. APC can protect cells by its endothelial 
barrier stabilizing, anti-inflammatory and anti-apoptotic functions. These cytoprotective 
effects and the molecular mechanisms identified so far are summarized in Figure 1B-D 
of  chapter 2. 
Chapter 2 presents an extensive overview of  the current state of  the art on the 
structure of  APC, its dual anticoagulant and cytoprotective functions and the effects 
of  natural and engineered mutations of  APC on its functions. Structural bioinformatics 
analyses allowed the identification of  the mosaic domain structure of  APC, containing 
an N-terminal γ-carboxyglutamic acid (Gla)-domain, two EGF-like domains, a linking 
peptide and a C-terminal trypsin-like serine protease domain which harbors the active 
site triad composed of  the residues D257, H211 and S360. Studies describing the 
effects of  both natural and engineered APC mutations on its function were analyzed 
and used to map the various APC functions and interactions onto its 3D structure 
(Figure 6, chapter 2). The active site triad in the serine protease domain is indispensable 
for proteolysis of  FVa and FVIIIa. Additionally, positively charged exosites on the APC 
surface, including the 191-loop (residues 190-193), the Ca2+-binding loop (residues 
225-235) and the autolysis loop (residues 302-317) are important for interaction with 
FVa cleavage sites. Furthermore, interactions of  APC with phospholipids, EPCR and 
protein S are essential for the anticoagulant function of  APC. For binding of  APC 
to phospholipid membranes and EPCR, the Ca2+-dependent conformation of  the 
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Gla-domain as well as several individual residues in the Gla-domain are essential. This 
information has provided a rational basis for protein engineering of  APC variants with 
improved membrane and EPCR binding capacities that show increased anticoagulation 
and are therefore more effective for the pharmacological use in thrombosis models (1-
3). For interaction with its cofactor protein S. the autolysis loop of  APC and residues in 
the Gla-domain (residue L38), EGF domain (residue D71) and linking peptide (residue 
E149) are important. 
Mutagenesis studies have indicated that the more recently discovered cytoprotective 
functions of  APC can be linked to residue E149 located in the EGF domain and 
residues E330, E333 and S360 located in the serine protease domain. The molecular 
mechanism which reconciles the influence of  E149 on cytoprotection is not known yet. 
E330 and E333 are essential for interaction with PAR-1 and S360 is part of  the catalytic 
triad and therefore needed for proteolysis of  PAR-1. However, we have shown in this 
thesis that even in the absence of  residue S360, APC can provide cytoprotection in an 
in vivo model of  acute myocardial I/R damage.
The effects of  a number of  APC variants, which have been characterized for their 
anticoagulant properties, have not yet been investigated in the context of  their 
cytoprotective properties, so potentially more residues involved in cytoprotection will 
be identified in the future. This will aid in the engineering of  an APC variant that is 
devoid of  anticoagulant function, but has increased cytoprotective properties and can 
therefore provide optimal cell-protection in a number of  relevant clinical conditions 
without causing bleeding complications.
Identification of novel small molecule inhibitors of APC
Several in vitro and in vivo observations suggest that APC resistance and a decreased 
activity of  APC are associated with a relative shift in the haemostatic balance towards a 
more procoagulant state. Hemophilia A patients who have co-inherited the FV Leiden 
mutation, resulting in APC resistance, have a delayed onset of  symptoms after birth and 
a decreased bleeding frequency and factor concentrate utilization (4, 5). We show that ex 
vivo FVa activity in human plasma is stable when its proteolytic downregulator APC is 
inhibited, which may lead to increased in vitro thrombin generation. So, possibly therapy 
based on the inhibition of  APC has potential to prolong the in vivo lifetime of  FVa 
and give rise to increased thrombin generation in individuals with bleeding tendencies, 
such as hemophilia A patients. In chapter 3 we used a validated in silico structure-
based virtual screening approach to rationally discover small drug-like molecules that 
inhibit the interaction of  a predominant exosite on the surface of  the serine protease 
domain of  APC with its substrate FVa. By targeting this exosite and leaving the catalytic 
site unaffected, we hypothesize that the compounds will only affect the anticoagulant 
properties of  APC and will not influence its cytoprotective functions. After in silico 
screening and prioritizing, the predicted best 624 compounds were selected and 
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purchased for in vitro assessment of  their properties in a functional assay that quantitates 
their capacity to inhibit the inactivation of  FVa by APC. At a concentration of  100 μM, 
the selected small molecules did not show complete inhibition of  FVa inactivation, 
which most likely reflects the relatively extended surface that is involved in the interaction 
between APC and FVa. The top 20 functionally active compounds were further tested 
for their direct binding ability to APC via surface plasmon resonance (SPR). Kd values 
of  the best 15 compounds were in the range of  10-3– 10-5 M. To check whether the 
compounds were directed at the targeted exosite, two different APC variants containing 
mutations in the targeted exosite were constructed and binding of  the compounds 
to these APC variants was investigated. Five compounds showed a ~100-500-fold 
decreased affinity for the APC variants compared to wt-APC. This loss of  affinity can 
be explained by the reduction of  molecular interactions that could be formed between 
the mutated exosites and the compounds. Four compounds showed 10-fold increased 
affinity for at least one of  the APC variants. Most likely this is explained by the fact that 
these compounds become (positively) charged upon solvation and therefore bind better 
when the big aromatic ring containing tyrosine residue or the positively charged lysine/
arginine residues present in wt-APC are replaced by alanine residues. 
Finally we studied potential preference of  the compounds for APC-catalyzed cleavage 
at either R506 or R306, since it was described that the targeted site is particularly 
important for proteolysis at R506 (6, 7). 60% of  compounds had no preference for 
either of  the cleavage sites, while 20% of  compounds showed preferred cleavage at 
either R306 or R506. These findings are in line with earlier studies concluding that the 
APC exosite involved in interaction with FVa is large and that the epitopes important 
for cleavage at R306 or R506 do not fully overlap (6-10). Of  note, the compounds 
specific for R506 scored on average better in the functional FVa inactivation assay than 
the compounds specific for R306. This appears in contradiction to an earlier study that 
described that R306 is the most important APC-cleavage site for FVa inactivation in vitro 
(11), but may merely illustrate the fact that the functional assay used is more sensitive to 
functional changes due to cleavage at R506 than to cleavage at R306.
Interestingly, there was little correlation between the functional activity of  the best 20 
compounds and their direct binding affinity to APC. This implies that tight binding per 
se is not sufficient to prevent the interaction between APC and FVa, but that the exact 
position where the compound binds on the relatively large exosite surface plays an 
important role. Thus, when the goal of  a virtual ligand screening campaign is to identify 
compounds that interfere with the function of  a protein, it is recommended to include 
a functional screening assay at an early stage of  the discovery pipeline and not only to 
measure binding affinity. In our case the functional assay measurements in the absence 
of  APC yielded additional information on the potential binding of  compounds to off-
targets like the homologous serine proteases FXa and thrombin and therefore we could 
exclude non-specific compounds from further study already after an initial screening. 
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Previous studies (11-14) have already identified peptidic and peptide-like compounds, 
RNA aptamers and ssDNA aptamers that inhibit the proteolytic activity of  APC with 
reasonably good specificity. The disadvantage of  those types of  inhibitors is that they 
inhibit the amidolytic activity of  APC and therefore possibly affect the cytoprotective 
functions of  APC. A further drawback of  the peptide-like compound (13) is that it 
contains a hydrophilic benzamidine moiety that possibly can raise hepatotoxicity. The 
inhibitors identified by others show higher affinity for APC than the small molecules 
we identified, but the big advantage of  the use of  low molecular weight compounds is 
that they have better in vivo bioavailability and metabolic stability and have the potential 
to evolve into orally administered molecules (15).
This study shows that small molecules identified via in silico virtual ligand screening 
and selected through application of  in vitro functional and direct binding assays, 
can inhibit protein-protein interaction between APC and FVa. The identified small 
molecules should be further optimized and developed to increase their affinity and 
functional activity. Subsequently they can potentially be used to increase in vivo thrombin 
generation by specific inhibition of  the anticoagulant functions of  APC in individuals 
with bleeding tendencies, like hemophilia A patients. 
Effects of exogenous APC in murine myocardial I/R injury and atherosclerosis 
We hypothesized that the anti-inflammatory properties of  APC (summarized in Figure 
1B, chapter 2) can influence the development of  acute and chronic inflammatory 
diseases. In chapter 4 we investigated the effects of  exogenous human (h) wt- and 
hS360A-(A)PC administration in murine models of  acute myocardial I/R injury and the 
chronic inflammatory disease atherosclerosis. 
First, the effects of  exogenous hAPC administration on infarct area and IL-6 levels 
were examined in a murine myocardial I/R model. Mice received 0.4 mg/kg hwt-
PC, hS360A-PC, hwt-APC, hS360A-APC or placebo (saline) both 15 minutes after 
induction of  ischemia and 5 minutes after induction of  reperfusion. We show that hwt, 
hPC, hS360A-PC, hwt-APC and hS360A-APC all significantly reduced the myocardial 
infarct area. This finding can be explained by the fact that binding of  either wt-(A)PC or 
S360A-(A)PC to EPCR, leads to dissociation of  EPCR from caveolin-1 in lipid rafts. In 
this condition, PAR-1 cleavage by either thrombin or APC results in anti-inflammatory 
PAR-1 signaling via β-arrestin-2 and Gi/o G-proteins and subsequent activation of  Rac1 
and inhibition of  NFκB signaling (16-19). Next to the aforementioned mechanism, (A)
PC can interact via its Gla-domain with phospholipids incorporated in LDL particles, 
resulting in decreased ROS formation and lipid peroxidation. Additionally, the protective 
effect of  zymogen PC can potentially involve in vivo activation to APC. The advantage 
of  S360A-(A)PC administration over wt-(A)PC administration in a clinical therapeutic 
context is that this variant will not induce bleeding complications and will have a longer 
in vivo half  life, because it cannot be inhibited by circulating serpins (20).
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S360A-(A)PC has some residual anticoagulant activity, but we believe that this did not 
contribute to the reduced myocardial infarct area observed in S360A-(A)PC treated mice. 
In vivo thrombin inhibition by heparin or dansyl glutamyl-glycyl-arginyl chloromethyl 
ketone-treated activated factor X (DEGR-FXa) failed to reduce I/R injury (21 ,22). 
Wang and coworkers (23) showed in a murine focal ischemic stroke model that the 
cytoprotective-selective 5A-mutant (that has much reduced anticoagulant properties) 
decreased infarct volume and improved neurological outcome, while an anticoagulant-
selective E149A-APC variant worsened neurological outcome, increased infarct volume 
and increased bleeding risk.
Contradictory to the results of  Loubele and coworkers (22) we did not observe an effect 
of  h(A)PC administration on the lowering of  IL-6 levels in heart homogenates after 
acute myocardial I/R injury. This can partially be explained by the 5-fold lower IL-6 
levels that we observed in placebo treated mice, leaving less room for a further decrease 
by h(A)PC treatment. The fact that we used h(A)PC and the study by Loubele et al. (22) 
murine (m)APC may also have contributed to the observed discrepancy. Both hAPC 
and mAPC have equal in vitro proteolytic activities, but mAPC has a higher affinity for 
mPAR-1 and is more potent in murine stroke models than hAPC, probably due to its 
different sequence and post-translational modifications (24,25,26).  
Having observed that both hwt- and hS360A-(A)PC provide protection in the acute 
inflammatory myocardial I/R model, we subsequently investigated the effect of  8 weeks 
twice weekly administration of  0.2 mg/kg hwt-PC, hS360A-PC, hwt-APC, hS360A-
APC or placebo (saline) in a murine ApoE-/- model of  the chronic inflammatory disease 
atherosclerosis where we studied plaque development. Surprisingly, in none of  the 
treatment groups the development of  atherosclerotic plaques was significantly altered 
by hwt- or hS360A-(A)PC administration. In both hS360A-APC and hwt-PC treated 
mice, the collagen content of  the plaques was significantly decreased. Moreover, in 
hS360A-APC treated mice, increased infiltration of  leukocytes and T-lymphocytes into 
the plaques was observed. None of  the treatments changed the innate and adaptive 
immune system as assessed by analysis of  immune cells isolated from blood and spleen. 
Mice that had received hS360A-PC and hwt-APC had significantly decreased plasma 
IL-6 levels, which were in hS360A-PC treated mice accompanied by increased MCP-1 
levels. Mice in all treatment groups had slightly but significantly increased cholesterol 
levels. 
The inability of  h(A)PC to influence plaque development can possibly be explained 
from its limited bioavailability. Previous research (27, 28) demonstrated that after i.p. 
administration of  APC, its concentration in circulation was increased above baseline 
for 3 hours with a maximum reached after 20 min. Apparently the transient rises in 
concentration that were achieved twice weekly in our study, were not sufficient to 
initiate protective anti-inflammatory signaling that lasted long enough to provide long 
term protection against atherosclerosis during the time span of  our study. To increase 
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the efficacy of  APC in future chronic disease studies it is recommendable to use a slow-
release device to administer APC, but this will require thermal stability of  APC over 
time at body temperature. When this is not feasible, intravenous and more frequent 
APC injections will be the best alternative to improve the in vivo bioavailability and 
potency of  APC. 
In conclusion, we showed that both hS360A- and hwt-(A)PC reduce acute myocardial 
I/R injury and have the potential to influence development of  chronic inflammation as 
occurring during atherosclerosis. 
Effect of APC cleavage of histones on their cytotoxic properties
It was recently discovered that APC has, next to its anticoagulant and cytoprotective 
effects, the ability to cleave extracellular histones (29). In chapter 5 we first explored 
the effect of  calcium and phospholipids, known effectors of  in vitro APC activity, on 
the proteolytic activity of  wt- and 5A-APC towards histones and we next investigated 
the cytotoxicity of  APC-cleaved histones towards endothelial cells. 5A-APC has, due to 
mutation of  five positively charged amino-acids, located in an APC exosite important 
for electrostatic interaction with FVa, a reported minimal anticoagulant activity but 
normal cytoprotective activity (30). 
During a time-course of  APC-catalyzed histone inactivation, proteolysis of  histone H3 
by either wt-APC or 5A-APC yields different cleavage products over time. Finally, end 
products of  ~12.3 kDa and ~9.7 kDa are observed. The molecular weight (MW) of  
full length histone H3 is 15.3 kDa, so next to the observed end products two smaller 
fragments of  ~3 kDa and ~5.6 kDa must have arisen simultaneously. The antibody used 
for Western blotting is raised against an epitope at the C-terminus of  histone H3, so 
therefore these N-terminal cleavage products are not visible on Western Blot. 5A-APC 
cleaves histone H3 with significantly higher efficiency than wt-APC. Neutralization of  
the positive charge in the exosite important for FVa binding probably increased the 
interaction with the highly positively charged histones and thereby resulted in more 
efficient binding and proteolysis.
Calcium ions are important for maintenance of  the Ca2+-dependent conformation 
of  APC and for interaction of  APC with phospholipids. Therefore, the presence of  
calcium is indispensible for proper anticoagulant functioning of  APC (31). We observed 
that optimal proteolysis of  histone H3 occurs at Ca2+ concentrations of  1 and 2.5 mM. 
This is in line with the optimum of  ~2 mM found for proteolysis of  FVa by APC (32). 
These concentrations are very similar to the physiological range in plasma for total 
calcium of  2.10-2.55 mM and for ionized calcium of  1.15-1.30 mM (33). 
Disruption of  cell walls is a mechanism used by histones to facilitate killing of  
parasites and bacteria (34-36). Histones are capable of  binding to phospholipid 
membranes of  eukaryotic cells, they can transverse multilamellar and large unilamellar 
vesicle lipid bilayers and induce channel formation in plasma membranes (37, 38). 
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The ability of  histones to form channels is enhanced by the presence of  negatively 
charged phospholipids, possibly because increased electrostatic interactions result in 
enhanced histone binding or increased stability of  the bound histones to the membrane 
(38). In the present study we used small purified synthetic unilamellar phospholipid 
vesicles and have shown that these vesicles interacted with histones and reduced their 
cytotoxicity towards endothelial cells. In the presence of  APC, phospholipids enhance 
the cleavage rate of  histones by APC. Both in the absence and presence of  APC, 
maximum protective effects were reached when vesicles contained PS and PE, next to 
the neutral phospholipid PC. Histones have a positive electrical charge and it is shown 
that they bind with high avidity to the anionic phospholipid PS (39). It has prior been 
demonstrated that vesicles containing a mix of  PS and PC were optimal for proteolysis 
of  FVa by APC (32, 40, 41). However, two research groups (42, 43) showed that PE has 
added value for optimal anticoagulant activity of  APC.
Next, we have investigated the effect of  histone H3 cleavage on histone-mediated 
cytotoxicity and found that the cleavage products of  ~12.3 kDa and ~9.7 kDa are 
not cytotoxic towards endothelial cells. Thus, histone cleavage by APC annihilates its 
detrimental effects towards cells. Finally we developed an algorhythm to predict at 
which positions APC can proteolyse its substrates and applied this to histone H3. For 
the prediction of  possible cleavage sites in histone H3, information about cleavage 
sites of  APC in different substrates and the expected MW of  the histone H3 fragments 
estimated by Western blotting were implemented. To verify the results of  the algorhythm 
we determined two cleavage sites of  APC via N terminal sequencing. We found that the 
cleavage products of  ~12.3 kDa and ~9.7 kDa originated from cleavages C-terminal 
of  R26 and C-terminal of  R52. These cleavage sites were correctly identified by our 
algorhythm, that further predicted R8/K9, R18, R128 and R131 as potential cleavage 
sites matching the MW of  the other histone cleavage fragments. The R26 cleavage site 
had prior to our study already been identified in murine histone H3 (29), but the R52 
cleavage site has been newly discovered by our research group. 
The end products of  histone H3 cleavage by APC did not possess cytotoxic properties 
towards endothelial cells. This explains why APC can potentially be used as a therapy for 
pathologic conditions accompanied by increased extracellular histone and nucleosome 
levels and supports earlier studies (29, 44) that have shown a survival benefit and histone 
H3 cleavage in APC treated baboons that had been subjected to a septic trigger. We 
hypothesize that 5A-APC administration will likewise be beneficial for this purpose, 
because this variant proteolyses histones more efficiently than wt-APC, is safe for 
administration in patients with a bleeding risk and its dose in other patients can safely 
be raised to increase the therapeutic potential even further.
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Extracellular histones are associated with mortality and organ failure in sepsis
In patients with systemic inflammation and sepsis, increased concentrations of  
circulatory nucleosomes were found (45, 46, 47) and it was shown that traumatic injury 
patients had increased levels of  circulating histones (48). In chapter 6 we measured 
extracellular histone H3 levels in plasma samples of  43 sepsis patients withdrawn within 
24 hours after ICU admittance. We explored possible correlations of  these plasma 
histone levels with disease severity, mortality and coagulation- and tissue-homeostasis 
parameters. 
We found that 6 sepsis patients presented with high plasma histone H3 levels ranging 
from 22-126 μg/ml, while all other patients had histone H3 levels below 10 μg/ml. 
Extracellular histone H3 levels were comparable in sepsis, severe sepsis and septic 
shock patients. In non-survivors the concentration of  circulating histones in plasma 
was significantly higher than in survivors of  sepsis (P=0.038, Figure 1, Chapter 6). 
Extracellular histone H3 levels showed a significant positive correlation with sepsis-
induced organ failure as assessed by the SOFA score (P=0.023), lactate dehydrogenase 
(LDH) activity (P=0.000) and lactate levels (P=0.011). Significant negative correlations 
were observed between histone H3 levels and both platelet count (P=0.013) and 
antithrombin levels (P=0.025). 
Extracellular histones can induce cell death via three different mechanisms. Firstly, they 
can directly induce cell death by interaction with and transversion over phospholipid 
membranes and formation of  membrane pores (37, 38). Secondly, extracellular histones 
can induce MyD88 signaling via TLR2 and TLR4. This results in up-regulation of  
NF-κB and MAPK target gene expression and enhancement of  cytokine production, 
leukocyte recruitment, inflammation, endothelial cell death and vascular permeability. 
Furthermore, extracellular histones can affect platelet function in a TLR2- and TLR4-
dependent way, resulting in activation of  ERK, P38, AKT and NF-κB signaling 
pathways. Activation of  platelets increases thrombin generation and induces platelet 
aggregation and clotting, resulting in rapid and profound thrombocytopenia (49-51). 
Finally, circulating histones can induce intracellular oxidative stress and consequently 
activate the NLRP3 inflammasome, a cytosolic platform that controls host responses to 
infection and injury, via caspase-1-dependent IL-1β and IL-18 release (52, 53). Together 
these mechanisms contribute to tissue injury and death in the context of  disseminated 
intravascular coagulation (DIC) and sepsis (29, 54-56).
In both septic shock patients and non-survivors of  sepsis a hypocoagulable state, 
characterized by increased PT and CAT lag times, decreased prothrombin/antithrombin 
levels and reduced platelet count, was observed. Parameters reflecting tissue homeostasis 
(LDH activity and lactate) were increased in non-survivors and septic shock patients. 
The presence of  a hypocoagulable state in most severely ill patients is in agreement 
with results of  thrombin generation experiments in sepsis patients in literature (57-
60). The observed reduction in platelet count and coagulation factors and prolonged 
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clotting times in septic shock patients confirm previous observations (57, 60). Before 
development of  a hypocoagulable state, the coagulation system of  sepsis patients is 
typically systemically over-activated and DIC frequently occurs, causing consumption 
of  platelets and pro- and anticoagulant factors (61). At the same time, concentrations 
of  anticoagulant factors can drop due to decreased hepatic synthesis during the acute 
phase response and due to degradation by elastases released from activated neutrophils 
(62). Activated neutrophils can trigger NET formation and thereby form, in addition to 
dying cells, a source of  extracellular histones. Increased lactate and LDH activity in sepsis 
patients can possibly originate from hypoxia and subsequent necrosis in organs due to 
deposition of  fibrin and (micro)thrombi in afferent blood vessels (61). Alternatively a 
combination of  increased aerobic glycolysis and decreased clearance of  lactate by the 
liver during the acute phase response can cause elevation of  LDH activity and lactate 
levels (63, 64). Increased lactate levels or inability of  the body to clear lactate/LDH 
were identified as strong predictors of  mortality in sepsis patients during the first 24-48 
hours after ICU admittance (65-67), in agreement with the significantly increased LDH 
activity levels that we observed in non-survivors (P=0.001), compared to survivors of  
sepsis.
The development and progression of  sepsis is a multi-factorial process. We proof  
that there is a strong correlation between extracellular histone levels and parameters 
reflecting coagulation- and tissue-homeostasis. All reflect ongoing systemic 
inflammation, coagulation, and organ failure and these parameters can potentially be 
used as biomarkers for prediction of  disease severity and mortality in sepsis patients.
Effect of non-anticoagulant heparin on histone-mediated cytotoxicity 
We hypothesized that heparin, due to its negative charge, could be a good candidate 
to bind to positively charged histones and neutralize their detrimental effects. The 
drawback of  heparin for in vivo use is its associated risk for bleeding complications. 
Therefore we developed a non-anticoagulant antithrombin affinity-depleted heparin 
(AADH) and investigated its in vitro and in vivo properties in chapter 7. 
We found that AADH possessed only 0.2% to 0.5% of  the anticoagulant activity of  
UFH in a thrombin generation assay, but inhibited the cytotoxicity of  purified histones 
towards endothelial cells dose-dependently and to the same extent as UFH. We have 
shown via surface plasmon resonance that AADH binds to single histones with an 
affinity characterized by a dissociation constant of  86 nM and that AADH co-localizes 
with NET-associated extracellular histones.  
Next, we investigated the cytoprotective properties of  AADH in three different in vivo 
murine models: a model of  ConA-induced sterile inflammation wherein histones are 
the major mediators of  death (54), in a CLP model that mimics human sepsis (68) 
and in a LPS model mimicking TLR-mediated septic shock (68). We confirmed that 
ConA-injection increased plasma levels of  extracellular histones in mice. Concomitant 
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injection of  AADH delayed the appearance of  histones in plasma. Surprisingly, six 
hours after ConA-challenge histone levels in both the AADH-treated and control 
group were comparable, while the treated group showed a clear survival benefit (Figure 
3B, chapter 7). To explain this apparent paradoxal appearance of  extracellular histones, 
we hypothesize that the histones detected in the AADH-treated group were at least 
partly complexed with AADH. Via Western blotting of  mouse plasma samples under 
non-denaturating conditions we found indications that this might indeed be the most 
plausible explanation. We showed that complexed histones do not possess cytotoxicity 
towards endothelial cells in vitro. AADH treatment significantly increased survival 
of  mice in all three murine sepsis models compared to mice in the control groups. 
Even when AADH was administered 4 hours after induction of  sepsis, mimicking 
a treatment regimen, survival was significantly improved. The beneficial effects of  
AADH on survival can be at least partly attributed to protection of  organs since 
AADH administration reduced acute lung injury, decreased neutrophil influx and 
cytokine production in the lungs and protected against intrapulmonary protein leakage 
and capillary-alveolar leakage. Additionally, the viability of  liver cells was significantly 
increased by AADH administration. 
AADH administration had only moderately and short termed effects on thrombin 
generation and tail bleeding times that rapidly normalized after 3-6 hours (Figure 3D, 
Figure 4A-B, chapter 7). This residual anticoagulant effect of  AADH can most likely 
be attributed to a stimulation of  heparin cofactor II. The plasma concentration of  this 
anticoagulant cofactor of  ~1 μM (69, 70) does however not allow complete inhibition 
of  thrombin generation (given a prothrombin plasma concentration of  ~1.5 μM (71-
73). The mice in our experiments were carefully checked for signs of  bleedings, but in 
none of  the AADH treated mice bleeding complications were observed. 
In conclusion, we propose that AADH can be beneficial for the treatment of  sepsis and 
other hyperinflammatory conditions that are characterized by excessive NET formation 
and extracellular histone levels. Based on extensive clinical experience available on the 
use of  UFH and the observation that AADH did not induce bleedings in mice, we 
expect that AADH can be safely used in future clinical studies.
Overall conclusions and future perspectives
This thesis demonstrates that by careful study of  their structure-function, the 
anticoagulant properties of  the biomolecules APC and heparin can be manipulated, 
without affecting their anti-inflammatory, anti-apoptotic, endothelial barrier stabilizing 
and histone-neutralizing properties. Employing the 3D structure of  APC, an exosite at 
the APC surface that is exclusively important for the anticoagulant function of  APC 
can be targeted through a combination of  computational and biochemical methods, 
by small molecules to increase in vivo thrombin generation for the potential benefit of  
individuals with bleeding tendencies, such as in hemophilia A patients. Administration 
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of  exogenous APC and heparin biomolecules that have greatly diminished anticoagulant 
properties, effectively reduced infarct size in a murine acute myocardial I/R injury 
model and protected organs and increased survival in three different murine models 
mimicking human sepsis. The great advantage of  biomolecules that possess reduced 
anticoagulant properties is that they can safely be administered in patients who are 
already at risk for bleeding and that the dose can safely be raised in other patients to 
increase the therapeutic potential even further. 
It is very conceivable that APC and heparin molecules with reduced anticoagulant 
properties will be further optimized in the near future to increase their cytoprotective 
properties. Since these molecules can provide cell-protection without causing bleeding 
complications the prospect of  starting clinical studies exploring the efficacy of  
optimized molecules in patients suffering from hyper-inflammatory diseases such as 
sepsis is a realistic and attractive opportunity to translate the current state-of-the-art on 
APC and heparin into novel life-saving pharmacotherapeutic products. 
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In hoofdstuk 1 wordt het onderwerp van dit proefschrift geïntroduceerd. De extrinsieke 
en intrinsieke bloedstolling en de verschillende functies van geactiveerd proteïne C (APC) 
en heparine worden beschreven. Beide biomoleculen bezitten naast hun antistollende 
eigenschappen ook celbeschermende functies en zijn in staat om de schadelijke effecten 
van histonen te neutraliseren. In vivo toediening van zowel APC als heparine kan echter 
bloedingscomplicaties veroorzaken. In hoofdstuk 1 zijn daarom varianten van APC en 
heparine beschreven die sterk verminderde antistollende eigenschappen hebben. De 
celbeschermende eigenschappen zijn intact gelaten en onderzocht in atherosclerose, 
hartinfarct en sepsis muismodellen. 
De relatie tussen de structuur en functie van APC wordt besproken in hoofdstuk 2. 
APC bestaat uit verschillende domeinen: een γ-carboxyglutamaat (Gla)-domein, twee 
epidermale groei factor (EGF) domeinen, een verbindingspeptide en een trypsine-
gelijkend serine protease domein. Onderzoek naar zowel natuurlijk voorkomende APC 
varianten, als naar varianten waarin door onderzoekers bewust mutaties aangebracht 
zijn, heeft veel informatie opgeleverd over de relatie tussen de structuur en de functie 
van APC. Hierdoor is het mogelijk geworden om de verschillende functies van APC 
te koppelen aan specifieke gebieden in de 3D structuur. Niet alle beschreven APC 
varianten zijn tot op heden onderzocht op hun celbeschermende effecten, noch zijn 
alle mogelijke varianten gemaakt, dus mogelijk worden in de toekomst nog meer 
aminozuren geïdentificeerd die belangrijk zijn voor de celbeschermende functie van 
APC. Dit zal helpen bij het ontwerpen van nieuwe APC mutanten die niet antistollend 
en in verhoogde mate celbeschermend zijn en daardoor een optimale celbescherming 
bieden in een aantal klinisch relevante condities, zonder dat ze een verhoogd risico op 
bloedingscomplicaties geven.
Verschillende in vitro en in vivo waarnemingen suggereren dat resistentie tegen APC 
of  een verminderde activiteit van APC geassocieerd zijn met een verschuiving van de 
hemostatische balans naar een meer procoagulante staat, doordat FVa in plasma minder 
geremd wordt waardoor meer trombine gevormd kan worden. Remming van APC zou 
dus hypothetisch bij kunnen dragen aan het verminderen van de bloedingsneiging in 
hemofilie A patiënten. In hoofdstuk 3 is een gevalideerde in silico structuur-gedreven 
virtuele screenings methode gebruikt voor de selectie van kleine moleculen die specifiek 
de interactie tussen APC en FVa remmen, zonder dat ze de celbeschermende effecten 
van APC beïnvloeden. Na in silico selectie zijn 624 kleine moleculen in een functionele 
test onderzocht op hun vermogen om de inactivatie van FVa door APC te kunnen 
remmen. Van de 20 beste compounds is vervolgens de bindingsaffiniteit en –specificiteit 
bepaald. Verdere optimalisatie en ontwikkeling van de beste kleine moleculen is nodig 
om hun affiniteit en functionele activiteit te verbeteren, zodat ze effectief  gebruikt 
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kunnen worden om in vivo trombine generatie te verhogen in individuen met een 
bloedingsneiging, zoals hemofilie A patiënten. 
In hoofdstuk 4 zijn de celbeschermende effecten van wild type (wt)-APC en de 
verminderd antistollende S360A-APC variant onderzocht in een acuut hartinfarct model 
en een chronisch atherosclerose model, waarbij zowel het enzym als het zymogeen 
van deze twee APC varianten is getest. Zowel wt-PC, S360A-PC, wt-APC en S360A-
APC reduceerden de grootte van het geïnfarcteerde gebied in het hart in gelijke mate, 
maar hadden geen effect op IL-6 concentraties in het hart. De S360A-varianten zijn 
niet in staat om FVa, FVIIIa en PAR-1 proteolytisch te splitsen, dus mechanismen 
onafhankelijk van de actieve site moeten een rol hebben gespeeld bij het gevonden 
beschermende effect. Mogelijk hebben de varianten een dissociatie tussen EPCR en 
caveolin-1 geïnitieerd, waarna proteolyse van PAR-1 door zowel trombine als APC 
voor anti-inflammatoire signalering zorgt. Daarnaast kunnen alle varianten via hun Gla-
domein een interactie aangegaan zijn met fosfolipiden in LDL deeltjes en daardoor de 
productie van reactieve zuurstofradicalen en de oxidatie van vetten verminderd hebben. 
Het uitblijven van een effect van APC op IL-6 concentraties kan verklaard worden 
door de lage concentratie IL-6 in onze placebo groep of  doordat wij humaan APC 
toegediend hebben in plaats van muizen APC. Het is bekend dat muizen APC een iets 
hogere affiniteit heeft voor de muizen PAR-1 receptor dan humaan APC. Wij zijn van 
mening dat voor toediening in een klinische setting, 360A-(A)PC geschikter is dan wt-
(A)PC, omdat de in vivo halfwaardetijd van 360A-(A)PC langer is en deze variant de kans 
op bloedingscomplicaties reduceert. 
Vervolgens is het effect van dezelfde (A)PC varianten op het ontstaan van atherosclerose 
onderzocht. Helaas werd in geen van de behandelgroepen een effect op de grootte 
van atherosclerotische plaques gevonden. Sommige varianten hadden wel effect op de 
samenstelling van de atherosclerotische plaques en zowel S360A-PC en wt-APC zorgden 
voor verlaagde IL-6 plasma concentraties. Waarschijnlijk was de biobeschikbaarheid 
van (A)PC te gelimiteerd om het chronische proces van plaque ontwikkeling te 
kunnen beïnvloeden. Wij geloven dat de varianten in potentie ook het ontstaan van 
atherosclerose kunnen beïnvloeden als voor een hogere biobeschikbaarheid van APC 
gezorgd kan worden. 
Recentelijk is ontdekt dat APC de capaciteit heeft om extracellulaire histonen te 
knippen en daarmee onschadelijk te maken. In hoofdstuk 5 is het effect van calcium en 
fosfolipiden op de proteolytische inactivatie van histonen door zowel wt- als 5A-APC 
onderzocht. 5A-APC heeft een normale celbeschermende- maar minimale antistollende 
activiteit. 5A-APC knipt histon H3 significant sneller dan wt-APC en beschermt hierdoor 
endotheelcellen beter tegen de cytotoxische effecten van histonen. De verklaring 
hiervoor is waarschijnlijk dat de affiniteit van deze variant voor sterk positief  geladen 
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histonen verhoogd is, doordat 5 positief  geladen aminozuren door neutrale aminozuren 
vervangen zijn. Optimale proteolyse van histon H3 vindt plaats in aanwezigheid van 
fysiologische calcium concentraties en van fosfolipiden vesikels die zowel PS, PE en 
PC bevatten. Wt-APC en 5A-APC knippen histon H3 beiden op dezelfde posities. 
Door middel van Edman sequencing is vastgesteld dat de belangrijkste knipplaatsen 
C-terminaal van aminozuren R26 en R52 liggen. De resulterende eindproducten die 
ontstaan door deze proteolyse zijn niet meer cytotoxisch. APC zou dus in de toekomst 
mogelijk ingezet kunnen worden bij de behandeling van pathologische condities waarbij 
verhoogde concentraties extracellulaire histonen voorkomen, zoals bijvoorbeeld sepsis 
en trauma. 5A-APC heeft de voorkeur boven wt-APC omdat deze variant histonen 
efficiënter proteolyseert en een verminderd bloedingsrisico geeft in vergelijking met 
wt-APC. 
In patiënten met systemische ontsteking en sepsis zijn verhoogde concentraties 
extracellulaire histonen gevonden, die direct celdood kunnen induceren door schade 
toe te brengen aan celmembranen en indirect celdood kunnen veroorzaken via activatie 
van TLR2- en TLR4-signalering en NLRP3 inflammasomen. Deze celdood zorgt voor 
verdere vrijkomst van histonen, waardoor een vicieuze cirkel ontstaat. Histonen in de 
circulatie kunnen daarnaast afkomstig zijn van NETs die door neutrofielen gemaakt 
worden om infecties te bestrijden. In hoofdstuk 6 zijn in plasma samples van 43 
sepsis patiënten histon H3 concentraties gemeten en mogelijke correlaties met de 
ernst van de ziekte, mortaliteit en weefselschade- en stollingsparameters onderzocht. 
Niet-overlevenden bleken significant hogere concentraties histon H3 in hun plasma te 
hebben dan patiënten die de ziekte overleefden. Extracellulaire histon H3 concentraties 
correleerden significant positief  met de mate van sepsis-geïnduceerd orgaanfalen en 
weefselschadeparameters (lactaat dehydrogenase activiteit en lactaat concentratie). 
Significant negatieve correlaties waren aanwezig tussen histon H3 concentraties en de 
hoeveelheid bloedplaatjes en de antitrombine concentratie. De ontwikkeling en progressie 
van sepsis is een multi-factorieel proces. We hebben laten zien dat er correlaties zijn 
tussen de hoeveelheid extracellulaire histonen en weefselschade- en stollingsparameters. 
Deze reflecteren allemaal de ernst van de systemische ontsteking, stollingsproblemen en 
orgaanfalen en kunnen dus mogelijk gebruikt worden als biomarkers om de ernst van 
de ziekte en mortaliteit te voorspellen.
Heparine is door zijn sterke negatieve lading een goed molecuul om door middel van 
de binding aan positief  geladen histonen, de schadelijke effecten van deze laatsten te 
neutraliseren. Het nadeel van heparine is echter dat het als complicatie bloedingen 
kan veroorzaken en daarom niet veilig toe te dienen is aan sepsis patiënten die vaak 
al bloedstollingsproblemen hebben. We hebben daarom in hoofdstuk 7 een niet-
antistollend heparine molecuul ontwikkeld en onderzocht: antitrombine affiniteit-
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gedepleteerd heparine (AADH). In vitro heeft AADH hetzelfde beschermende effect 
op histon-geïnduceerde celdood als UFH. We hebben aangetoond dat AADH een 
bindingsaffiniteit van 86 nM heeft voor histonen en co-lokaliseert met histonen die in 
NETs geïncorporeerd zijn. Vervolgens zijn de effecten van AADH in 3 verschillende 
in vivo muismodellen onderzocht. In het ConA-geïnduceerde steriele ontstekingsmodel 
model hebben we gezien dat toediening van AADH op korte termijn de vrijkomst van 
histonen remt. Op de langere termijn was er geen onderscheid tussen de concentraties 
extracellulaire histonen in de controle- en AADH-behandelde groep, maar waren de 
overlevingskansen in de AADH-behandelde groep door complexatie van de histonen 
toch duidelijk verhoogd. Ook in het CLP sepsis model en in het LPS septische shock 
model zorgde behandeling met AADH voor significant lagere mortaliteit. Zelfs als 
AADH in een behandel-regime pas 4 uur na de inductie van sepsis toegediend werd, was 
de mortaliteit significant verlaagd. Het beschermende effect van AADH is op zijn minst 
deels toe te schrijven aan een verminderde incidentie van orgaanfalen. Behandeling met 
AADH vermindert de kans op acute longonsteking en zorgt voor een toename van de 
celviabiliteit in de lever. 
AADH heeft alleen op korte termijn licht antistollende effecten die toe te schrijven 
zijn aan stimulatie van heparine cofactor II. Alle muizen zijn uitgebreid gecontroleerd 
op tekenen van bloedingen, maar in geen enkel geval werden bloedingscomplicaties 
gevonden. AADH kan dus veilig in vivo toegediend worden en een toegevoegde waarde 
hebben bij de behandeling van sepsis en andere ziekten waarin verhoogde concentraties 
extracellulaire histonen voorkomen. Vanwege het feit dat er al veel klinische ervaring is 
met de toediening van UFH en dat AADH geen bloedingen veroorzaakt, verwachten 
wij dat het in de toekomst veilig getest kan worden in klinische studies.
In hoofdstuk 8 worden de voornaamste bevindingen van dit proefschrift besproken. 
Dit proefschrift laat zien dat gedegen kennis van de structuur-functie relatie het mogelijk 
maakt om biomoleculen zodanig te manipuleren dat hun ongewenste antistollende 
effecten sterk beperkt worden, terwijl hun gewenste celbeschermende effecten 
behouden blijven of  zelfs versterkt worden. Structuur-functie informatie maakt het 
ook mogelijk om met kleine moleculen selectief  bepaalde functies van biomoleculen te 
remmen, zonder andere functies te verstoren. 
APC en heparine varianten met sterk verminderde antistollende eigenschappen waren 
in staat infarctgroottes te verkleinen in een acuut hartinfarct model en te zorgen 
voor verminderde orgaanschade en een grotere overlevingskans in 3 verschillende 
ontstekingsmodellen. Het grote voordeel van deze varianten ten opzichte van de 
originele biomoleculen is dat de toegediende dosis, door hun verminderde risico op 
bloedingen, verhoogd kan worden, waardoor maximale doeltreffendheid bereikt kan 
worden. Hopelijk is het in de toekomst mogelijk deze varianten te testen in klinische 
studies en kunnen deze varianten bijdragen aan een verbetering van de huidige 
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behandeling voor sepsis en andere klinische condities waarin verhoogde concentraties 
extracellulaire histonen voorkomen.
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Structure function relationship of activated protein C
In Chapter 2 the structure-function relationship of  activated protein C (APC) is 
described. APC is an anticoagulant protein that is essential for maintenance of  a 
haemostatic balance. We have studied the influence of  natural and engineered mutations 
in the PC gene on the function of  APC. The most important functions of  APC comprise 
its anticoagulant and its cytoprotective properties. Chapter 2 provides an overview of  
the effects of  several mutations on the different functions of  APC and links certain 
parts of  the APC structure to specific functions. This information is interesting for 
individuals who have mutations in their PC gene and, as a result of  a lower functional 
activity of  (A)PC, are at an increased risk to develop venous thrombosis. Information 
about the structure-function relationship of  PC provides both clinicians and patients 
additional insights in the mechanism(s) responsible for the pro-thrombotic tendency. 
When the mutation that causes a disease is known and it may become clear which 
particular function of  PC is affected by a certain mutation, a better insight in the 
pathogenesis can be provided. Potentially a deepened understanding of  the molecular 
mechanism may provide new insights for design of  novel methods for prevention of  
venous thrombosis in this group of  patients. Therefore we have published a Dutch 
summary of  this review in the magazine of  the Federation of  Dutch Thrombosis 
Services (FNT). One of  the aims of  the FNT is to improve the quality of  anticoagulant 
treatment for thrombosis patients. By providing their members with information about 
relevant scientific research, they keep the scientific knowledge of  the medical doctors 
working at the thrombosis services up-to-date.
Worldwide, several research groups are working on the development of  engineered 
(A)PC variants that are specifically tailored for application in certain treatments, such 
as in anticoagulation or anti-inflammatory treatments. Detailed information about the 
structure-function relation relationship of  (A)PC is indispensable for the engineering of  
(A)PC variants without unwanted side effects and that provide optimal in vivo efficacy.
Small molecule inhibitors of Activated Protein C
APC is an attractive target for inhibition to provide support of  in vivo thrombin generation 
in individuals where thrombin formation is compromised and the haemostatic balance 
is tipped towards bleeding, such as in hemophilia A patients. Hemophilia A is an X 
chromosome-linked bleeding disorder with an estimated incidence of  1 in 5000 male 
life births [1] that is caused by mutation of  the FVIII gene. Hemophilia A is usually 
treated by intravenous infusions of  FVIII concentrates. In spite of  these infusions and 
advanced medical care, individuals with severe hemophilia regularly develop bleedings 
and musculoskeletal complications. Up to 30% of  severe hemophilia A patients develop 
neutralizing antibodies to infused FVIII concentrates, making the infusions no longer 
useful for coagulation [2].
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We discovered several small molecule inhibitors that are able to inhibit the interaction 
of  APC with its natural substrate FVa with weak to moderate binding affinities. These 
molecules could function as starting molecules for further development into orally 
available small molecules that could eventually become of  clinical interest for patients 
with hemophilia A. 
Activated protein C mutants
According to the WHO [3], cardiovascular diseases are the number one cause of  death 
worldwide. Yearly, 30% of  all deaths are related to cardiovascular diseases. Among 
cardiovascular diseases, mortality from ischemic heart disease is most frequent, with 
worldwide 7.4 million deaths per year. These numbers underline that improvement of  
treatment of  cardiovascular diseases could have a great impact on society. 
Activated protein C (APC) possesses cytoprotective effects that comprise in vitro anti-
inflammatory, anti-apoptoic and endothelial barrier stabilizing effects on different cell 
types [4, 5]. Recently Xu et al. [6] discovered that APC can cleave histones in vitro and 
in vivo, providing an additional cytoprotective mechanism of  action. APC provides 
protection in mouse models of  ischemic/embolic stroke, myocardial infarction, 
sepsis and lung injury [7-12]. The disadvantage of  in vivo administration of  APC is 
that it is accompanied with an increased bleeding risk. Therefore we investigated 
the cytoprotective properties of  engineered APC variants with limited anticoagulant 
properties, such as S360A-APC and 5A-APC. 
In chapter 4, we investigated the effect of  S360A-APC administration in a myocardial 
ischemia/reperfusion mouse model. This study showed that administration of  equal 
doses of  S360A-APC or wt-APC, resulted both in a two times reduced infarcted area in 
the heart. We hypothesize that S360A-APC can potentially reduce the infarcted area of  
the heart even further than wt-APC, because its dose of  administration can be higher 
than that of  wt-APC due to its reduced anticoagulant activity. We conclude that S360A 
has the potential to improve the treatment of  ischemic heart disease in the future, but 
more data need to be generated before such improvements can indeed be verified.
In chapter 5, we compared the in vitro proteolytic capacities of  the low-anticoagulant 
5A-APC variant towards histones with those of  wt-APC and found that 5A-APC 
proteolyzes histones more efficiently than wt-APC. From this observation we conclude 
that 5A-APC can potentially be used to treat sepsis and other diseases that are 
accompanied with cell death and/or NET formation in the future.
Antithrombin affinity-depleted heparin
Sepsis is a severe complication to infections, with an estimated worldwide incidence 
rate of  at least 19 million cases per year [13]. The incidence of  sepsis increases with age 
[14], and due to increasing life expectancies, the incidence rate of  sepsis is expected to 
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increase even further in the near future [15]. In order to tackle an infection, the human 
immune system initiates several different strategies, one of  these is the production 
of  neutrophil extracellular traps (NETs). These NETs do unfortunately not only kill 
bacteria, but are in addition cytotoxic to the bodies’ own cells, resulting in the release of  
additional histones into the blood stream. Extracellular histones damage the cell walls 
of  internal organs, resulting in a combination of  thrombosis, internal bleedings and 
inflammatory reactions. When one or more organs are failing due to this combination 
of  complications, this can evolve into a life threatening condition that is very difficult 
to treat. Despite the use of  potent antibiotics and advances made in supportive therapy 
for failing organs, the mortality rates of  severe sepsis and septic shock are still around 
30% [16]. 
Heparin has a strong affinity for positively charged histones [17, 18] due to its extremely 
high negative charge density ratio [19]. Therefore we hypothesized that heparin could 
possibly neutralize in vivo histone-induced cytotoxicity. In a clinital trial low dose 
unfractionated heparin (UFH) has been administered as a complementary treatment of  
sepsis [20]. The authors of  this study linked the presence of  infection, inflammation 
and coagulation in sepsis and aimed to inhibit the coagulation part with low doses 
of  heparin so as not to increase the bleeding risk in these patients who are already at 
risk due to sepsis-associated consumption coagulopathy [20, 21]. Although this study 
failed to demonstrate a significant benefit on 28-day mortality rate, we believe that 
the minor beneficial effects of  heparin observed might be attributed to its histone-
neutralizing capacity and were independent of  its anticoagulant properties. To test this 
hypothesis we used affinity chromatography to eliminate the anticoagulant properties 
of  unfractionated heparin (UFH), without interfering with its capacity to bind and 
neutralize histones. The resulting product, antithrombin affinity-depleted heparin 
(AADH), has only an estimated 0.2% to 0.5% of  the anticoagulant activity of  UFH 
and accordingly AADH has the advantage that the administered concentration can be 
safely increased to enhance the in vivo capacity to bind and eliminate histones. We tested 
the in vivo cytoprotective capacity of  AADH in three different sepsis mouse models and 
found that AADH significantly limited organ failure, the most dangerous complication 
of  bacterial infections, and thereby increased survival in all models. 
Maastricht University has filed a patent application based on the key results of  our 
research that claims the use of  pentasaccharide-depleted heparin in the treatment or 
prevention of  sepsis, SIRS, severe sepsis or septic shock (European Patent Office 
(EP2731616 A1), Patent Cooperation Treaty or PCT (WO2013007771 A1), United 
States Patent and Trademark Office (US20140162978 A1) and the Canadian Intellectual 
Property Office (CA2842060 A1)). The patent application will help to develop AADH 
into a clinical product and to monetize the invention. 
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Dit proefschrift was nooit tot stand gekomen zonder de hulp van vele mensen zowel 
binnen als buiten de Universiteit Maastricht. Ik kijk met veel plezier terug op de 
afgelopen jaren dat ik bij de afdeling Biochemie gewerkt heb en zal de gezelligheid en 
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had bij teksten voor papers of  bij presentaties en posters die ik voorbereidde, dan 
maakte je daar altijd zo snel mogelijk tijd voor en voorzag me van uitgebreide feedback. 
Dat heeft in grote mate bijgedragen aan mijn ontwikkeling als wetenschapper en de 
voltooiing van dit proefschrift. Buiten het werk heb ik goede herinneringen aan de 
Sinterklaasavonden die je samen met je vrouw Silvie ieder jaar organiseerde bij jou thuis.
Prof. dr. Hackeng, beste Tilman, ik wil je bedanken voor alle suggesties en adviezen 
die je hebt gegeven tijdens de werkbesprekingen op donderdagochtend en daarbuiten. 
Hierdoor heb ik vanuit een andere invalshoek naar mijn onderzoek leren kijken 
en dit heeft me erg geholpen bij het tot stand komen van mijn proefschrift. Als 
vakgroepvoorzitter heb je een belangrijke bijdrage geleverd aan de ontwikkeling van 
de afdeling Biochemie. Door je optimistische houding was het altijd fijn om met je 
te praten. Ik heb goede herinneringen aan de openingen van het academisch jaar die 
bij jou thuis in de tuin gehouden werden en aan de vele belevenissen die we in India 
gezamenlijk meegemaakt hebben.
Prof. dr. Reutelingsperger, beste Chris, dankzij jou heb ik een hoop bijgeleerd over 
verschillende manieren van celdood (apoptose, necrose, necroptose) en de methoden 
die gebruikt kunnen worden om deze te onderzoeken. Je betrokkenheid bij het AADH 
project heeft in mijn ogen in belangrijke mate bijgedragen aan het succes van dit project. 
Ik wil je bedanken voor de tijd die je geïnvesteerd hebt in het meedenken over de opzet 
van mijn proefschrift en in het geven van constructieve feedback.
De leden van de beoordelingscommissie: Prof. dr. E.A.L. Biessen, Prof. dr. F.C.S. 
Ramaekers, Prof. dr. J.J. Voorberg en Prof. dr. G. Vriend, wil ik hartelijk bedanken voor 
de tijd die zij hebben besteed aan het lezen en beoordelen van mijn proefschrift. 
Tijdens mijn PhD-periode heb ik de kans gehad om samen te werken met verschillende 
mensen van afdelingen in het azM en universiteiten in binnen- en buitenland. Prof. 
dr. Lutgens, beste Esther, van jou heb ik een hoop geleerd over atherosclerose en het 
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immuunsysteem. Zowel op wetenschappelijk als persoonlijk vlak heb ik veel gehad aan 
jouw adviezen. Jouw kennis was onmisbaar voor het opzetten van mijn muisexperiment 
naar het effect van APC op atherosclerose. Voor alle hulp bij de muisexperimenten, 
FACS analyse en kleuring/analyse van coupes wil ik Linda, Tom, David, Jeroen, Erwin, 
Jack, Anique en Judith van de afdeling Vasculaire Pathologie van het azM in Maastricht 
van harte bedanken. Daarnaast wil ik Prof. dr. van der Poll, Prof. dr. Schultz, Dr. Horn 
en Maryse van het AMC in Amsterdam bedanken voor het verzamelen en beschikbaar 
stellen van plasma samples van sepsis patiënten en voor hulp bij het analyseren van 
data en het schrijven van het manuscript. I would like to thank Dr. Villoutreix and Dr. 
Sperandio from the University of  Paris Diderot for their contribution to the in silico 
virtual ligand screening of  small molecule inhibitors of  activated protein C. For their 
contribution to chapter 7 of  my thesis I would like to thank Dr. García de Frutos and 
Dr. Aresté from the Institute of  Biomedical Research of  Barcelona, Prof. dr. Söhnlein 
(AMC Amsterdam and Ludwig-Maximilians-University Munich) and Dr. Ortega-
Gómez (Ludwig-Maximilians-University Munich).
Prof. dr. ten Cate, beste Hugo, ik wil jou en Sarah bedanken voor de tijd die jullie 
gestoken hebben in ons gezamelijke onderzoek naar het effect van APC varianten op 
ischemie/reperfusie schade en voor jullie bijdrage aan mijn review artikel. Prof. dr. 
Hemker, bedankt voor het goede idee om een niet-antistollende heparine variant te 
gebruiken in ons onderzoek en voor de hulp bij het schrijven van het manuscript en de 
analyse van muizen trombine generatie data. Dr. Wagenvoord, bedankt voor de hulp 
bij de productie van AADH. Niko, bedankt voor de lange dagen die je gemaakt hebt 
om neutrofielen te isoleren, deze te stimuleren tot NET vorming en deze NETs te 
visualiseren met elektronen- en fluorescentie miscroscopie. Deze experimenten waren 
cruciaal voor de acceptatie van mijn manuscript.
Ik wil al mijn directe collega’s bedanken voor alle gezellige momenten en hulp in de 
afgelopen jaren. Dr. Du, I enjoyed being your roommate and your friend. You were 
always very friendly and I could always talk to you about what I had on my mind. It was 
always fun to play Mahjong and badminton together with you and other friends. It’s a 
pity that you will be back in China at the 25th of  November, but I am sure we will meet 
again in the future.
Mijn 2 paranimfen: Farida en Francesca, wil ik ook graag bedanken. Zowel op het 
werk als daarbuiten heb ik veel goede gesprekken met jullie gehad. Jullie waren altijd 
geïnteresseerd in hoe het met me ging, ook nadat ik naar Mannheim verhuisd was. Ik heb 
goede herinneringen aan de wandelingen die we samen gemaakt hebben. Francesca, jij 
was het laatste jaar mijn vaste badmintonpartner op donderdagavond en liet me kennis 
maken met de beste Italiaanse restaurants in Maastricht. Bedankt voor de keren dat ik je 
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laptop mocht lenen voor sollicitatiegesprekken via Skype. Farida, jij hield net als ik van 
lekker eten en drinken. Ik vond het altijd gezellig met jou op borrels en feestjes en heb 
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